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in the presence of rapamycin over seven days 
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^ŝŶĐĞ ƚŚĞŝƌ ĨŝƌƐƚ ĐůŝŶŝĐĂů ĂƉƉůŝĐĂƚŝŽŶ ŝŶ ƚŚĞ  ? ? ? ? ?Ɛ ƌĞĐŽŵďŝŶĂŶƚ ƉƌŽƚĞŝŶƐ ŚĂǀĞ ďĞĐŽŵĞ ĂŶ
increasingly larger section of the drug market, growing into a multi-billion dollar global market. 
The pursuit of improving the design, production, and application of recombinant proteins for 
biotherapeutic uses is a key driver in industry and academia. The majority of the recombinant 
biotherapeutic proteins used in the clinic are produced in mammalian cell express ion systems 
due to their capability to undertake human-like complex post translational modifications. The 
ĐƵƌƌĞŶƚůǇ ‘ŐŽůĚƐƚĂŶĚĂƌĚ ?ŵĂŵŵĂůŝĂŶĐĞůůĞǆƉƌĞƐƐŝŽŶƐǇƐƚĞŵĨŽƌƚŚĞƉƌŽĚƵĐƚŝŽŶŽĨƌĞĐŽŵďŝŶĂŶƚ
proteins is the Chinese hamster ovary (CHO) cell line. However, even with advances in 
mammalian cell expression technology, there is still a high cost and a long development period 
required for a recombinant protein therapeutic to go from design to market. As such, 
bottlenecks include the time taken for mammalian cells to grow and divide with slow doubling 
times compared to microbial systems and limited capacity to synthesise and secrete 
recombinant proteins. One of the cellular processes that underpins both cell growth and 
recombinant protein production is the translation of mRNA. Translation consists of three 
distinct steps: initiation, elongation and termination. One major cell signalling pathway that is 
considered a master regulator of both initiation and elongation of translation is mTOR, also 
involved in regulating ribosome biogenesis and cell proliferation. During the process of 
polypeptide elongation (mRNA translation), elongation factor 2 (eEF2) is a key control point 
that regulates protein synthesis via its de/phosphorylation. Phosphorylation of eEF2 results in 
its inactivation; slowing or halting elongation resulting in the attenuating of protein synthesis. 
This study set out to establish if manipulation of the mTOR signalling pathway and/or 
manipulation of phosphorylation of elongation factor 2 and the kinase that inactivates eEF2, 
eEF2K, in CHO cells impacts upon CHO cell growth and recombinant protein production yields. 
Transient expression of wild type and a Thr56Ala eEF2 mutant in CHOK1 cells affected the 
short term (24-48 hour) phosphorylation of eEF2 but did not appear to have an effect upon 
intracellular recombinant protein production and cellular growth in culture over 96 hours. 
Stable over expression of the wild type eEF2 construct in CHO cells resulted in a 2-fold increase 
in expression of eEF2 and a decrease in phosphorylation of eEF2 at the protein level; but the 
there was no change in the levels of total eEF2 mRNA expression. Stable expression of the 
Thr56Ala and Thr56Glu eEF2 mutants had a greater effect upon eEF2 expression resulting in a 
3-5 fold increase in total eEF2 expression, however the phosphorylation of eEF2 was almost 
unchanged in an Ala56 eEF2 cell line, whereas it was reduced in the Glu56 eEF2 mutant cell 
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line. Growth of the CHO cells lines expressing the eEF2 mutants show that ove r expression of 
any of the eEF2 mutants resulted in a change in growth, but the Ala56 eEF2 mutant showed 
the largest change in cellular growth. Short term transient expression of recombinant firefly 
luciferase in the stable eEF2 cell lines revealed that the Thr56Ala mutant greatly increases the 
CHO cells total recombinant protein production. Further, mutation of eEF2 to Ala56 or Glu56 
had little effect upon the mis-incorporation of amino acids during translation. The transient 
knockdown of eEF2K was achieved and this was shown to prevent eEF2 phosphorylation. 
However, CHO cells do not appear to tolerate the knockdown of eEF2K stably or at only very 
low levels. This suggests that a sustained, high level of eEF2K knockdown is lethal to the cell; 
which would result in the loss of eEF2 regulation for an extended period of time. Transient 
expression of the eEF2K shRNA into CHOK1D6 cells stably expressing firefly luciferase, a non-
secreted protein, resulted in a 5-fold increase in luciferase expression showing that knockdown 
of eEF2K increased the short term productivity of these cells. Interestingly, the study of CHO 
cell lines with varying recombinant monoclonal antibody protein production capacities 
revealed that levels of total and phosphorylated eEF2 did not appear to change in correlation 
with the mAb titre. These data suggest that eEF2 activity is tightly regulated across cell lines 
and is not directly related to recombinant protein secretion in these industrially used CHO cell 
lines The addition of 2 µM of PMA, an activator of mTOR signalling, increased antibody 
production in a low producer cell line but had no effect upon the antibody production from a 
high producing cell line. Together the data presented here shows that manipulation of eEF2 
and eEF2K activity can enhance cellular growth and recombinant protein production from CHO 
cells. As such, new engineering approaches that allow the manipulation of both elongation and 
polypeptide synthesis combined with the secretory capacity of the cell are likely to yie ld new 
CHO host cells with more predictable recombinant protein capacity and further advance our 
understanding of the role of mRNA translation in controlling cell proliferation, and both global 










1.1 Biotherapeutic Recombinant Proteins  
Recombinant proteins are proteins that have been produced by recombinant DNA (rDNA) 
technology using a specific expression system to generate the target protein of choice. These 
can be proteins made for example, for research purposes, for use in diagnostics or for 
biotherapeutic use in the clinic to treat a wide range of diseases (Holt et al. 2000; Amadori et al. 
2002). Almost all recombinant proteins are made using cell expression systems, including the 
use of expression systems from both prokaryotes and eukaryotes such as plants and plant cells, 
insect cells, mammalian cells, yeasts, and bacteria. In the majority of cases the rDNA is 
delivered into the cell expression system on a plasmid to allow subsequent transcription and 
translation of the target gene of interest in live cells cultured under laboratory conditions. 
More details on particular expression systems are discussed below. 
 
The use of recombinant proteins as medical therapeutics has become common-place since the 
first approved molecule in the 1980s. Naturally occurring proteins were the first recombinant 
proteins that were put into trials to be use as a medical therapeutic (Gulan et al. 1987). 
Through the study of protein sequencing and rational design the first recombinant therapeutic 
to be put into clinical use was Humulin®, recombinant human insulin, which was approved by 
the FDA in 1982 (Butler 2005). Since the commercialisation of insulin, other biotherapeutic 
proteins have become available through recombinant techniques that are able to treat other 
disorders and diseases.  
 
^ŝŶĐĞƚŚĞůĂƵŶĐŚŽĨƚŚĞĨŝƌƐƚƌĞĐŽŵďŝŶĂŶƚďŝŽƚŚĞƌĂƉĞƵƚŝĐƉƌŽƚĞŝŶŝŶƚŚĞ ? ? ? ? ?Ɛ ?ďŝŽƚŚĞƌĂƉĞƵƚŝĐ
proteins have constituted a large and growing proportion of the total pharmaceutical market 
(which includes traditional small molecule drugs, e.g. antibiotics). As such, biologics based 
medicines as a whole now represent a major portion of total pharmaceutical sales, with a 
value of $150 billion (US$) in 2011, and are predicted to reach $252 billion in total sales by 
22 
 
2017. Of this $252 billion, monoclonal antibody (mAb) based products, are predicted to 
account for $89.9 billion of sales (Highsmith 2013). The majority of recombinant protein 
biopharmaceuticals are produced in cultured mammalian cells (Walsh 2010a), with the most 
commonly used industrial mammalian cell host being the Chinese hamster ovary (CHO) cell 
(Kim et al. 2012). As of 2010, the number of approved recombinant protein products in Europe 
and the US was 200 (Walsh 2010a) ?ŽĨǁŚŝĐŚ ? ?ŚĂĚ ‘ďůŽĐŬďƵƐƚĞƌ ?ƐƚĂƚƵƐ ?ƐĂůĞƐŽǀĞƌ ? ?ďŝůůŝŽŶ
per year).  
 
Biotherapeutic proteins therefore constitute an important section of health care medicines, 
but as these continue to grow in terms of the number of such biologic drugs and indications 
they can be used for they also contribute to increasing health costs globally (Sibbald 1999). In 
2011, biopharmaceuticals accounted for more than half of all molecules in the drug 
development pipeline (Carter 2011). The costs to develop a biotherapeutic drug have been 
estimated as ranging from approximately $2000 to $20000 US$ per gram (Kelley 2009), 
associated with this high cost of development is the fact that the majority of drugs do not 
produce revenues that recover their research and development costs (Vernon et al. 2010). As a 
result there is a need to be able to develop and produce recombinant biotherapeutics more 
rapidly, efficiently, and cost-effectively, whilst maintaining or improving upon the product 
quality and authenticity of the final product molecule. 
 
One of the ways to address the challenges of reducing time-lines for the development of such 
complex molecules, as well as improving efficiency and product quality whilst reducing costs 
would be to generate new host expression systems that are more amenable to production of a 
wider range of molecules, grow faster to higher biomass (thus reducing time lines) and 
produce higher yields of a high quality product. The work undertaken in this thesis was focused 
upon improvements to CHO host expression systems as outlined in more detail below to 
potentially improve product yield and quality therefore ultimately impacting upon the ability 
to produce the required quantities of these high value biotherapeutic molecules. Given the 





1.2 The Biotherapeutic Protein Landscape 
Of the top ten pharmaceutical sales in the US in 2012, eight were protein-based 
biotechnology-produced products with only two being traditional small molecules synthesized 
by organic chemistry (Staton 2012). Of the eight protein biotherapeutic molecules, six were 
monoclonal antibodies demonstrating the importance of this class of molecule in the market 
place (Modjtahedi et al. 2012; Parkinson et al. 2012; Staton 2012). These represent the top 
protein based drugs by sale. When biopharmaceuticals are looked at in terms of their use in 
different clinical areas, the top three applications in 2010/2011 were: haematopoietics, for the 
treatment of blood disorders; monoclonal antibodies for treatment of a large number of 
different indications, and cytokines (Figure 1.1). Monoclonal antibodies therefore currently 
constitute the greatest number of biotherapeutic molecules in the R&D pipeline, the majority 
of top selling pharmaceuticals and a major portion of total amount of protein used in the 
clinical setting. Currently in development there are a large number of biopharmaceuticals, 















Product name Function/ disease treatment Company  Year  
Alemtuzumab  Multiple sclerosis Genzyme 2014 
Acid 
sphingomyelinase  Familial amyloid cardiomyopathy Genzyme 2014 
Neo-GAA Pompe disease (2nd generation enzyme) Genzyme 2014 
Brodalumab Psoriasis Amgen 2014 
Blinatumomab Acute lumphoblastoc leukemia Amgen 2014 
Rilotumumab Gastric cancer Amgen 2014 
Bococizumab 
(RN316) (PF-
04950615)  Hyperlipidemia Pfizer 2014 
Inotuzumab 
ozogamicin Actue Lymphoblastic Leukemia  Pfizer 2014 
MabThera/Rituxan 
Non-Hodgkins lymphoma, chronic lymphocytic 
leukemia and rheumatiod arhritis  Roche 2013 
Avastin 
Colorectal, breast, lung, kidney, ovraian cancer and 
glioblastomna  Roche 2013 
Herceptin HER2-positive breast  and gastric cancer  Roche 2013 
 
Table 1.1 Biological therpetuics currently in development or recently released. The information 
ǁĂƐƐŽƵƌĐĞƐĨƌŽŵƚŚĞƌĞƐƉĞĐƚŝǀĞĐŽŵƉĂŶŝĞƐ ?ƉƵďůŝĐƉŝƉĞůŝŶĞǁĞďƉĂŐĞƐ ?/ŶĨŽƌŵĂƚŝŽŶĨƌŽŵZŽĐŚĞ














Figure 1.1 The distribution of the different classes of recombinant proteins in terms of how 




1.3 Monoclonal Antibodies (mAbs) 
Antibodies are naturally synthesised proteins produced by B-cells in complex organisms as a 
defence mechanism against foreign bodies or antigens (Reddy & Corley 1999). Antibodies are 
generated as part of the immune response whereby B-cell lymphocytes differentiate into Ig 
(antibody) secreting plasma cells when a foreign body is recognised (van Anken et al. 2003; 
Schmidlin et al. 2009). In order for the cell to be able to synthesis, assemble, post-
translationally modify and secrete large amounts of antibody material, the plasma cell 
undergoes a wave of reprogramming events to support and enhance the required metabolic 
and secretory capacity of the cell to deliver the required Ig amounts (van Anken et al. 2003). 
Antibodies are made that are specific to a particular epitope of the foreign body, and via the 
immune response a pool of antibodies to different epitopes of the antigen are produced, thus 
generating a so called polyclonal pool of antibodies. For biotherapeutic purposes, monoclonal 
antibodies (mAbs) are usually used or desired where a specific antibody to a specific epitope is 
produced recombinantly. 
 
The Ig monomer is traditionally depicted in the form a Y-shape structure as shown in Figure 1.2 
and is approximately 150 kDa in size (Schroeder & Cavacini 2010). Each individual Ig molecule 
is assembled from two identical heavy chains (HC) and two identical light chains (LC) with each 
chain being made up of a number of different domains: the constant and variable domains. It 
is the variable domains that come together to form the antigen binding site with specificity for 
a particular epitope whilst the constant region of the heavy chain defines the class of Ig an 
antibody molecule belongs to. There are five Ig classes, IgA, IgD, IgE, IgG and IgM; in humans 
each isoform has a distinct function and localisation i.e. IgA is main found in saliva (Jefferis & 
Lefranc 2009). 
 
As shown in Figure 1.2, the Ig structure is comprised of two Heavy chains (HCs, approximately 
50 kDa each) and 2 light chains (LCs, approximately 25 kDa each). These chains form a Y 
shaped structure, with the two heavy chains forming the base of the structure and the li ght 
chains form the arms, with a hinge region at the intersect of the Y shape (Wang et al. 2007).  
The lower half of the heavy chain structure (CH2 and CH3) form the fragment crystallisable 
region (Fc), this being a sequence of amino acids that has a highly conserved sequence and 
structure for recognition within the immune system, which actives the compliment response 
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(Heyman 2000; Ochsenbein & Zinkernagel 2000; Sörman et al. 2014). Conversely, at the head 
of each arm of the antibody is the fragment antigen binding region (Fab); this region is 
produced on an antigen specific basis, making each antibody highly specific for its target 
(Arevalo et al. 1994). It is this Fab and Fc region functionality which makes antibodies a 
desirable therapeutic, the Fab can be engineered for a specific target where the Fc can be used 
to activate cell killing, to be inactive and use only the antigen binding region to neutralise a 
target or be modified to either carry a small molecule, or be probed using another antibody or 
molecule in an analytical test or experiment (Zola & Swart 2005). 
 
Of the five isoforms, it is the IgG isoform that is currently and almost exclusively used in 
biotherapeutics applications. The IgG isoform has 4 sub classes IgG1-4, which are dependent 
upon the inter- and intra-chain bonding between the HCs and LCs and identified by these 
substructures and bonding patterns and their abundance in serum levels (Schroeder & Cavacini 
2010). Mammalian cells are engineered to produce and secrete one of the four sub classes, 
IgG1 being the most commonly used sub class. It should also be noted that the heavy chain is 
N-glycosylated and the correct glycosylation is often important for the function of the 
molecule as a biotherapeutic molecule and can affect the in vivo half-life of the molecule 
(Zheng et al. 2011). Due to the complex nature of antibodies, their synthesis and assembly 
requires the correct folding, assembly and post-translational modification of two heavy chain 
(HC) and two light chain (LC) Ig polypeptides in the ER (Feige & Buchner 2014; Hendershot et al. 
1987; Leitzgen et al. 1997)  assisted by molecular chaperones, transport to the Golgi for further 
glycosylation processing (Werner et al. 2007) and then secretion out of the cell (Jefferis 2005; 
Holland et al. 2006). The manufacture of such complex molecules is therefore usually 
undertaken in cultured mammalian cells as these contain the correct machinery to correctly 
synthesise and assemble the desired product and provide human-like post-translational 



















Figure 1.2 Schematic depicting the make up of an Ig antibody. The antigen binding regions are 
design specifically per antigen. The sub classes of the IgGs differ in disulphide bonds between 
the CH2 regions of the FC region and the CH1 and Cl regions of the Fab regions. 
 
In addition to classical antibody molecules, there has been a great deal of interest in 
generating novel types of antibody based molecule for biotherapeutic applications that are not 
naturally found or made.  For example, monoclonal antibodies have been modified to carry 
small molecules and radioisotopes to specific targets, allowing for a greater specificity when 
treating disease such as cancer (Adams & Weiner 2005; Carter 2001). Novel molecules such as 
a mAb Fc region conjugated to a different small molecule or protein such as a cytokine, 
designed as an alternative to mAb therapy have also been investigated, often referred to as 
FC- fusion proteins. Such molecules are shown schematically in figure 1.3. These types of 
molecule have different properties compared to antibodies and allow for an increase in the 
half-life of the conjugated molecule and by preventing absorption of the Fc-fusion by the 
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Figure 1.3 Fc fusion recombinant proteins; Fc regions of a monoclonal antibody, with a 
recombinant protein therapeutic or a small molecule replacing the Fab region. 
 
1.4 Different Expression Systems for the Commercial Production of Biotherapeutic Proteins 
As stated above, CHO cells are the predominant expression system used for the production of 
biotherapeutic proteins. However, a number of other expression systems are used and the 
capacity of these bacterial, insect, yeast and mammalian cells to produce high yields of 
recombinant biotherapeutic proteins in large-scale fermentations have been greatly enhanced 
through a combination of rational and empirical manipulations of host, vector and bioprocess 
engineering (Kotsopoulou et al. 2010; Le Fourn et al. 2014; Wurm 2004). Each system has 
advantages and disadvantages with respect to their application for the production of 

















production of biotherapeutic proteins in addition to CHO, E. coli and the yeast S. cerevisiae, 
together these three expression systems being responsible for >90% of all the 
biopharmaceuticals in clinical use, the majority of which are secretory proteins (Walsh 2010b). 
 
E. coli are used to produce about a third of all biotherapeutic rPs approved to date (Walsh 
2010b) , this includes the production of antibody fragments, insulin and various cytokines and 
growth factors. Biotherapeutic proteins expressed in E.coli can be expressed in the cytoplasm 
as a soluble protein, expressed as insoluble inclusion bodies (IBs) that require subsequent 
solubilisation and refolding; or can be exported into the periplasmic space (Balasundaram et al. 
2009). The advantages of this expression system are that the bacteria grow rapidly, therefore 
fermentation times can be reduced, high yields can be achieved, transformation can be 
undertaken with small amounts of DNA and the physiology of E. coli is well characterised. 
However, there is a limited repertoire of folding and post-translational modification (PTM) 
machinery in these cells (e.g. lack ability to form disulphide bonds in the cytoplasm (Baneyx & 
Mujacic 2004) and hence the production of complex molecules that require human like PTMs 
is not possible.  
 
On-the-other-hand, the use of the yeast (particularly S. cerevisiae) has advantages over the 
prokaryotic E. coli system as a eukaryotic expression host for biotherapeutic recombinant 
protein production because it can be easily genetically manipulated and has relatively simple 
downstream processing (Idiris et al. 2010) ?ĞůŝŬ ?ĂůŦŬ ? ? ? ? ?. Unfortunately, although yeasts 
are able to undertake complex folding and PTMs, it is often limited in its ability to cope with 
the demands of high recombinant protein expression and secretion, and the glycosylation 
profiles are not human like. Such bottlenecks can potentially limit the yield and authenticity of 
the resulting recombinant target product (Idiris et al. 2010) ?ĞůŝŬ ?ĂůŦŬ ? ? ? ? ?. In summary, 
yeast are able to grow fast, perform PTMs and secrete target proteins into the growth medium 
but have inappropriate human glycosylation, are inefficient as secretion and can produce 
proteases that can degrade the target product (Frenzel et al. 2013). 
 
The mammalian CHO cell line is the current cell line of choice for the industrial production of 
complex biopharmaceuticals. This is demonstrated by the fact that of 58 new 
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biopharmaceutical products approved in the period 2006-2010, 32 were expressed in CHO 
cells (Walsh 2010a). CHO cells have a track record of approval by regulatory agencies for the 
production of biopharmaceuticals, and have complex cellular machinery required to complete 
the folding, assembly and post-translational modifications essential to the production of fully 
functional recombinant glycoproteins (Li et al. 2010)(Birch & Racher 2006). However, CHO cells 
are expensive to maintain due to the complex medium used to grow them, have a slow 
doubling rate meaning production cycles are lengthy as are the development processes and 
the high production cost. Further, whilst high yields of some products can be achieved, the 
yields of other products can be low. Therefore there is a need to further improve product 
quality (i.e. product heterogeneity, aggregation, glycosylation) to meet regulatory 
requirements and to further enhance yields and product activity, resulting in reduced costs 
and improve supply of biotherapeutic drugs. 
 
1.5 The Chinese Hamster Ovary Cell Lines 
As described above, the production of biotheraputic proteins, especially mass production in 
industry, relies upon the cells used to produce them. A number of different cell types from 
prokaryotes and eukaryotes, have been used as a production system over the years since the 
first implementation of recombinant proteins in medical therapies but the CHO cell has 
emerged as the expression system of choice in the majority of cases as described above.  Other 
mammalian cells are also used in industry, such as human embryonic kidney-293 (HEK-293) 
cells and NS0 cells (a human carcinoma cell line) (Butler 2005)(Chu & Robinson 2001).  
 
dŚĞŽƌŝŐŝŶĂů,KĐĞůůůŝŶĞǁĂƐĚĞǀĞůŽƉĞĚŝŶƚŚĞ ? ? ? ? ?Ɛ(Robinson 1958) and has since emerged 
as a preferred host for the large scale production of biotherapeutic proteins. This is due to the 
fact they are robust and easy to handle and culture, they proliferate/divide approximately 
every 24 hours, tDNA can be transfected both transiently (Geisse & Henke 2005; Kim & 
Eberwine 2010; Daramola et al. 2013) and stably (Baldwin et al. 2003; Wurm 2004) into CHO 
cells which can then secrete the recombinant product into the culture medium, they are 
adaptable to different growth conditions, can undertake human like glycosylation and fold and 
assemble multi-domain/subunit proteins (e.g. antibodies).  There are actually are number of 
different CHO cell hosts used industrially derived from the initial CHO cell line isolated by Puck. 
These include CHO-K1, a subclone from the parental CHO cell line in 1957 requiring proline for 
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growth (Robinson 1958). From the initial proline-dependent strains, a number of additional 
CHO cell lines have been subsequently generated (Urlaub & Chasin 1980; Urlaub et al. 1983; 
Hacker et al. 2009). 
 
Major advances in the yields of recombinant proteins from CHO cells have been achieved since 
the 1980s. In the late 1980s yields of 10-20 pg/cell/day specific activity and 50-100 mg/L 
volumetric activity from a 7 day culture with a maximum cell density of 1-2 million cells/ml 
were being achieved (Hacker et al. 2009). More recently, up to 50-90 pg/cell/day specific 
activity and 1-5 g/L volumetric activity from a 21 day fed batch culture with a maximum cell 
density of 10-15 million cells/ml have been achieved (Li et al. 2010; Hacker et al. 2009). Further, 
the recent publication of the CHO genome in 2011 has made genetic engineering of CHO cells 
much easier. However, there have been a number of different approaches already taken to try 
and engineer CHO cells for improve culture lifetime, enhanced product yield and authenticity. 
These are discussed further below.  
 
1.6 Approaches Taken to Date to Improve Biotherapeutic Recombinant Protein Expression 
from CHO Cells 
There have been several advances in recombinant since their introduction into commercial use 
as bio-therapeutics. Research in every part of recombinant protein production has been 
conducted to improve recombinant protein yield from mammalian cells. Studies of cells 
capable of expressing recombinant proteins have revealed several limiting factors in the 
process of recombinant protein production. Several approaches have been taken to improve 
upon these limitations.  
 
One such approach is to optimise the culture medium formulation to increase the recombinant 
protein produced from the mammalian cell lines used. Jordan et al. (2013) report that the 
 ‘ƌĞƐŚƵĨĨůŝŶŐ ?ŽĨ ƚŚĞĐĞůů ĐƵůƚƵƌĞŵĞĚŝĂĐŽŵƉŽŶĞŶƚƐ ƌĞƐƵůƚĞĚ ŝŶĂŶ ŝŵƉƌŽǀĞŵĞŶƚŽĨŵďƚŝƚƌĞ
from the CHO cells used in the study. Therefore provision of essential nutrients and 
components to the mAb expressing CHO cells can remove certain nutrient limiting factors 
regarding recombinant protein expression and provide data for further optimisation of the 
culture medium.  
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A review by Gustafsson et al. (2004) collated studies of gene/codon optimisation in various cell 
lines; stating that different cell lines show bias towards certain sequences from protein 
translation and that optimisation of the codon sequence improves the recombinant protein 
expression from the host cell line (Gustafsson et al. 2004). In 2010 Kotsopoulou et al. then 
show that optimisation of codons resulted in a lower copy number of mRNA, and subsequently 
stated that via improving the codon optimisation and increase the copy number results in an 
increase in recombinant protein production (Kotsopoulou et al. 2010).   
 
Of course if the culture of cells producing recombinant protein longevity increases so would 
the total recombinant protein secretion. Sanchez et al. (2014) report that the depletion of miR-
7 (mirco RNA 7), improves CHO cell culture longevity and recombinant protein yields. Although, 
it is possible that the depletion of miR-7 is responsible for the improved recombiant protein 
expression as well as the culture longevity. Le Forn et al. (2014) demonstrated that there are 
also limiting components within the secretory pathway e.g. SRP14, and suggests that 
engineering of this secretory pathway could improve upon the recombinant protein expression 
from CHO cells in the future (Le Fourn et al. 2014).  
 
An area of particular relevance to this thesis where work has been undertaken with regard to 
identifying limitations in CHO cells with respect to recombinant protein production is the 
process of mRNA translation, are discussed in more detail is the following sections. Indeed, 
mRNA translation is important in controlling global and mRNA specific translation rates and 
hence protein synthesis. Before a cell can divide and produce more biomass, it must first 
double its protein biomass, an energy-expensive process which involves extensive protein 
synthesis. As described above, one of the rate limiting steps in the development of mammalian 
cell lines for the production of recombinant proteins is the doubling rate of the host cells used 
for bioproduction, which is typically around 24 h. As a result, much of the development time 
involves waiting for cells to reach sufficient biomass. Reducing the doubling time (increasing 
the proliferation rate) would allow faster cell line development times and hence reduce 
production costs and timelines, resulting in quicker delivery of material for clinical trial. Apart 
from cell growth, there are now a number of reports that suggest that the major cellular 
constraints upon therapeutic recombinant protein production throughout the gene expression 
pathway in mammalian cells are post-transcriptional  ?K ?ĂůůĂŐŚĂŶĞƚĂů ? ? ? ? ? ?&ƵƐƐĞŶĞŐŐĞƌ ?
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Betenbaugh 2002; Smales et al. 2004; Khoo & Al-Rubeai 2009; Mead et al. 2012). Among the 
key control points is mRNA translation: a number of reports having shown that translation is a 
key determinant of high producing cell lines  ?K ?ĂůůĂŐŚĂŶĞƚĂů ? ? ? ? ? ?<ŚŽŽ ?ů-Rubeai 2009; 
Mead et al. 2012) and others that report that manipulation of ribosome biosynthesis can lead 
to the enhancement of recombinant protein yields (Santoro et al. 2009) Therefore, control of 
mRNA translation and ribosome biogenesis is important in determining the yield of 
recombinant proteins from mammalian cells. One master regulator of ribosome biogenesis, 
mRNA translation and cell growth is mTOR, discussed in more detail below. Protein synthesis is 
catalysed by ribosomes, and mTOR is a master regulator ribosome biogenesis as well as mRNA 
translation (i.e., protein synthesis) (Foster & Fingar 2010). A recent report has shown that the 
manipulation of mTOR simultaneously improved key processes underpinning recombinant 
protein production from CHO cells including cell growth, proliferation, viability and cell specific 
productivity and concluded that mTOR-based engineering of mammalian cell lines has a 
promising future for the improvement of the bioprocessing of biotherapeutic proteins 
(Dreesen & Fussenegger 2011b). A further study has also reported that in plasma cells (the 
ĐĞůůƐ ƚŚĂƚ  ‘ŶĂƚƵƌĂůůǇ ? ƐǇŶƚŚĞƐŝǌĞĂŶĚƐĞĐƌĞƚĞ /Ő'Ɛ ?ƉƌŽƚĞŝŶƐǇŶƚŚĞƐŝƐ ŝƐ ƌĞŐƵůĂƚĞĚďǇĐƌŽƐƐƚĂůŬ
between endoplasmic reticulum stress and mTOR signalling (Goldfinger et al. 2011). As such, 
there is a compelling argument for investigating the manipulation of mRNA translation and 
mTOR signalling in CHO cells as part of a strategy to develop new CHO cell lines with enhanced 
properties for biotherapeutic recombinant protein production.  
 
1.7 mRNA Translation  
mRNA translation is a key regulatory step in the control of gene expression in eukaryotes and a 
recent study has reported that the cellular abundance of proteins is predominantly controlled 
at the level of translation (Schwanhäusser et al. 2011). The perception of stress or a change in 
environmental conditions by eukaryotic cells leads to the global attenuation of cap-dependent 
mRNA translation via a range of mechanisms whilst the translational efficiency of specific 
mRNAs is actually increased (Pain 1996). The general mechanism for controlling the activity of 
the translational machinery is via the phosphorylation of translation initiation or elongation 
factors leading to their (in)activation (Pain 1996). mRNA translation is a three-stage process 
comprised of initiation, elongation and termination (Sonenberg & Hinnebusch 2009). Although 
it has been proposed that translational control is mostly exerted at the initiation phase 
(Sonenberg & Hinnebusch 2009), recent data suggest that elongation makes a major 
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contribution to the overall regulation of this process (Kenney et al. 2014). The different phases 
of translation in mammalian cells are discussed in more detail below. 
 
1.7.1 Translation Initiation 
Initiation of mRNA translation is the assembly of the ribosome at the AUG start codon of the 
ŵZEĂŶĚŝƐĐĞŶƚƌĞĚĂƌŽƵŶĚĂĐƚŝǀŝƚŝĞƐĂƚƚŚĞ ? ?ƉƌŝŵĞĐĂƉŽĨƚŚĞŵZE ?dŚŝƐŽĐĐƵƌƐǀŝĂƚǁŽ
mechanisms: Cap-dependent and cap-independent translation. Only a small percentage of 
mRNAs are translated in a cap-independent manner in mammalian cells, around 5% (Merrick 
2004). Cap independent translation occurs via insertion/formation of the ribosome into an 
ŝŶƚĞƌŶĂůƌŝďŽƐŽŵĞĞŶƚƌǇƐŝƚĞ ?/Z^ ?ĐŽĚĞĚĨŽƌŝŶƚŚĞŵZEĚŽǁŶƐƚƌĞĂŵŽĨƚŚĞ ? ?-cap but before 
the start AUG codon and is the method used by viruses to hijack the cellular machinery when 
viral infection results in shut-down of the cap-dependent mechanism (Spahn et al. 2001).  Cap-
dependant translation is a highly regulated process involving several eukaryotic initiation 
factors (eIFs) and is discussed in detail below.  
 
1.7.1.1 Cap Dependant mRNA Translation Initiation   
The  ?഻ĐĂƉŽŶĂŶŵZEŝƐadded in the nucleus and aids export out of the nucleus as well as 
translation initiation and consists of a guanine nucleotide connected to the mRNA via a 
triphosphate linkage. The guanosine itself is methylated on the 7-position directly after 
capping in vivo by a specific methyl transferase and hence the cap is referred to as a 7-
methylguanylate cap (abbreviated to m
7
G.) (Banerjee 1980). dŚĞ ‘ĐĂƉ ? ?ĂƐƐŚŽǁŶƐĐŚĞŵĂƚŝĐĂůůǇ
in Figure 1.4, is attached to the 5 prime end of the mRNA and is the site where the eukaryotic 
initiation factor (eIF) eIF4E binds to recruit additional eIFs to form the eIF4F complex (Figure 
1.4). Several of the eIFs involved in the formation of the ribosomal complex are regulated by 
mTOR as discussed further later in this chapter. 
 
1.7.1.2 Formation of the 80S Ribosome Complex 
&ŝŐƵƌĞ  ? ? ?ĂĚĞƉŝĐƚƐ ƚŚĞ ĨŽƌŵĂƚŝŽŶŽĨ ƚŚĞĞ/& ?&ĐŽŵƉůĞǆĂƌŽƵŶĚ ƚŚĞ  ? ?ƉƌŝŵĞŵZEĐĂƉ ? The 
cap is recognised by the cap binding protein eIF4E, which forms a complex with eIF4A/B (an 
ATP dependant RNA helicase) and eIF4G which binds both eIF4E and eIF4A to form the 
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complex eIF4F. eIF4G binds to the polyA binding protein PABP which binds to tŚĞ ? ?ƉŽůǇƚĂŝů
of the mRNA resulting in circularisation of the mRNA (Figure 1.4a). The eIF4F complex 
therefore consists of eIF4E (cap-binding protein), elF4G (scaffolding protein) and elF4A (RNA 
helicase) to form the larger eIF4F complex as shown in figure 1.4a (Sachs et al. 1997; Gingras et 
al. 1999a; Komar & Hatzoglou 2005). The eIF4F complex is then able to recruit the 43S 
ribosomal subunit to the mRNA (Pain 1996; Spahn et al. 2001). 
 
The 43S ribosomal subunit is formed from eIF3, eIF5, eIF1, eIF1A and a ternary complex (TC) 
comprised of eIF2, GTP and Met-tRNA ,and the 40S ribosomal subunit as depicted in Figure 
1.4b (Merrick 2004). This complex if formed by recruitment of the TC to the 40S subunit by 
eIF3, eIF5, eIF1, eIF1A (Merrick 2004). Specifically, at the 40S subunit the initiator methionyl-
tRNA (tRNAi
MET
) is recruited by eIF2·GTP (eIF2 complexed to GTP) and eIF5 (Shin et al. 2011). 
Along with these initiation factors, eIF3 and eIF1A (both prevent the 60S subunit binding at this 
stage) bind to the 40S subunit forming the 43S pre-initiation complex (Figure 1.4b) (Maag et al. 
2005; Maag et al. 2006) ?dŚĞ ? ?^ƐƵďƵŶŝƚŝŶƚĞƌĂĐƚƐǁŝƚŚƚŚĞ ? ?ĞŶĚŽĨƚŚĞŵZEƚŚƌŽƵŐŚƚŚĞ
interaction of eIF3 with eIF4F to form the 48S complex. The 48s complex then begins to scan 
the mRNA for the AUG start codon using eIF4G, eIF1 and eIF1A (Figure 1.5) (Pestova & 
Kolupaeva 2002; Merrick 2004). The first AUG is considered the initiating codon found in the 
consensus sequence of the mRNA during scanning (Gingras et al. 1999a). Factors eIF4A, eIF4B 
 ‘ƵŶǁŝŶĚ ?ƌĞŵŽǀĞ ? ĂŶǇ ƐĞĐŽŶĚĂƌǇ ƐƚƌƵĐƚƵƌĞƐ ŝŶ ƚŚĞ ŵZEƵƐŝŶŐ ĞŶĞƌŐǇ ŐĞŶĞƌĂƚĞĚ ďǇ dW
hydrolysis. Whist scanning, the GTP bound to the eIF2 unit is hydrolysed into GDP+Pi by eIF5, 
the GDP+pi+eIF2 complex is retained within the scanning complex unit, by eIF1, until a start 
codon is found (Merrick 2004; Sonenberg & Hinnebusch 2009). Once the initiator AUG is 
encountered, the initiation factors are released (Figure 1.5), these previously prohibiting the 
binding of the 60S subunit to the 40S. Once the eIFs are disassociated from the closed complex 
and the larger 60S ribosomal subunit is recruited by eIF5b via hydrolysis for GTP (Pestova et al. 
2000) and translation elongation of the mRNA can begin (Figure 1.5b)  (Sachs et al. 1997; 





































































Figure 1.4 (a) Formation of the eIF4F cap complex around the m7GTP-mRNA. In a nutrient and 
energy rich environment mTOR:Raptor phosphorylates 4E binding protein 1 (4EBP1), reducing its 
affinity for eIF4E allowing it to recruit eIF4G, eIF4A, eIF4B and Poly A binding protein (PABP). (b) 
Formation of the 43S ribosomal subunit. When the 40S subunit is released from the 60S, eIF3 
recruits eIF1A, eIF1 and eIF5A to the 40S subunit. Once bound to the 40S unit eIF3 recruits the 


























Scanning of 48S complex and AUG 







































Figure 1.5 (a) via eIF3-eIF4G forming the 48S subunit; the mRNA is bound by the eIF5 to the 40S 
subunit. The subunit then begins to scan along the mRNA for a  AUG start codon, once found the 
methionine-tRNA found in the TC complex is bound to the start codon in a GTP-dependent 
manor. The eIFs in the 48S complex disassociate from the complex as the 60S ribosomal subunit 
is recruited by eIF5B:GTP (b) The 60S unit is bound to the 40S subunit is catalysed by eIF5B in a 






1.7.1.3 mRNA Translation Elongation  
Once the 80s ribosome is formed around the start AUG of the mRNA and the first Met amino 
acid has been placed in the P-site of the ribosome, elongation of the poly-peptide can proceed. 
There are two major factors involved in the elongation of a polypeptide, eukaryotic elongation 
factor 1A (eEF1A) and eEF2 (Figure 1.6). Elongation begins with eEF1A transporting an amino 
acid into the A-site of a ribosome in an eEF1A-GTP-aa-tRNA complex, by the tRNA having the 
complimentary anti-codon sequence to the 3 base pair codon sequence upon the mRNA within 
the A-site of the ribosome. Hydrolysis of the GTP moves the amino acid-tRNA complex into the 
A-site of the ribosome (Kaul et al. 2011; Browne & Proud 2002). Once in the A-site of the 
ƌŝďŽƐŽŵĞ ?Ğ& ? ‘ƉƵƐŚĞƐ ?ƚŚĞĂĂ-tRNA complex over into the P-site of the ribosome, moving the 
ribosome along the mRNA strand, freeing the A-site for the next aa-tRNA complex to enter 
(Kapp & Lorsch 2004). As the aa-tRNA complexes move from the A-site into the P-site of the 
ribosome, the amino acid bound to the tRNA is removed from the tRNA and bound to another 
amino acid of the preceding tRNA by the peptidyl transferase centre of the ribosome, leaving 
the tRNA in the P-site (Kaul et al. 2011; Kapp & Lorsch 2004). This results in the polypeptide 
chain elongating. The tRNA then moves out of the P-site into the E-site of the ribosome and is 
released from the ribosome (Figure 1.6 and 1.7). Elongation of a polypeptide chain has high 
energy requirements and is a heavily regulated process. For the movement of one aa-tRNA 
through one site of the ribosome requires a total of 4 high energy bonds (Kaul et al. 2011). 
Control of elongation is mainly achieved via the phosphorylation status of eEF2  W when 
phosphorylated at Thr56 it is inactivated and hence protein synthesis is slowed (Rose et al. 































































Figure 1.6 (a) Components of polypeptide elongation (b) As a result of completion of cap-
dependent initiation the 80S subunit has a met:tRNA prepared in the A-site (Acceptance site) 
of the ribosome, translocation of the met:tRNA into the P-site (poly-peptide site) is catalysed 
by elongation factor 2 (eEF2) in a GTP dependent manor, where the Met disassociates from 
the tRNA. A new aa:tRNA is inserted into the A-site of the ribosome by elongation factor 1A 
(eEF1A) via GTP hydrolysis; dependent upon the complimentary codon-anti-codon pairing 






















































Figure 1.7 (a) Once a new aa:tRNA is inserted into the A-site of the ribosome eEF2 then translocates it 
into the P-site, moving the tRNA already occupying the P-site into the E-site (Exit-site), where it is 
ejected from the ribosome as translocation of the tRNAs through the ribosome proceeds. The amino 
acid bound to the tRNA disassociate in the P-site; peptide binding between the two amino acids within 
the P-site is the catalysed by the peptidyl transferase centre of the ribosome. (b) Elongation then 
continues in this cycle of translocation of aa:tRNA through the ribosome,  with peptide binding 
occurring between the amino acids that enter the P-site in a  sequential fashion, producing a specific 
polypeptide chain.  Elongation continues, unless halted by regulators or a stop codon is reached in the 





1.7.1.4 mRNA Translation Termination 
Once elongation of the polypeptide is completed, when the ribosome encounters a stop codon 
in the mRNA, translation terminates.  Termination results in the release of the mRNA and the 
newly formed polypeptide from the ribosome. Release of the mRNA is orchestrated by 2 
distinct eukaryotic release factors (eRF): eRF1 and eRF3 (Figure 1.8).  The release factors are 
split into two classes, class 1, eRF1, which recognises the stop codons: UAA, UAG, and UGA; 
eRF1 facilitates the release of the polypeptide chain via interaction with the peptidyl 
transferase centre. Class 2 release factors, eRF3, catalyse the activity of eRF1 release factors in 
a GTP dependent manor (Hauryliuk et al. 2006; Kapp & Lorsch 2004). Release factor 1 and 3 
work in unison to terminate translation; eRF3 catalyses eRF1s activity within the A-site of the 
ribosome. Study of the release factors in yeast show that eRF3 GTP activity is the rate limiting 















































Figure 1.8 (a) Termination of polypeptide elongation is initiated when a stop codon, UAA, UAG or 
UGA enters the A-site of the ribosome, the stop codon is recognised by release factor 1 (eRF1). 
Entry of eRF1 in A-site of the ribosome is aided by eRF3 and hydrolysis of GTP. (b) Once in the A-
site eRF1 catalyses the release of the mRNA from the 80S ribosome by promoting disassociation 






1.8 Specific Translation Initiation Factors 
1.8.1 Eukaryotic initiation factor 3 (eIF3) 
Pertaining to this project and investigations into mTOR and a possible link to recombinant 
protein production, eIF3 is known to directly interact with the mTOR:Raptor and S6K1 
regulators (Peterson & Sabatini 2005). eIF3 consists of 13 subunits, named eIF3a-eIF3m, and 
the total complex is the largest of the initiation factors at approximately 700 kDa (Dong & 
Zhang 2006). Some mammalian eIF3 subunits have a yeast homolog, for example subunits a, b, 
c, g and i, which are considered to form a core unit of the initiation factor (Hinnebusch 2006). 
There is less known about other subunits such as eIF3j, which also has a homolog in yeast, and 
has been found to change the interactions of the 43S subunit with the mRNA (Hinnebusch 
2006). Deletion of eIF3j resulƚƐŝŶĂĐŚĂŶŐĞŝŶĐĞůůƵůĂƌŐƌŽǁƚŚďƵƚĚŽĞƐŶ ?ƚĂĨĨĞĐƚƚŚĞƐƵƌǀŝǀĂůŽĨ
cells (Fraser et al. 2007). Thus, the eIF3 core is still capable of executing its function, but eIF3j is 
not required for the core to function at full efficiency.  
 
The primary function of eiF3 is to regulate the formation of the 43S PIC, prevent the 60S 
subunit prematurely binding to the 40S subunit and to act as a bridge to the eIF4F complex 
from the 43S complex (Hinnebusch 2006; Holz et al. 2005). It has also been shown that the 
eIF3 subunits influence other cellular functions. For example, eIF3a, eIF3e and eIF3k have be en 
implemented in cell cycle regulation (Dong & Zhang 2006). Also, eIF3a over-expression has 
been linked to various cancers and is a possible target for cancer therapy (Dong & Zhang 2006). 
Changes in signalling and eIF3 expression has been shown to result in changes in cellular 
growth, therefore it is probable that it may influence recombination protein expression when 
signalling via mTOR is modified. 
 
1.8.2 Eukaryotic initiation factor 4E (eIF4E) 
As mention earlier, eIF4E is the mRNA cap binding protein that anchors the eIF4F complex to 
the mRNA cap. The regulation and binding of eIF4E is one of the rate limiting steps of 
translation inanition (Modrak-Wojcik et al. 2013). The structure of eIF4E resembles the shape 
of cupped hands, consisting of 8 anti-parallel beta sheets and 3 alpha helices (Rosettani et al. 
2007). The mRNA cap binds in the mRNA-cap pocket of eIF4E, and 4E binding protein 1 
(4EBP1)/eIF4G binds on the opposite side of the protein (Rosettani et al. 2007). 4EBP1 has 
44 
 
around a 10-fold higher affinity for eIF4E when it is hypophosphorylated at multiple potential 
phosphorylation sites (Abiko et al. 2007). During low nutrient/energy circumstances eIF4E is 
bound to a hypophosphorylated 4EBP1, blocking the binding of eIF4G and formation of the 
eIF4F cap complex. In conditions of high nutrients/energy, 4EBP1 is phosphorylated on 
multiple sites by an activated mTORC1, the level of phosphorylation being relative to the 
availability of the energy/nutrients (Fingar et al. 2002) causing 4EBP1s affinity for eIF4E to be 
reduce significantly and thus there is free eIF4E available to bind with eIF4G, allowi ng for 
translation to be initiated (Gingras et al. 1999a; Modrak-Wojcik et al. 2013). In recent years, 
the eIF4E, 4EBP1 and mTOR link to protein translation has garnered more attention as its 
regulation has been shown to be a bottle neck in protein synthesis (Gautsch et al. 1998) as well 
as being implicated in some cancers (Hsieh & Ruggero 2010).  
 
1.8.3 Eukaryotic Elongation factor 2 (eEF2) 
Elongation factor 2 is a 95.3 kDa protein, consisting of 857 amino acid monomeric chain, with a 
highly conserved amino acid sequence across mammalian species (Kaul et al. 2011). It has 3 
structural blocks comprised of 5 domains: domains I-II, domain III, and domains IV-V (Taylor et 
al. 2007). Domain I has several conserved sequences that resemble other GTP binding pockets 
and which is located near the N-terminus of the protein (Taylor et al. 2007). It is not currently 
known how the complex eEF2-GTP forms, which is located in the interfacing region of the 
three structural blocks, which suggests that GTP binding and hydrolysis affect structural 
changes in eEF2.  Elongation factor 2 is part of the G-protein super family, which undergo 
conformational changes when bound to GTP and upon hydrolysis of GTP. G-proteins have 3 
regions that facilitate the binding and hydrolysis of GTP:  a switch 1 region, also known as the 
effector loop, the switch 2 region which assists with the binding of Mg
2+
 and the P-loop, the 
phosphate-binding loop (Taylor et al. 2007; Spahn et al. 2004). Together these regions bind 
GTP in eEF2; hydrolysis of this GTP enables eEF2 to translocate the tRNAs within the ribosome.  
 
Elongation factor 2 is responsible for the translocation of the aa-tRNA ribosome complex from 
the A-site to the P-site within the ribosome.  Translocation of the tRNA within the ribosome via 
interaction with eEF2 is still not fully understood. It is known that translocation occurs when 
eEF2-GTP binds to the ribosome and eEF2 moves the aa-tRNA into the ribosome (Sengupta et 
al. 2008). When bound to the ribosome, eEF2 undergoes a conformational change, due to the 
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hydrolysis of GTP. The hydrolysis of GTP causes the domains within eEF2 to rotate, domains I-
III rotate relative to domains VI-V (Kaul et al. 2011; Taylor et al. 2007). Domain IV is seen to 
move into the ribosome upon hydrolysis of GTP, causing the translocation of the aa-tRNA from 
the A-site to the P-site. The inactive eEF2-GDP complex then detaches from the ribosome, GDP 
is then released from eEF2, allowing for a new GTP molecule to take its place. 
 
Elongation factor 2 has a unique histidine residue at position 715 in the amino acid sequence -
dipthaminde, 2-(3Craboryamido-3-(trimetheylammonia) propyl) histidine) (Figure 1. 9) (Abdel-
Fattah et al. 2013). Several steps are required for this post translation modification to be 
completed and studies conclude that it is required for regular eEF2s function (Kimata & Kohno 
1994). What is interesting about this residue is that it is a target of a bacterial exotoxin, 
exotoxin A, which is found in diphtheria toxin. The toxin inactivates eEF2 by transferring an 
ADP-ribosyl moiety of NAD+ onto the dipthamide imidazole (Kaul et al. 2011; Ortiz et al. 2006; 
Jørgensen et al. 2005). Although the function of the dipthaminde residue is not known, it is 
believed to have a role in translation, the sequence surrounding the dipthaminde residue is 
highly conserved in mammalian sequences suggesting that is does have some unknown 
function in translation or elsewhere (Kaul et al. 2011). The activity of elongation factor 2 is 
regulated by a single kinase, elongation factor 2 kinase (eEF2K). Elongation factor 2 is 
regulated by phosphorylation of its threonine 56 residue by eEF2K. Phosphorylation of the 
Thr56 residue deactivates eEF2, blocking its interaction with the ribosome and prevents 
polypeptide elongation (Kenney et al. 2014; Ma & Blenis 2009). In this way elongation rates 












1.8.4 Eukaryotic Elongation factor 2 kinase (eEF2K) 
ůŽŶŐĂƚŝŽŶĨĂĐƚŽƌ ?ŬŝŶĂƐĞŝƐĂŶɲ-kinase, monomeric protein around 100 kDa in size and is the 
sole regulator of elongation factor 2. There are two distinct structural domains, near the N-
terminus there is a calmodulin (CaM) binding motif, for binding Ca
2+
, immediately next to an ɲ-
kinase helix (Figure 1.10) (Kenney et al. 2014). Less is known about the C-terminus end of 
eEF2K, the predicted structure is that there are four ɲ-helical regions of unknown role, possibly 
for protein-protein interactions with eEF2 (Pavur et al. 2000). Elongation factor 2 kinase 
activity is regulated by several mechanisms within the mammalian cell.  There are four major 
regulatory pathways that regulate eEF2K activity. As mention above, eEF2K has a CaM binding 
site, meaning that eEF2K activity is Ca
2+
 dependent (Pigott et al. 2012). Other proteins 
phosphorylate eEF2K on various serine residues in its structure. For example, AMP-activated 
protein kinase (AMPK): Ser
378
, cAMP (cyclic adenosine monophosphate)-dependent protein 
kinase via PKA (Protein kinase A): Ser
499
, and S6K1 via mTORC1: Ser
78/359/366
 (Kenney et al. 2014; 
Ma & Blenis 2009). In this way mTOR signalling can directly influence polypeptide elongation. 
The CaM binding site, AMPK and cAMP all activate eEF2K, to repress elongation. On-the-other-
hand, mTOR controlled phosphorylation of S6K1 works to inactivate eEF2K and hence maintain 
or enhance elongation by maintaining eEF2 in a non-phosphorylated state. 
 
Calmodulin activates eEF2K by an unknown mechanism related to calcium flux in the cell, 
particularly a release of Ca
2+
 ions into the cystol (Pigott et al. 2012). AMPK responds to the 
increase of the of intracellular ratio of ATP:AMP and ATP:ADP. As the levels of ADP, AMP rise, 
AMPK activates various catabolic processes to preserve levels of ATP as well as activating 
eEF2K (Leprivier et al. 2013a). cAMP is produced by signalling from G-proteins to adenylyl 
cyclase which circularises AMP into cAMP. cAMP activates protein PKA; PKA then actives eEF2K 
(Kenney et al. 2014; Hovland et al. 1999). AMPK and cAMP are both sensors of intra cellular 
energy and nutrients; therefore AMPK and cAMP activation of eEF2K is to preserve the intra 
cellular levels of nutrients and conserve energy. In this way elongation factor 2 kinase is 
therefore capable of protecting the cells from nutrient and energy deprivation. It has also been 
suggested that eEF2K is capable for protecting certain tissues from autophagy and cytotoxic 










Figure 1.10 Schematic of elongation factor 2 kinase (eEF2K). The CaM binding region activates eEF2K 
upon Ca
2+
 ĂŶĚ ĐĂůŵŽĚƵůŝŶ ďŝŶĚŝŶŐ ? dŚĞ ɲ-kinase region directly phosphorylates elongation factor 2 
 ?Ğ& ? ? ŽŶ dŚƌ ? ? ǁŚĞŶ Ğ& ?< ŝƐ ĂĐƚŝǀĂƚĞ ? ĚĞĂĐƚŝǀĂƚŝŶŐ Ğ& ? ? &ŽƵƌ ɲ-helix repeats near the C-terminus 
function is not fully known, but believed to be responsible for protein-protein interactions. 
 
1.9 Mammalian Target of Rapamycin (mTOR) Signalling  ? A Master Regulator of Cell 
Proliferation and Protein Synthesis 
Mammalian target of Rapamycin (mTOR) is considered a master regulator within mammalian 
cells, tying together extra cellular signals to intra cellular mechanisms. mTOR is a serine 
threonine kinase  289kDa in size and is part of the phosphoinsitide 3-kinase related family 
(PI3K) (Laplante & Sabatini 2009b). mTOR is considered a master regulator of protein synthesis, 
ribosome biogenesis and cell proliferation, and has recently been reported to influence cell 
growth and recombinant protein synthesis from mammalian cells. Protein synthesis and 
ribosome biogenesis are key determinants of cellular biomass and protein productivity. 
However, the roles that this signalling pathway plays in underpinning these phenotypes, and 
whether it can be manipulated to enhance them, have yet to be fully elucidated. 
 
With respect to the growth of recombinant cell lines, mTOR regulates these processes via the 
coordination of signalling pathways in response to growth factors, nutrient availability (amino 
acids), energy status (ATP) and cell stress (Zoncu et al. 2011; Laplante & Sabatini 2009b), all 
factors that play key roles in regulating recombinant protein yields from mammalian cells. 
NH2





mTOR is therefore likely to be a key global regulator of exactly those properties that are 
essential to achieving and maintaining high level recombinant protein production from 
mammalian cells including regulating cell growth and proliferation rates, cellular responses to 
nutrient and oxygen supplies, anabolic metabolism including ribosome biogenesis and mRNA 
translation/protein synthesis, and consequently cell-specific productivity. 
 
Rapamycin was first derived from a bacterial strain called Streptomyes hygroscopius (Laplante 
& Sabatini 2012) ?ĨƚĞƌ ƚŚĞĚŝƐĐŽǀĞƌǇŽĨ ƌĂƉĂŵǇĐŝŶ ?ĂŶĂŶƚŝĨƵŶŐĂů ƌĞĂŐĞŶƚ ?ŝŶ ƚŚĞ  ? ? ? ? ?Ɛ ƚŚĞ
ƚĂƌŐĞƚ ŽĨ ƌĂƉĂŵǇŝĐŶ  ?dKZ ? ǁĂƐ ƐƵďƐĞƋƵĞŶƚůǇ ĚŝƐĐŽǀĞƌĞĚŝŶ ƚŚĞ  ? ? ? ? ?Ɛ ŝŶ ďƵĚĚŝŶŐ ǇĞĂƐƚ
(Heitman et al. 1991). Shortly after the discovery of TOR, the mammalian homologue of TOR, 
mTOR was discovered (Sabatini et al. 1995). The TOR makeup is conserved throughout 
eukaryotic cells. Near the N-terminus there are several HEAT repeats which are involved with 
protein-protein binding as well as two FAT (FRAT-ATM-TRRAP) repeats either side of the FRB 
(FKBP12-rapamycin) binding site (Ma & Blenis 2009). In cells, rapamycin binds to the FKB12, 
then the rapamycin:FKB12 complex binds to mTORs active site, causing it to lose functionality 













1.9.1 mTOR Complexes  
mTOR is the catalytic subunit of two functionally distinct complexes, mTORC1 and mTORC2. In 
the short term, the inhibitor rapamycin only effects mTORC1 signalling. mTORC1 consists of 
mTOR, regulatory-associated protein of mTOR (Raptor), mammalian lethal with Sec13 protein 
 ? ?ŵ>^d ? ?'ɴ> ? ?ƉƌŽůŝŶĞƌŝĐŚ<dƐƵďƐƚƌĂƚĞ ? ?ŬĂ ?WZ^  ? ?ĂŶĚW-domain-containing mTOR-
interacting protein (Deptor) (Laplante & Sabatini 2009b). mTORC2 complex consists of 
rapamycin-insensitive companion of mTOR (Rictor), mammalian stress-activated protein kinase 
interacting protein (mSIN1), protein observed with Rictor-1 (Protor-1), mLST8, and Deptor 
((Laplante & Sabatini 2009b). Thus, each complex contains mTOR, mLST8/GɴL (which binds the 
kinase domain) and Deptor, an inhibitor. However, the other partner proteins differ between 
the two complexes. mTORC1 contains raptor, which binds substrates for mTORC1, recruiting 
them for phosphorylation by mTOR, and PRAS40. mTORC2 contains the proteins rictor, mSin1 
and PRR5 whereby rictor and mSin1 promote mTORC2 signalling (Foster & Fingar 2010; 
Laplante & Sabatini 2009b). The function of the constituent parts of mTORC1 and 2 are still not 
fully understood, but it is believed that PRAS40 and Deptor are inhibitors of mTORC1. It has 
been shown activity of mTOR is reduced when PRAS40 and Deptor are recruited into mTROC1 
whereas, when mTORC1 activity is increased when they are phosphorylated and leave the 
complex (Peterson et al. 2010; Sancak et al. 2007). A schematic of mTOR and the complex is 























































Figure 1.11 (a) Structure of mTOR, depicted with various interactions with mTOR related proteins. HEAT 
repeats that promote protein-protein interaction, FAT (FRAT-ATM-TRRAP) binds Deptor and FATC (C 
terminus FAT) binds mLST, for the formation of the mTORC1 complex, FRB domain binds the inhibitory 
complex of FKBP12 and rapamycin which reduces the activity of the adjacent kinase site. (b) Structure of 





The signalling and role of mTORC1 in controlling cell growth, proliferation, ribosome 
biogenesis and protein synthesis are much better defined. mTORC1 senses extra- and intra-
cellular signals whereby growth factors, nutrients and energy promote mTORC1-dependent 
cell growth/proliferation and protein synthesis. At the same time, mTORC1 promotes 
ribosome biogenesis by enhanced transcription of ribosomal RNAs and translation of mRNAs 
for ribosomal (r-)proteins to increase protein synthetic capacity. In response to reduced levels 
of growth factors, nutrients (specifically amino acids), energy (ATP) or cell stresses such as that 
encountered during rPP, mTORC1 action is attenuated to ensure that the biosynthetic 
processes are maintained at levels appropriate for such suboptimal conditions. mTORC1 also 
activates lipogenesis (Laplante & Sabatini 2009a) while reduced mTORC1 activity leads to 
activated macroautophagy, which mediates the breakdown of cellular components into 
building blocks (e.g. amino acids and other small molecules) to compensate for deficient 
nutrient supply (Foster & Fingar 2010). Finally, mTOR regulates mitochondrial oxidative 
function and is a key control point in regulating the balance between nutrient availability and 
energy metabolism and between mitochondrial vs. non-mitochondrial ATP generation (Schieke 
et al. 2006). There is less known about mTORC2, but it has been linked to cell survival, 
proliferation, and metabolism (Gibbons, Abraham, & Yu, 2009; Laplante & Sabatini, 2009). Of 
the two complexes, mTORC1 is sensitive to the effects of rapamycin, whereas mTORC2 is not. 
This is shown by mTORC1s interaction with FKBP12, whereas mTORC2 does not. mTORC1 is of 
greater interest in this investigation, as it is responsible for the regulation of protein synthesis. 
1.9.2 Regulation of mTORC1 
There are several extra cellular and intra cellular signalling mechanisms that regulate the 
formation and activity of mTORC1. These mechanisms evolved to be responsive in a complex 
organism, therefore some of the signalling pathways would not have an effect upon cellular 
regulation when the cells are cultured in a simple culture i.e. mTORC1 responses to levels of 
insulin (Wang & Proud 2006; Wang et al. 2000); as there is no insulin, or changes to the 
concentration of insulin within culture, it is unlikely this will cause any signalling to mTOR. 
Therefore the relevant pathways that would regulate mTOR in culture are outline below 
(figure 1.12).Signalling to mTORC1 occurs directly through various mechanisms which all signal 
to mTORC1, or various single pathways converge on the TSC (tuberous sclerosis complex) 
complex which acts as a GTPase-activating protein, which deactivates Rheb (Ras homolog 
enriched in brain).(Ma & Blenis 2009; Zoncu et al. 2011)The inactivated Rheb is then incapable 
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Figure 1.12 Various signalling pathways that regulate mTORC1 that are pertinent to cellular signalling within cellular culture. Activation and inhibition of mTORC1 occurs 
either via direct interaction with mOTRC1 or via a signalling cascade via Rheb (Ras homolog enriched in brain), an activator of mTOR. Rhebs regulator, the TSC (tuberous 
sclerosis complex) is a GAP (GTPase activating protein) ,when active, which inhibits Rhebs activity  by reducing the GTP boun d to Rheb to GDP, inactivating Rheb. In a state 
of hypoxia, low oxygen levels signal to REDD1 via hypoxia -induced factor 1-ĂůƉŚĂ ?,/& ?ɲ ? ?ǁŚĞŶĂĐƚŝǀĂƚĞĚZ ?ǁŝůů ƌĞĐƌƵŝƚ  ? ?-3-3 (inhibitor of TSC2), removing it from 
d^ ? ?ĂĐƚŝǀĂƚŝŶŐd^ĂŶĚŝŶŚŝďŝƚZŚĞď ?,/& ?ɲĂůƐŽĂĐƚŝǀĂƚĞƐWD> ?ƉƌŽŵǇĞůŽĐƚŝĐůĞƵŬĂĞŵŝĂƚƵŵŽƵƌƐƵƉƉƌĞƐŽƌ ?ĂŶĚE/W ? ?> ? ?Ěenovirus E1B 19kD-Interacting Protein 3) 
prevent Rheb binding to mTOR during a state of hypoxia preventing Rhebs activation of mTOR. Reduction of energy/ATP levels and genotixoc stress activate AMPK (AMP-
activated protein kinase) via LBK1 and p53 respectively. AMPK then phosphorylates and subsequently activates the TSC complex resulting in reduced mTORC1 activity; 
AMPK has also been shown to interact with mTORC1 directly by phosphorylation and inhibition of Raptor, an activator of mTOR. In a nutrient/amino acid rich 
environment, RAG A/B and RAG C/D, are active by their regulator, Ragulator, which switches the positions of GTP and GDP between the monomers. The RAG dimer then 
recruits mTORC1 to the membrane of a lysosome where it is then activated by Rheb. Phosphatidic acid (PA) is produced by hydrolysis of phosphatidylcholine (PC) via PLD 
(phospholipase D). PC is derived from fatty acids found in several foods. PA stabilises mTORC1 which is essential for its activity. mTORC2 activates AKT, which then 
phosphorylates and inhibits PRAS40, a  direct inhibitor of mTOR, and TSC2, ultimately activating mTOR. 
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1.9.2.1 TSC1:TSC2 Complex Regulation of mTORC1 
The TSC complex consists of 3 proteins, two hetero dimers TSC1 and TSC2, and TBC1D7 
(Tre2-Bub2-Cdc16-1 domain family member 7) (Dibble et al. 2012). As a complex these 
proteins regulate mTOR via Rheb (Figure 1.12). TSC2 is a GAP (GTPase activating protein), 
whilst TSC1 acts as a stabilising scaffold for the other two proteins. AMPK, which responds 
to genotoxic stress and levels of ADP, phosphorylates and activates TSC2 (Figure 1.12). 
REDD1 also activates TSC2 by removal of a 14-3-3 inhibitor of TSC2 (Tan & Hagen 2013; 
Schneider et al. 2008; Ma & Blenis 2009). Activation of TSC2 causes it to deactivate Rheb 
preventing it from mTORC1 activation. AKT, insulin and various TNFs inhibit the TSC 
complex, usually in energy and nutrient rich environments, allowing for mTORC1 activation 
(Long et al. 2005; Ma & Blenis 2009). The mechanism by which the TSC complex regulates 
Rheb is still not fully understood. 
 
1.9.2.2 Amino acids and mTORC1 Signalling 
It has been shown that mTORC1 is capable of sensing and responding to the intra cellular 
levels of amino acids, specifically leucine (Lynch 2001; Gran & Cameron-Smith 2011; Proud 
2004). Until recently the mechanisms for sensing the levels of amino acids had been 
unknown, but it has now been revealed that amino acid sensing and metabolism occurs on 
the membrane of the lysosome (Figure 1.13) (Bar-Peled & Sabatini 2014). There are several 
factors that recruit mTOR to the lysosome. Rag (Ras-related GTPase) A:C/B:D dimers, 
Ragulator v-ATPase, folliculn (FLCN) and GATOR (GAP activity towards Rags) 1 and 2 (Bar-
Peled & Sabatini 2014). In an environment of low amino acids, v-ATPase and folliculn are 
inactive upon the membrane of the lysosome; the Rag A/C or Rag B/D have GDP bound to 
Rag A/B and GTP to Rag C/D and GATOR1 inhibits the Ragulators guanine nucleotide 
exchange factor activity which swaps the GDP/GTP binding on the Rag A/C: Rag B/D dimers. 
When there is an abundance of amino acids, GATOR1 becomes inhibited by GATOR2 and 
the TSC complex is inhibited; v-ATPase and Ragulator are activated, changing the position of 
the GTP from RagC/D to Rag A/B, which then recruits mTOR to the lysosome where it is 
subsequently activated by Rheb (Bar-Peled & Sabatini 2014; Abraham 2010; Sancak et al. 






























































Figure 1.13 A more 
detailed view of mTOR 
recruitment and activation 
at the lysosome membrane 
in a nutrient/amino acid 
rich environment. 
Regulated by v-ATPase an 
amino acid sensor; GATOR 
(GAP activity towards Rags) 
1 and 2, and Folliculin 
regulators of the Rag 
heterodimers; and the TSC 
complex regulator of Rheb, 
activator of mTOR. (a) In a 
staved state, mTOR 
remains inactive in the 
cystol; v-ATPase and 
folliculn are inactive upon 
the surface of the 
lysosome membrane. 
GATOR1 inhibits the 
exchange of GTP and GDP 
between the Rag 
monomers, and the TSC 
deactivates Rheb. (b) In the 
presence of amino acids V-
ATPase is activated and 
GATOR1 is inhibited by 
GATOR2, this allows for 
Ragulator to transfer the 
GTP and GDP upon the 
Ragmonomers. Folliculin is 
also activated and prevents 
the GTP and GDP 
exchanging back to their 
inactive positions upon the 
Rag monomers, promoting 
Rag activity. The now 
active Rag A/B C/D dimer 
then recruits mTOR to the 
lysosome membrane (c) In 
a nutrient/amino acid rich 
environment the TSC 
complex is deactivated, 
activating Rheb. Once 
mTOR has translocated to 
the membrane it is 




1.9.2.3 Oxygen and mTORC1 Signalling 
There have been several studies into the effects of hypoxia and its effects upon mTOR 
signalling. Some of these studies have shown that the regulation of mTOR is linked to 
hypoxia-induced factor 1-ĂůƉŚĂ ?,/& ?ɲ ?(Connolly et al. 2006; Wouters & Koritzinsky 2008). 
ƵƌŝŶŐ ŚǇƉŽǆŝĂ ? ,/& ?ɲ ďĞĐŽŵĞƐ ƉŚŽƐƉŚŽƌǇůĂƚĞĚ ĂŶĚ ĚŽǁŶ ƌĞŐƵůĂƚĞƐ ŵdKZ ? ĂĐƚŝǀŝƚǇ
through REDD1, a DNA damage response agent which increases the activity of the TSC1:2 
complex (Figure 1.12) (Schneider et al. 2008) ?,/& ?ɲĂůƐŽ ƚĂƌŐĞƚƐE/W ?  ?> ? ?ĚĞŶŽǀŝƌƵƐ
E1B 19kD-Interacting Protein 3), which inhibits Rheb activity, down regulating mTOR 
activity. 
 
1.9.2.4 Glucose, ATP/ADP and mTORC1 Signalling 
Intra cellular levels of key energy molecules are sensed by LKB1-AMPK pathway (Hardie et 
al. 2012). When the levels of ATP drops, AMPK then activates the TSC1:2 complex which 
down regulates mTOR activity (Figure 1.12) (Gleason et al. 2007; Chan et al. 2004). AMK has 
also been reported to interact with mTOC1 directly, by phosphorylation and deactivation of 
Raptor, preventing raptor from activating mTOR (Gwinn et al. 2008). 
 
1.9.2.5 Phosphatidic acid (PA) and mTORC1 Signalling 
PA is produced from intra cellular hydrolysis of phosphatidylcholine (PC) by phospholipase 
D (PLD). PA can also be produced from lysophosphatidic acid (LPA) and diacylglycerol, but 
the main sourse of PA is thought to be phosphatidylcholine (Foster 2009). PA directly 
interacts with mTOR, by binding to the same active site as rapamycin:FKBP12 on the mTOR 
molecule (Foster 2007; Toschi et al. 2009). PA has been shown to be essential to the 
stabilisation of the mTORC1 and mTORC2 complexes, but it still requires other signals for 
mTOR activation (Foster 2007; Foster 2009).   
1.9.3 mTORC1 and Protein synthesis  
mTORC1 is involved in a number of mechanisms of signalling and control over protein 
synthesis. It has been shown to regulate mRNA synthesis, mRNA translation initiation and 











Figure 1.14 (a) An overview of mTORC1 signalling and control of protein synthesis within 
mammalian cells.  (b) A detailed view of mTOR regulation of mRNA translation initiation.  In 
a starved/low energy state eIF4E is bound to 4EBP1 (4e binding protein 1) which prevents 
formation of the the cap by blocking eIF4E binding with eIF4G; and an inactive S6K1 is 
bound to eIF3 preventing formation of the 43S complex. In a enriched nutrient/high energy 


















Phosphorylation of S6K1 
causes it to disassociate 
from eIF3, allowing it to 



































then phosphorylates the S6K1 bound to eIF3, activating it, leading to is disassociation with 
eIF3. This allows eIF3 to being formation of the 43S pre-initiation complex. mTOR also 
phosphorylates 4EBP1 on multiple phosphorylation sites, causing it to loose affinity for 
eIF4E, releasing eIF4E to for the eIF4F cap complex for translation initiation. 
 
1.9.3.1 mTORC1 and Translation Initiation 
mTORC1 influences cap regulated translation through several regulatory mechanisms 
(Figure 1.14). The regulation of eukaryotic initiation factor 4E (eIF4E) through mTORC1 
activation of 4E binding protein 1 (4EBP1) has been described previously (Dowling, 
Topisirovic, Fonseca, & Sonenberg, 2010; Fingar et al., 2002; Gingras, Raught, & Sonenberg, 
1999) ?Ğ/& ?ĨŽƌŵƐĂĐĂƉďŝŶĚŝŶŐĐŽŵƉůĞǆǁŝƚŚĞ/& ?&ǁŚŝĐŚďŝŶĚƐƚŽƚŚĞ ? ?ŵZEĐĂƉĂŶĚ
recruits the 43S pre-initiation complex to the mRNA (Gingras et al. 1999b; Pestova & 
Kolupaeva 2002) and interacts with eIF4G to recruit the ribosome to the capped mRNA.   
 ?W ?ŚĂƐĂ ? ?ĨŽůĚŚŝŐŚĞƌĂĨĨŝŶŝƚǇĨŽƌĞ/& ?ƚŚĞŶƚŚĞ ? ?ŵZEĐĂƉĚŽĞƐƐŽǁŚĞŶŝƚŝƐĂĐƚŝǀĞ ?
4EBP1 binds eIF4E and prevents 4E/4F cap binding complex formation and translation 
beginning. 4EBP1 has several phosphorylation sites, which act as its regulatory sites for the 
protein. The more sites that are phosphorylated, the less active 4EBP1 becomes allowing 
eIF4E to become more active, reflecting the level of mTORC1 activity (Fingar et al. 2002; 
Foster & Fingar 2010). 
 
As described previously, mTORC1 has also been shown to interact with eIF3, which also 
interacts with the eIF4F complex. eIF3 has 13 subunits, several that have implicated in 
various forms of cancer i.e. eIF3i, eIF3h. REF eIF3 is an integral part of the 43S pre-initiation 
complex, under certain conditions eIF3 is shown to bind to an inactive S6K1 and recruits the 
ŵdKZ PZĂƉƚŽƌ ĐŽŵƉůĞǆ ƚŽ Ă  ? ? ĐĂƉƉĞĚ ŵZE PĞ/& ?Ğ P ?ĞW ? ĐŽŵƉůĞǆ ? ƚŚŝƐ ĂůůŽǁƐ ƚŚĞ
mTOR:raptor complex to phosphorylate and deactivate 4EBP1 (Peterson & Sabatini 2005). 
Full activation of mTOR:Raptor  leads to phosphorylation of S6K1, which releases eIF3 





1.9.3.2 mTORC1 and Translation Elongation 
As well as initiation, mTOR is capable of regulating polypeptide elongation. When mTOR is 
active, it activates S6K1, which in turn deactivates eukaryotic elongation factor 2 kinase 
(eEF2K) by phosphorylation on the Ser
78/359/366
 (Ma & Blenis 2009; Kenney et al. 2014). 
Deactivation of eEF2K prevents it from phosphorylating eukaryotic elongation factor 2, this 
allows for eEF2 to remain active and allows translation elongation to continue (Browne & 
Proud 2002).  
 
1.10 Aims of this Project  
Production of recombinant proteins and biopharmaceuticals/biotherapeutics is a multi-
billion dollar industry, and their use in the place of small molecules has become more 
common place as medical treatment. As described above, mTORC1 is mediated through the 
binding of raptor to ribosomal S6 protein kinase 1 (S6K1) and eukaryotic initiation factor 4E 
binding protein 1 (4E-BP1), which recruits these substrates to be phosphorylated by mTOR. 
When hypophosphorylated, 4E-BP1 acts as a translational repressor by binding to eIF4E, 
and preventing it interacting with eIF4G to promote ribosome recruitment to the mRNA. 
Ğ/& ?ĂůƐŽďŝŶĚƐĚŝƌĞĐƚůǇƚŽƚŚĞŵZE ?Ɛ ? ?-cap structure. By directly phosphorylating 4E-BP1 






), mTORC1 promotes its dissociation from eIF4E 
allowing the formation of the eIF4F complex and the initiation of cap-dependent translation. 
Recent work has shown that increased 4E-BP1 phosphorylation is correlated with enhanced 
recombinant interferon-J production in CHO cells. The authors suggest this was due to the 
alleviation by mTORC1 of translation initiation repression (Chong et al. 2009). Others have 
also previously shown that, with respect to culturing Chinese hamster ovary (CHO) cells at 
reduced temperature (<37
o
C), transient overexpression of eIF4E resulted in enhanced 
recombinant protein expression (Underhill et al. 2006). On the other hand, mTORC1-
promoted phosphorylation of S6K1 may enhance translation via several possible 
mechanisms. Relevant substrates of S6K1 include the ribosomal protein S6, eIF4B and the 






Several key environmental cues promote or attenuate mTORC1 signalling. They are all 
directly relevant to culturing mammalian cells for the production of rPs (e.g. growth factors, 
amino acids, osmolarity, the energy status of the cell, cell stress). With respect to 
recombinant production from mammalian cells, a recent report has shown that the 
manipulation of mTOR simultaneously improved key processes underpinning recombinant 
protein production from CHO cells including cell growth, proliferation, viability and cell 
specific productivity and concluded that mTOR-based engineering of mammalian cell lines 
has a promising future for the improvement of the bioprocessing of biotherapeutic proteins 
(Dreesen & Fussenegger 2011b). As described previously, a further study has also reported 
that in plasma cells (the cellƐƚŚĂƚ ‘ŶĂƚƵƌĂůůǇ ?ƐǇŶƚŚĞƐŝǌĞĂŶĚƐĞĐƌĞƚĞ/Ő'Ɛ ?ƉƌŽƚĞŝŶƐǇ ƚŚĞƐŝƐ
is regulated by crosstalk between endoplasmic reticulum stress and mTOR signalling 
(Goldfinger et al. 2011) .  
This project therefore set out to establish if manipulation of the mTOR signalling pathway 
and/or manipulation of phosphorylation of elongation factor 2 in CHO cells impacts upon 
CHO cell growth and recombinant protein production yields. The specific aims of the 
project were to: 
x To investigate the effects of over expression of elongation factor 2 upon CHO 
cellular growth and recombinant protein production.  
x Observe the effects of eEF2 mutation at the Thr56 residue, changing its regulation 
and the effects of this mutant eEF2 upon CHO cell growth and recombinant protein 
production.  
x Investigate the effect of shRNA silencing of elongation factor 2 kinase upon CHO 
cellular growth metabolism and recombinant protein production.  
x Investigate mTOR signalling within recombinant CHO cells that have different 
recombinant protein production capacity. 
x Investigate the use of small molecule stimulation of mTOR and its effects upon 
recombinant protein production   





Materials and Methods 
 
2.1 General Reagents 
All reagents and materials used throughout the work described in this thesis were of 
analytical grade quality or better unless otherwise stated. All water used was of Milli-Q 
standard. 
 
2.1 Mammalian cell culture  
2.1.1 Cell culture maintenance  
All adherent cell lines were maintained in flat T flasks (T25, T75 and T175; Starstedt) at 37°C 
in a 5% CO2 atmosphere. To passage cells, spent medium was aspirated off and the cells 
washed with sterile phosphate buffered saline (PBS). The PBS was then aspirated off and 
trypsin (Invitrogen) added to detach the cells. Upon the addition of trypsin the cells were 
incubated for 2-5 min at 37°C, 5% CO2. 10 ml of medium was then added to the flask to 
inhibit the trypsin and the desired number of cells/ volume for the seeding of a new flask 
was then added to a new flask which was then immediately placed back into the incubator. 
The adherent CHO lines were maintained in a number of different media as described 
below.  
 
CHO Flp-In variant cell lines were routinely cultured in Ham ?s F12 medium containing 10% 
fetal bovine serum (FBS, Lonza). Every 4
th
 passage, the Parental CHO Flp-In cell lines were 
cultured with 100 µg/ml zeocin (stock 100 mg/ml, Invitrogen), to maintain selection for 
CHO cells that contained the recombinase site within their genome. Stable cell lines that 
had been generated using the CHO Flp-In system, were cultured with 500 µg/ml 
hygromycin (Invitrogen) every 4
th
 passage to maintain the selection for cells containing the 
gene of interest (GOI). All CHO Flp-In cells were cultured with their respective antibiotic 
selection before experimentation to ensure the cells within the culture were expressing 
their relevant GOI.  
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CHOK1 variant cell lines were routinely cultured in DEMEM containing 10% FBS with the 
addition of 15 ml of 200 mM L-glutamine, 5ml of L-glutamic acid + asparagine (6µg/ml of 
both L-glutamic acid and asparagine in ddH2O), 10ml of nucleoside stock (175 mg each of 
adenosine, guanosine, cytidine, uridine and 60 mg of thymidine in 500 ml ddH2O) and 5ml 
of non-essential amino acid solution (Sigma) in a total of 500 mL of medium. All CHO cell 
lines were maintained on a 3/4 day cycle of passage schedule, passaging at 1/50
th
 of the cell 
concentration each passage. 
 
Adherent HEK cells were maintained in DMEM containing 10% FBS and maintained on a 
once a week passage schedule, passaging at ~1/50 each passage. HEK Flp-In cells were 
maintained in the same manor with the addition of 150 µg/ml hygromycin (Invitrogen) 
every 3/4
th
 passage to maintain the selection for cells containing the gene of interest (GOI). 
 
Suspension CHO cell lines were maintained in 125 ml disposable Erlenmeyer flasks (Corning 
Inc), in CD-CHO medium (Invitrogen) containing 25 mM L-methionine sulfoximine (MSX). 
Cells were passaged once a week to a cell concentration of 0.3x10
6
 viable cells/ml (cells 
were counted using a ViCell system (Beckman Coulter) in 10 ml of medium. Cells were then 
gassed with 5% CO2 balanced air for 12 seconds each passage.  
 
2.1.2 Recovery and cryopreservation of cells 
Cryo stocks of all mammalian cells were made and preserved in liquid nitrogen. Cells were 
passaged for a minimum of 3 times in preparation for cyro preservation and cells for 
cryopreservation were taken from mid-exponential phase of growth. Prior to 
cryopreservation, cell cultures were assessed for cell numbers and viability using a 
commercially available ViCell instrument (Beckman Coulter).  Cyropreservation of 1x10
7
 
viable cells/ml/vial in the appropriate medium (the medium the cells were maintained in) 
with 10% v/v DMSO were prepared and aliquot into 1.8 ml cryo-vials (Nunc). Vials were 
then stored in a Cryo 1°C freezing container (NALGENE, 5100-0001) and stored at -80°C 
overnight or at -20°C for 3-5 hours then -80°C overnight. Stocks were then stored in liquid 
nitrogen in a cryostat until required for further use.   
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When reviving cells from cryostorage, one vial of the desired cell line was thawed in a water 
bath at 37
o
C rapidly. The vial contents were then added to 10 ml of the appropriate media, 
the solution centrifuged at 1,000 rpm for 5 min and the supernatant removed.  The cell 
pellet was then resuspended in 10 ml of fresh growth medium and placed in a T25 flask for 
24-48 h at 37
o
C at which time the cells were then inspected under a microscope. Cells were 
then passaged 3 times before any experimentation was undertaken on them.  
 
2.1.3 Counting of cells  
Cells were either counted manually using a haemocytometer for determining cell viability 
and concentration by counting the number of cells in four large squares and then using the 
equation: 
  Ȁ ൌ Ǥ ൈ  ൈ  ? ?ସ  
 
  ൌ Ǥ ൈ  ? ? ?Ǥ   
 
and using the trypan blue exclusion method. Alternatively, cell numbers were determined 
using a ViCell (Beckman Coulter) instrument. 
 
2.1.4 xCELLegence monitoring of adherent cell growth  
Prior to experimentation, mammalian cells were cultured in their appropriate medium with 
the required antibiotic selection. The xCELegence equipment programme for cell culture 
monitoring was prepared according the manufactures protocol. Electronic sweeps of the 
plates were set for every 30 minutes for 168 hours (7 days). 
CHO/HEK cells were then taken from mid-log phase growth and seeded at 3000/5000 viable 
ĐĞůůƐƉĞƌǁĞůůƌĞƐƉĞĐƚŝǀĞůǇŝŶƚŚĞĂƉƉƌŽƉƌŝĂƚĞ ‘-ƉůĂƚĞ ? ?ŵŐĞŶ ?ŝŶƚŚĞĚĞƐŝƌĞĚĐŽŶĚŝƚŝŽŶƐ ?ŝ ?Ğ ?
32°C, 10nM rapamycin. 
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2.1. Generation of stable CHOK1 cell lines with the commercially available Invitrogen Flp-
In system 
 
CHOK1 cell lines expressing exogenous target genes of interest or shRNAs were generated 
using the commercially available CHOK1 Flp-In system essentially as described in the 
manufacturers manual (see Invitrogen Website). This system uses a Flp recombinase to 
insert the gene of interest into a specific loci in the genome. Briefly, CHOK1 Flp-In cells, 
maintained in Ham ?s F12 medium containing 10% v/v FBS and 100 µg/ml zeocin (stock 100 
mg/ml, Invitrogen) were seeded 24 hours before transfection at one T25 flask per 
transfection, at a viable cell concentration of 5x105 cells in a volume of 6.25 ml of medium 
without zeocin. 
 
For transfection of the gene of interest into the CHOK1 cells, 9 µg of the pOG44 vector 
provided with the Flp-In system plus 1 µg of the FRT-cloning plasmid containing the gene of 
interest in the multiple cloning site were prepared in 625 µl of Optimum reagent 
(Invitrogen). In a separate tube, 30 µl of Lipofectamine 2000 transfection reagent 
(Invitrogen) was prepared in 625 µl Optimem. These preparations were then incubated for 
5 minutes before being combined and mixed. The mixed solutions were then incubated for 
a further 20 minutes before adding all of the mixed preparation directly to the T25 flask of 
CHO Flp-In cells prepared 24 h previously as described above.  
  
After the addition of the transfection reagent to the T25 flask, the cells were incubated for 
5.5 hours at 37
o
C, after which time the culture medium was removed, the cells washed with 
10 ml PBS and fresh medium without zeocin added. This process was repeated again 24 
hours post transfection. After a further 24 hours the cells were washed with 10 ml of PBS 
then incubated for 5 mins in 200 µl of trypsin-EDTA (Invitrogen), until the cells had 
detached from the surface of the T25 flask. The detached cells were then diluted into 20 ml 
of Flp-In medium containing 500 µg/ml hygromycin (Invitrogen). Into different wells of a 6 
well tissue culture plate 2 ml per well of this cell suspension was then added and the plates 
put in an incubator at 37°C, 5% CO2. The medium was then changed every 72 hours until 
colonies began to be observed by eye. Once cell colonies were visible by eye, the cell lines 
were either cloned or sub-cultured into T25 flasks and then T75 flasks so that 
cryopreservation of stocks could be performed. At this stage cells were considered ready 
for experimentation and validation of expression of target genes. 
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2.2 Construction, manipulation, transformation, mutation and transfection of DNA and 
RNA 
2.2.1 Generation of cDNA from RNA 
CHOK1 cells were cultured in T175 flasks for 72 hours before being lysed using a RLT lysis 
buffer provided by Qiagen. Total RNA was extracted from the lysate using a QIAGEN 
Shredder and RNease kit. The RNA was then used in a reverse transcriptase reaction 
consisting of 4 µg RNA + 4 µl oligo DT + 7 µl RNAse free water in a 1.5 ml Eppendorf tube, 
and then incubated for 5 minutes at 70°C before being transferred on to ice for 2 minutes. 
Once on ice, 10 µl of 5x MMLV buffer (Promega), 2.6 µl of 10 mM dNTPs, 1.4  µl RNase, 4 µl 
nuclease free water and 2 µl MMLV reverse transcriptase (Promega) was added to the 
reaction and left for 1 hour. The subsequently generated cDNA was then cleaned up using 
the wizard PCR clean-up kit (Promega) and stored at -20 or - ? ? ?ƵŶƚŝl required for use in 
experiments. 
 
2.2.2 RNA extraction from mammalian cells for cloning or PCR amplification of target 
genes 
Adherent CHO cell total RNA lysates were extracted from cells cultured in 6 well plates. 
Extraction of total RNA from mammalian cells was undertaken using the commercially 
available RNease kit and the protocol provided by the manufacturer (Qiagen). The total 
RNA was extracted from the lysate using a QIAGEN Shredder kit and the amount of RNA 
extracted determined by A260 nm measurement. Total RNA was stored at -80°C. 
 
2.2.3 PCR methods  
2.2.3.1 Amplification of target gene sequences  
Primers designed for PCR generation of target genes of interest (GOI) are described in the 
relevant results chapters (see section 3.2.1.1). Genes were amplified from cDNA templates 
and hence are from mature mRNA transcripts and do not include any introns but the open 
reading frame only. UTRs were not amplified. For PCR amplification of target genes the 
Phusion high fidelity DNA polymerase (New England Bioloabs, NEB) was used to amplify 
specific sequences using the primers designed for amplification of the target GOI. Reaction 
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mixes for PCR of the GOI were prepared following the protocol provided with the 
polymerase and as detailed below. 
  
PCR conditions:  
x Initial denaturation step: 98°C, 30 sec.  
x 30-35 cycles:  
o Denaturation: 98°C, 10 sec 
o  Annealing: 60-64°C, 30 sec 
o  Elongation: 72°C, 20 sec/1 kb of DNA 
x 72°C hold, 10 mins  
x final hold 20°C    
 
For a 50 µl reaction PCR reaction:  
x NF water (nuclease free water) to 50 µl (variable)  
x 10 µl 5x  Phusion HF buffer (The default buffer provided for High Fidelity PCR 
reactions) or GC buffer (A buffer to be used with GC-rich templates, of those that 
have secondary structure)  
x 1 µl 10 mM dNTPS  
x 2.5 µl 10 µM forward primer 
x 2.5 µl 10 µM reverse primer  
x 1µg template cDNA  
x 1.5 µl DMSO (optional) 
x 0.5 µl Phusion DNA polymerase 
 
 ? ? ? ? ? ? ? WZ ĐŽůŽŶǇ ƐĐƌĞĞŶŝŶŐ ŽĨ ĐŽŵƉĞƚĞŶƚ , ?ɲ  ?ĐŽůŝ ĐĞůůƐ ƚƌĂŶƐĨŽƌŵĞĚ ǁŝƚŚ Ă
GOI+vector 
GoTaq Polymerase (Promega) was used to screen colonies produced by transformation of a 
GOI PCR product after digestion with the appropriate restriction enzymes and ligation with 
ƚŚĞƚĂƌŐĞƚĂĐĐĞƉƚŽƌƉůĂƐŵŝĚǀĞĐƚŽƌĨŽůůŽǁĞĚďǇƚƌĂŶƐĨŽƌŵĂƚŝŽŶŽĨƚŚĞůŝŐĂƚŝŽŶŝŶƚŽ, ?ɲE. 
coli competent cells. Colonies were picked from the LB agar plates (with the appropriate 
selection antibiotic) using 200 µl sterile pipettes. Part of the colony was suspended in 5 µl 
of NF water for the PCR reaction; the remainder was streaked onto another LB agar plate, 
as a preparation for if the screened colony was positive for the presence of the GOI insert. 
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The PCR parameters and conditions for colony screening for the presence of the correct 
insert/GOI are detailed in table 2.1. The resulting PCR products were analysed by agarose 
electrophoresis to determine if a band of the expected size was present. For PCR colony 
screening universal T7 (taatacgactcactataggg) and BGHR (tagaaggcacagtcgagg) cloning 
primers were used to amplify the desired target sequence. When agarose gel 
electrophoresis confirmed the presence of the desired target insert, the corresponding 
colony was grown in an overnight culture in a liquid LB broth as described in section 2.2.11. 
PCR cycles were set according to the protocol provided with the GoTaq kits used.  The PCR 
conditions were as follows:  
x Initial denaturation step: 94°C, 5 mins  
x 30 cycles:  
o Denaturation: 94°C, 30 sec 
o  Annealing: 50°C, 30 sec 
o  Elongation: 72°C, 1 min/1 kb of DNA 
x 72°C hold, 7 mins 
x  final hold 20°C  
 
Table 2.1 Reaction constituents for PCR colony screens of , ?ɲE. coli cells for the 
presence of the required plasmid and GOI insert 
GoTaq screening   GoTaq Hot start Green Master mix 
25 µl reaction: 
x 5 µl of NF water + colony 
x 7.3 µl NF water 
x 4 µl GoTaq x5 Buffer 
x 1.6 µl 25 mM MgCl2 
x 0.4 µl 10 mM dNTPs 
x 0.8 µl Forward primer (T7) 
x 0.8 µl Reverse primer (BGHR) 
x 0.1 µl Gotaq polymerase 
For a 25µl reaction: 
x 5 µl of NF water + colony 
x 12.5 µl GoTaq master mix x2 
x 1 µl Forward primer 10 µM 
x 1 µl Reverse primer 10 µM 







2.2.4 DNA and RNA quantification 
Quantification of DNA and RNA samples was carried out using a Nano-Drop Spectrometer 
ND-1000. For quantitation, 2 µl of the DNA/RNA solution was dotted into the Nano-Drops 
platform and measured at OD 260 nm. DNA/RNA was then quantified in ng/µl.  
 
2.2.5 DNA and plasmid DNA analysis and separation via gel electrophoresis  
DNA and plasmid DNA samples were analysed and separated using 1% (w/v) agarose/TAE 
gels and 3 µl of SyBR Green per 50 ml of agarose/TAE solution. Samples were suspended in 
6x DNA sample buffer (Promega) and run at 100 V or70 V for 30 mins or 60 mins. DNA 
bands were then visualised using a Transiluminator BioView UV lamp (Biostep) in a Gel logic 
100 imaging system (Kodak). When required, DNA bands were cut from the agarose gel and 
the subjected to a gel clean-up using a commercially available kit to recover the DNA for 
further use. 
 
2.2.6 DNA restriction enzyme digestion 
All DNA digestions were undertaken using Promega or Fermentas restriction enzymes and 
the appropriate buffers as instructed by the manufacturers. Each restriction digest enzyme 
was used with the appropriate restriction site sequence as specified in the results section. 
The primer tables 3.1 and 3.2 show the specific DNA sequences on primers and hence the 
restriction enzymes used for the cloning of each GOI. Digests were undertaken following 









2.2.7 DNA ligation reactions 
Ligation of DNA inserts amplified by PCR was generally achieved using a commercially 
available T4 DNA ligase (Promega) following the protocol provided with the enzyme. The 
exception to this was the ligation of the wild type elongation factor 2 (eEF2) PCR i nto the 
FRT vector. This ligation was undertaken using the T4 ligase and a difference buffer. 
Concentrations of the various components of the buffer were:  
x 132 mM Tris-HCl  
x 20 mM MgCl2  
x 2 mM ATP  
x 2 mM DTT  
x 15% (v/v) PEG 6000  
x Calibrate to pH 7.6 at 25°C  
  
2.2.8 Generation of an shRNA for the knockdown of the kinase eEF2K 
An shRNA for the knockdown/silencing of elongation factor 2 kinase (eEF2K) was 
constructed using the Gene clip U1 hairipin cloning system-Pyromycin  (Promega, C8760), 
following the instructions provided with the kit. Further details on the primer design and 
exact protocol are described in section 4.2.1. 
 
2.2.9 Generation of competent DH5a E.coli cells  
dŽƉƌĞƉĂƌĞĐŽŵƉĞƚĞŶƚ, ?ɲE.coli cells, cells were initially streaked onto and cultured on 
an LB agar plate over night at 37°C. A single colony from the plate was then picked and 
incubated overnight in 2 ml of liquid LB broth in a 15 ml falcon tube at 37°C with orbital 
shaking at 200 rpm. 0.5 ml of this starter culture was then used to inoculate 40 ml of liquid 
LB broth and incubated at 37°C with shaking at 200 rpm, until an OD600 nm of between 0.3-
 ? ? ?ĂďƐŽƌďĂŶĐĞǁĂƐŽďƚĂŝŶĞĚ ?dŚĞ, ?ɲĐĞůůƐǁĞƌĞƚŚĞŶƉ ůůĞƚĞĚ ? ? ? ? ?ŐĨŽƌ ?ŵŝŶƵƚĞƐ ?ĂŶĚ
then resuspended in 20 ml of 50 mM CaCl2 and incubated on ice for 30 minutes. The cells 
were then pelleted again (2500 g for 5 minutes) and resuspended in 4 ml of ice-cold 50 mM 
CaCl2 and incubated on ice for a further 30 minutes. 100 µl aliquots of the cell suspension 
were then placed into sterile 1.8 ml cryo-vials on dry ice. Aliquots of the competent cells 
were then stored at -80
o
C until required.  
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2.2.10 Transformation of competent E.coli cells with plasmid DNA 
 ? ? ?A?ůĂůŝƋƵŽƚƐŽĨĐŽŵƉĞƚĞŶƚ, ?ɲĐĞůůƐǁĞƌe removed from storage at - ? ? ?ĂŶĚƚŚĂǁĞĚ
on ice. Either 1 µg of the required plasmid DNA construct or all of a recently ligated 
ĐŽŶƐƚƌƵĐƚ ?ǁĂƐĂĚĚĞĚ ƚŽĂƐŝŶŐůĞ, ?ɲĂůŝƋƵŽƚĂŶĚŝŶĐƵďĂƚĞĚĨŽƌ  ? ?ŵŝŶƵƚĞƐŽŶ ŝĐĞ ?dŚĞ
, ?ɲĐĞůůƐǁŚĞƌĞƚŚĞŶŚĞĂƚƐŚŽĐŬĞĚŝŶĂ ǁĂƚĞƌďĂƚŚĨŽƌ ? ?ƐĞĐŽŶĚƐĂƚ ? ? ?ĂŶĚƚŚĞŶƌĞ-
ŝŶĐƵďĂƚĞĚŽŶŝĐĞ ?dŚĞĐĞůůƐǁĞƌĞƚŚĞŶŝŶĐƵďĂƚĞĚĨŽƌ ?ŚŽƵƌĂƚ ? ? ?ǁŝƚŚƐŚĂŬŝŶŐĂƚ ? ? ?ƌƉŵ
with 900 µl LB medium added to each aliquot. 100 µl of the culture was then plated on LB 
ampicillin 50 µg/ml plates anĚŝŶĐƵďĂƚĞĚŽǀĞƌŶŝŐŚƚĂƚ ? ? ? ? 
 
2.2.11 Plasmid DNA recovery from E.coli cells 
, ?ɲE.coli cells transformed with DNA constructs were cultured in 6 ml or 250 ml liquid LB 
broth overnight with 50 µg/ml ampicillin antibiotic selection at 37°C with shaking at 200 
ƌƉŵ ? E ǁĂƐ ĞǆƚƌĂĐƚĞĚ ĂŶĚ ƌĞĐŽǀĞƌĞĚ ĨƌŽŵ ƚƌĂŶƐĨŽƌŵĞĚ, ?ɲE.coli cells using the 
commercially available mini prep/high speed maxi prep kits from Qiagen following the 
protocols provided with each kit.  
 
2.2.12 DNA sequencing 
Aliquots of prepared DNA were sequenced using a sequencing service provided by 
Beckman-Coulter.  
 
2.2.13 Site directed mutagenesis of DNA 
Site directed mutagenesis of various DNA sequences described in the results sections of this 
thesis (see sections 3.2.1.1) were achieved using the commercially available QuikChange® 
Lightning Site-Directed Mutagenesis Kit (Aligent Technologies) and the protocol included 
within the kit. Primers for each of the relevant mutations generated are described in the 
relevant results sections (see sections 3.2.1.1 and 3.2.1.2). The presence of the correct 




2.2.14 Transfection of DNA into mammalian cells  
Mammalian cells were seeded as follows for transfection. For experiments in 6 well tissue 
culture plates, 2x10
5
 viable cells in 2.5 ml of media/well; for 24 well tissue culture plates, 
6x10
4
 viable cells in 600 µl of media /well. Cells were seeded into tissue culture plates 24 
hours prior to transfection with the appropriate DNA. For transfection 1-2 µg (6 well plates) 
or 0.8 µg (24 well plates) of DNA was suspended in 250 µl or 50 µl of Optimen (invitrogen) 
respectively whilst in a separate tube 12 µl of the commercially available lipofectamine 
2000 transfection reagent in 250 µl or 50 µl of Optimen was prepared per well. Both tubes 
were then incubated for 5 minutes at room temperature before  the contents of each tube 
were mixed together and incubated for a further 20 minutes. 500 µl (6 well plates) or 100 µl 
(24 well plates) of the resulting solution was then added to each well and incubated at 37°C 
or 32°C, dependent upon the experiment, for the period of time required before cells or 
supernatants (or both) were harvested for analysis.  
 
2.2.15 Quantitative PCR analysis (qRT-PCR) of target mRNA amounts 
2.2.15.1 qRT-PCR analysis of eEF2 and eEF2K mRNA amounts 
qRT-PCR analysis to determine the relative amounts of target mRNAs (relative to a house 
ŬĞĞƉŝŶŐ ŵZE ? ɴ-actin that was assumed not to change between samples) between 
samples was undertaken using the commercially available iScript
TM
 One-Step RT-PCR Kit 
with SYBR
®
 Green Kit (BioRad) and a Eppendorf Realplex master cycler instrument. RNA 
samples were diluted to a concentration of 25 ng/µl in sterile nuclease free water (sNF). 
Separate master mixes (25 µl per a reaction) for each experimental and housekeeping gene 
primer pairs were prepared on ice under sterile conditions following the dilutions described 












Reagent Volume per reaction (µl) 
sNF 8.5 
2x SYBR Green 12.5 
Forward primer (10 µM) 0.75 
Reverse primer (10 µM) 0.75 
Reverse transcriptase 0.5 
Template RNA  2 
 
25 µl per a reaction of the master mixes were the pipetted into a Bio-Rad 96-well optical 
plate on ice. The plate was then sealed and placed in the Eppendorf Realplex master cycler 
(Thermocycler) and the following program used: 
x 50°C for 10 minutes 
x 95°C for 5 minutes 
x 40 cycles of  
o 95°C for 10 seconds 
o 55°C for 30 seconds, SYBR emission reading 
x 95°C for 15 seconds  
x 55°C for 15 seconds 
x Melting curve: 55°C to 95°C with 0.5°C 
x 95°C for 15 seconds 
The Eppendorf instrument excites the fluorescent dye used and the software calculates 
ǁŚĞŶƚŚĞ ĨůƵŽƌĞƐĐĞŶĐĞ ƌĞĂĐŚĞƐ ƚŚĞĐƌŝƚŝĐĂů ƚŚƌĞƐŚŽůĚ ? I ? ? dŚĞ IǀĂůƵĞ ŝƐƚŚĂƚǁŚĞŶƚŚĞ
ĨůƵŽƌĞƐĐĞŶĐĞ ďĞĐŽŵĞƐ ĚĞƚĞĐƚĂďůĞ ĂďŽǀĞ ƚŚĞ ďĂĐŬŐƌŽƵŶĚ ?  dŚĞ  I ǀĂůƵĞ ŝƐ ŝŶǀĞƌƐĞůǇ 
proportional to the logarithm of the initial copies of template DNA (Livak & Schmittgen 
2001) ?  ĂůĐƵůĂƚŝŽŶƐ ƵƐŝŶŐ ƚŚĞ  I ǀĂůƵĞƐ ŽĨ ƚŚĞ ƐĂŵƉůĞ ǁĞƌĞ ŶŽƌŵĂůŝƐĞĚ ƚŽ ƚŚĂƚ ŽĨ ƚŚĞ
ŚŽƵƐĞŬĞĞƉŝŶŐŐĞŶĞ ?ƚŚĞĞŶĚŽŐĞŶŽƵƐĐŽŶƚƌŽů ?ɴ-actin.  This comparative method follows the 
ĐŽŵƉĂƌĂƚŝǀĞ IŵĞƚŚŽĚĞƋƵĂƚŝŽŶƐŚŽǁŶďĞůŽǁ P 
   Relative Expression = 2
-A?A?  I 
 
Table 2.2 Reaction mixture volumes for qRT-PCR analysis 
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2.2.15.2 Qiagen RT2 Profiler PCR Array Mouse mTOR Signalling plates and analysis 
cDNA from samples for analysis was prepared for the PCR array using a Qiagen RT2 First 
Strand Kit from CHO Flp-In RNA lysates. The cDNA and RT2 SYBR Green ROX qPCR 
Mastermix (Qiagen) was then added to the commercially available array plate (Catalogue 
number PAMM-098Z) in accordance with the protocol provided with the array. The Plates 
were then run in an Eppendorf Realplex master cycler (Thermocylcer) in accordance with 
the protocol provided with the kit. Analysis of the resulting data was undertaken using the 
Excel spread sheet provided by the manufacturer. The outputs of this are provided in 
Appendix 7.6.2. 
 
2.3 Protein extraction and analysis protocols 
2.3.1 Preparation of total protein cell lysates from cultured mammalian cells  
2.3.1.1 Lysis buffer preparation  
Mammalian cells were lysed in a buffer consisting of 200 mM HEPES-NaOH pH7.2, 100 mM 
NaCl, 1% v/v TX 100 and 10 mM Na-ɴ-glycerophopate. Before use a complete mini, EDTA-
free protease inhibitor tablet (Roche) was added to 10 ml of the lysis buffer as well as 50 
mM NaF and 1 mM NaV (Na-Vanidate) (New England Biolabs). 
 
2.3.1.2 Protein extraction  
Protein from cells cultured in 6 well plates were extracted by washing the cells in 1 ml of 
PBS for each well and then the cells were incubated in 200 µl of cell lysis buffer per well on 
ice for 5 minutes. The wells were then scraped and the contents put into a sterile 1.5 ml 
Eppendorf tube. An additional 200 µl cell lysis buffer per well was used to wash each well 
and this was then collected and placed into the corresponding Eppendorf tube so that a 
combined 400 µl of cell lysate was collected per 6-well plate. 
 
2.3.2 Bradford assay quantification of protein concentration in cell lysates 
Protein quantification of cell lysates was determined using a Bradford assay with each 
lysate being measured in duplicate. Cell lysates were centrifuged for 1 minute at 13000 rpm 
and then kept on ice. 5 µl of lysate was then diluted in 45 µl with ddH2O and then 1 ml of 
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Bradford reagent (BioRad) was added to the solution. The Bradford solution was then 
mixed and incubated for 10 minutes. The total protein was then quantified by reading the 
absorption of the solution at a wavelength of 600 nm using an Eppendorf BioPhotometer. 
The concentration of protein in each lysate was then calculated by comparison to a 
standard curve generated using known amounts of bovine serum albumin (BSA). 
 
2.3.3 SDS-PAGE analysis of protein extracts 
Tris-glycine SDS-polyacrylamide gels were routinely used for protein analysis. SDS page gels 
were prepared using: www.changbioscience.com/calculator/sdspc.htm for dilution 
calculations; 30% 29:1 polyacrylamide (BioRad), ammonium persulphate and 
tetramethylelthylenediaine (TEMED), all sourced from BioRad. SDS gels were prepared in 
Novex 1 mm gel cassettes (Invitrogen).  
 
Protein lysate samples for analysis were diluted in NuPAGE LDS sample buffer x4 
(Invitrogen) to the volume appropriate for the well size used or concentration of protein 
required (typically 5-20 µg/well) and number of runs per sample (well volume (µl) x  number 
of runs = total volume of sample). Prior to loading, samples were boiled for 5 minutes at 85-
95
o
C, then loaded into the SDS gel for analysis. Gels were assembled in a Novex mini cell 
tank (Invitrogen) and loaded with the prepared samples and electrophoresis undertaken at 
125 V for 1 hour and 30 minutes or until the dye front of the samples had reached the 
bottom of the gel.  Gels were extracted from the gel cassettes and either stained with 
Coomassie blue R-250 for 20-60 minutes and then destained until protein bands were 
visualised or prepared for transfer onto nitrocellulose for western blot analysis. 
 
2.3.4 Western blot analysis of proteins 
Proteins separated by SDS-PAGE were transferred to 0.45 µm nitrocellulose blotting 
membrane (Amersham Hybond ECL) via electrophoresis using a TE series transfer 
electrophoresis unit (Hoefer) for 1 hour at 4
o
C. After transfer, the blots were incubated in 
20-30 ml of blocking buffer (5% powdered milk (Marvel) in TBST) for 30 minutes-1 hour. 
Blots were then washed in 0.1% TBST three times for 5 minutes per wash, then incubated 
overnight in a 10 ml dilution of the appropriate primary antibody prepared in 3% BSA-TBS. 
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After overnight incubation, the blots were washed 3 times with 0.1% TBST for 10 minutes, 
and then incubated in the appropriate secondary antibody dilution in blocking buffer for 1 
hour. Blots were then washed again 3 times with 0.1% TBST for 10 minutes, and incubated 
for 5 minutes in ECL western blotting detection reagents (Amersham), following the 
instructions provided with the reagents by the manufacturer. The blots were then exposed 
to High performance chemiluminecsese film (Amersham Hyperfilm ECL), which was 
subsequently processed using a Compact X4 processor (Xograph imaging systems). 
 
2.3.5 Luciferase assays 
Mammalian cell cultures were prepared for firefly luciferase assays in 6 or 24 well plates 
seeded as follows; 6 well plates: 2x10
5
 viable cells in 2.5 ml of media per well, 24 well 
plates: 6x10
4
 viable cells in 600 µl of media per well. Cells were washed with warm (37°C) 
PBS then incubated for 5 minutes in 200 µl of luciferase lysis buffer (LLB) (500 µl PBS A [348 
mM Na2HPO4, 70 mM NaH2PO4], 500 µl PBS B [18 mM CaCl2ඵ2H2O, 70 mM KCl, 18 mM 
MgSO4ඵ6H2O, 2740 mM NaCl] , 0.1% v/v Triton X, 8 ml ddH2O, 1 mini-complete EDTA-free 
tablet (Roche)) for 5 minutes and lysates then scraped and collected into sterile 1.5 ml 
Eppendorf tubes. Samples could then be stored at -80°C. Lysate total protein concentration 
was then quantified using a Bradford assay. The luciferase assay was undertaken using 75 µl 
of lysate in a 96 well flat bottom white polystyrene plate (Optiplate) and 75µl of steady lite 
reagent provided with the kit (Prepared according to instructions provided with the kit, 
PerkinElmer). The plate was incubated for 10-15 minutes at room temperature, then light 
was measured as light counts per a second using a FLUOomega plate reader (BMG Labtech). 
 
Luciferase assays were also undertaken using the steady lite kit directly on cells in a 24 well 
plate. For these assays, cells were washed with 1 ml of warm PBS (37°C), then 200 µl steady 
lite solution added directly onto cells and incubated for 15 minutes. Two aliquots of 100 µl 
of each lysate was added to a 96 well plate and light was measured as light counts per a 




2.3.6 Florescence imaging of live cells expressing FRET 
For live cell imaging, mammalian cells were seeded into glass bottom petri dishes, with 
cover slides that have a collagen coating (MatTek, part number P35GCol-10-14-C), at 
2.5x10
5
 viable cells in 2.5 ml of media per dish. Cells were left overnight to adhere, then 
transfected with the appropriate GOI using the same transfection protocol as described for 
6 well plate transfections. The plates were then incubated for 24 hours then imaged using a 
temperature controlled LEICA DMIRE2 confocal microscope (TCSSP2 AOBS). 
 
2.3.7 Immunoflorescence imaging of fixed CHO cells  
For immunofluorescence imaging of cells, prior to seeding cells before transfection, cover 
slides were sterilised and placed 1 per well in 24 well plates. Cells were then seeded at 
6x10
4
 viable cells per well and incubated for 24 hours. 0.8 µg of the selected DNA plasmid 
was then added per well in triplicate wells using the 24 well plate transfection protocol 
described above and incubated for 24 hours. Cells were then prepared according to the 
following protocol: 
Methanol (MeOH) fixing of cells 
Cells were required to be fixed to the cover slips within each well:  
x Siphon media from wells 
x Wash the cells with 1 ml warm PBS (37°C) 
x Siphon off PBS  
x Add 1 ml MeOH (-20°C)  
x Incubate the plate for 5 minutes on ice 
x Siphon off MeOH and air dry (about 5 minutes) 
x Keep plates at 4°C (for up to 1 week) 
  
Antibody probing of the cover slides 
Once the cells were fixed to the cover slides, the slides were probed using antibodies to 
visualise specific targets. This was achieved using the following protocol: 
x MeOH fixed cells were rehydrated with 1 ml of PBS (room temperature, RT) for 5min 
x PBS was then siphoned off 
x The cover slips were then incubated with 250 µl blocking buffer (3% w/v BSA in PBS) 
per well for 15 minutes at RT 
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x 25 µl droplets of 1° antibody (diluted 1:500, anti-v5 (Sigma) or anti-eEF2) in 3% w/v 
BSA were placed on a sheet of parafilm in a ĚĂŵƉďŽǆĂŶĚƚŚĞƐůŝĚĞƐĂƉƉůŝĞĚ ‘ĐĞůůƐŝĚĞ ?
down. The slides were incubated overnight at 4°C in the damp box. 
x 4 sets of 100 µl  PBS with 0.1% Tween wash droplets were prepared on sheets of 
parafilm.  
x Cover slips were then transferred from the damp box to the 1st wash droplet (being 
dipped in PBS and 0.1% v/v Tween between 1st antibody and 1st wash droplet). The 
ĐŽǀĞƌƐůŝƉƐǁĞƌĞƚŚĞŶƚƌĂŶƐĨĞƌƌĞĚ ‘ĐĞůůƐŝĚĞĚŽǁŶ ?ƚŚƌŽƵŐŚƚŚĞǁĂƐŚĚƌŽƉůĞƚƐ ?ĂůůŽǁŝŶŐ
5 minutes per wash. 
x Whilst the cover slips were on the 1st droplet the 2° antibody was prepared: FITC and 
TRITC antibodies (Sigma) were diluted 1:100  in 3% w/v BSA dilutions prepared in 
light protected Eppendorf tubes and centrifuged (10 minutes, 13000 rpm) to remove 
ĂŐŐƌĞŐĂƚĞƐ ?ƚŚĞ ‘ƐƵƉĞƌŶĂƚĂŶƚ ?ǁĂƐƚŚĞŶƚƌĂŶƐĨĞƌred to a fresh light protected tube. 
x 25 µl droplets of 2° antibody were then aliquoted on to parafilm in a light protected 
damp box. Cover slips were transferred cells side down onto the 2° antibody droplets; 
blotting off any excess liquid from previous washes. 
x The cover slips were then incubated in the dark for 2 hour at RT 
x The cover slips were then washed again in 100 µl PBS with 0.1% Tween as they were 
after incubation with the 1° antibody.  
 
Nuclear staining of DNA 
x 25 µl droplets of DAPI (10 mg/ml) were prepared on parafilm in a light protected box. 
x Cover slips were then placed cell side down on the DAPI droplets and incubated for 1 
minute. 
x Cover slips were then washed twice for 10 minutes in 100 µl PBS droplets, prepared 
on parafilm.   
 
Anti-fading and preparation of slides for imaging 
x During the washing process, either after incubation of 2° antibody or post staining 
with DAPI, 900 µl of Mowiol was mixed with with 100 µl of phendinediamine. 
x 5 µl of  the Mowiol/Phendinediamine mixture was then dripped on to a microscope 
slide and the cover slip applied on top of the 5 µl cell side down.  




Slide preparation for imaging 
x The edges around cover slips were sealed with clear nail  varnish and the top of the 
cover slip washed with ddH2O and a cotton bud. 
x Cells were then imaged on a LEICA LEITZ DMRD or a LEICA DMIRE2 confocal 
microscope (TCSSP2 AOBS). 





Excitation wavelength (nm) Emission wavelength (nm)  
340-380 (Blue) LP 425 (Blue) 
450-490 (Blue) LP 515 (Green) 
515-560 (Green) LP 590 (Red) 
 
2.3.8 ELISA assays 
 
ELISA Buffers 
The following buffers were prepared and used for ELISA assays. 
x Coating buffer: 0.8 g Na2CO3, 1.47 g NaHCO3 in 500 ml water. Calibrate to pH 9.7  
x Block solution: 1.59 g Na2CO3, 2.93 g NaHCO3 in 1 litre water. Before use dissolve 
1.0 g casein to 200 ml in block solution overnight. 
Wash buffer: 5.84 g NaCl, 1.15 g Na2HPO4, 0.29 g NaH2PO4.H2
Tween-20, 10 ml L-butanol in 1 litre water. Calibrate to pH 7.2  
x Sample buffer: 12.1 g Tris-HCl, 5.84 g NaCl, 200 µl Tween-20, in 1 litre water. 
Calibrate to pH 7.0  
x Substrate buffe: 8.2 g Na acetate in 1 litre water. Calibrate to pH 5.0 (1 M citric 
acid)  
 




ELISA IgG standards preparation  
5 µl Human IgG (Human IgG reagent grade, 10 mg/ml, Sigma) in 5 ml sample buffer was 
prepared. Then 25 µl of the preparation was diluted in 975 µl of sample buffer. Seven serial 
dilutions were then prepared to provide a standard curve ranging from 250 ng/ml  to 3.9 
ng/ml of IgG. 
 
ELISA Protocol 
Prior to plating of samples, 96 well plates (Nunc) were coated with 100 µl/well AffiniPure 
& ?Ăď ? ? ? &ƌĂŐŵĞŶƚ 'ŽĂƚ Ŷƚŝ-Human IgG Fc fragment specific (minimal cross-reaction to 
Bovine, Horse, Mouse serum proteins) (Jackson Immune Research). The plates were stored 
in light protected conditions at 4°C overnight. Samples were then serial diluted using 
sample buffer and stored at 4°C. When required, the plates were washed twice with excess 
amounts of the wash buffer and the following steps were then taken to prepare the 
sample:  
(Note, between each step the plates were washed twice with excess amounts of the wash 
buffer)  
1. 200 µl per well of blocking solution was placed in each well for 1 hour with shaking 
at room temperature (RT).  
2. 100 µl per well of sample/IgG standard was then added per well with shaking at RT 
for 1 hour. 
3. 100 µl per well of secondary antibody solution (Anti-human kappa light chain 
(bound and free) HRP conjugate raised in goat (Sigma) diluted 1:10 000 in wash 
buffer) per well was then added for one hour with shaking and at room 
temperature (RT). 
4. 100 µl per well of TMB (Sigma) substrate per well was then added. 
 
The samples and standards would turn blue. Once the standards had developed to an 
appropriate depth of blue colour, 50 µl per well of 2.5 M H2SO4 was added, and the colour 
changed to yellow. The plate OD was then read at 450 nm using a jBio 96 well plate reader. 
The concentration of samples was then determined from the standard curve from the 




Manipulation of Translation Elongation Factor 2 (eEF2) and 
the Effect on Recombinant Protein Expression from Chinese 
Hamster Ovary (CHO) Cells 
 
3.1 Introduction 
Studies on elongation factor 2 (eEF2) have shown that it is a key regulator of translation 
and polypeptide synthesis, specifically of polypeptide elongation, and that increasing the 
activity and/or the level of eEF2 increases cellular protein production and growth, as well as 
the up regulation of eEF2 has been implicated in cancer (Nakamura et al. 2009), indicating 
that an increase in eEF2 activity results in an increase in cellular proliferation and global 
protein production.  
Elongation factor 2 kinase (eEF2K) is the only known regulator of eEF2 protein, which 
phosphorylates eEF2 on the Thr56 residue of the protein (Kaul et al. 2011). Phosphorylation 
of eEF2 results in its inactivation; slowing or halting elongation and hence attenuating 
protein synthesis. Activation of eEF2K and the subsequent phosphorylation of eEF2 is 
regulated by a number of mechanisms, but particularly via the mTOR (mammalian target of 
rapamycin) signalling pathway. Of the two mTOR complexes mTORC1 is responsible for 
eEF2K regulation via S6K1.  
This chapter describes investigations into the manipulation by over-expression and 
mutation of eEF2 in Chinese hamster ovary (CHO) cells and the effects this has upon cellular 
growth and recombinant protein production. Through the construction and profiling of 
stable (CHO) cell lines over expressing eEF2 and mutated variants: Thr56Ala and Thr56Glu it 
was possible to investigate the effect of eEF2/amount/activity and regulation upon cellular 






3.2.1 Transient Expression of eEF2 in CHO Cells 
The initial investigations into the role or effect of translation elongation factor 2 (eEF2) in 
regulating recombinant protein production from cultured CHO cells was undertaken by 
transiently over-expressing either human of Chinese hamster eEF2 in CHO cells. In order to 
undertake such studies it was first necessary to generate mammalian expression vectors for 
the over-expression of CHO or human eEF2.  
 
3.2.1.1 Construction of eEF2 Mammalian Expression Vectors 
The initial step to clone the eEF2 gene was to identify the sequence using the NCBI 
database. The sequence for both human (NCBI accession number AY942181) and Chinese 
hamster (NCBI accession number M13708) eEF2 were retrieved and sequence alignment 
revealed that the sequences had 99.2% homology at the amino acid level and therefore are 
likely to be functionally interchangeable. At the nucleotide level the homology was much 
less at 87.3% (Appendix 7.1 & 7.2). At this stage it was anticipated that studies might be 
undertaken in both human (HEK/HELA) cells and CHO cells and hence both human and 
Chinese hamster eEF2 sequences were cloned. As these are 99% homologous at the amino 
ĂĐŝĚůĞǀĞůǁĞŵŝŐŚƚĞǆƉĞĐƚƚŚĞƐĞƚŽ ‘ďĞŚĂǀĞ ?ŝŶĂƐŝŵŝůĂƌŵĂŶŶĞƌǁŚĞŶĞǆƉƌĞƐƐĞĚŝŶ,K
cells. The human sequence was obtained by isolating total RNA from HELA cells, the 
Chinese hamster from total RNA extracted from CHO cells and then cDNA generated from 
this material by a reverse transcriptase reaction. The eEF2 sequence was then amplified 
from the resulting cDNA by PCR using the primers described in table 3.1. The primers were 
designed to allow cloning into the commercially available pcDNA3.1 expression vector. The 
PCR product was then ligated into the commercially available pcDNA3.1V5tag (Appe ndix 
7.3) mammalian expression vector after digestion of the vector and the PCR insert with the 
appropriate restriction enzymes. Following transformation into competent E.coli cells the 
presence of the insert was confirmed by colony PCR screening (Figure 3.1). Finally, the 
correct sequence of the wild-type eEF2 (WT eEF2) was confirmed by DNA sequencing using 




Using the Chinese hamster wild-type eEF2 construct, a number of mutants were then 
constructed. Control of the activity of eEF2 has been shown to be switched on and off by 
phosphorylation of threonine residue 56 (Thr56) (Kaul et al. 2011) as outlined in the 
introduction to this thesis. The usual approach to mutate such threonine (or indeed serine) 
residues that may be phosphorylated to prevent this is to mutate these to alanine (Ala) 
residues (Browne & Proud 2004; Pavur et al. 2000). Such residues may also be mutated to a 
glutamic acid (Glu) in order to try and mimic a phosphorylated threonine residue. The Ala 
mutates eEF2 in such a way that it cannot be phosphorylated at Thr56 and hence is always 
ŝŶƚŚĞ ‘ŽŶ ?ƐƚĂƚĞĂŶĚƚŚĞŵŝŵŝĐƐŽĨĂƉĞƌŵĂŶĞŶƚƉŚŽƐƉŚŽƌǇůĂƚĞĚdŚƌ ? ?ƌĞƐŝĚƵĞ ?'ůƵ ?ƚŚĂƚ
Ğ& ?ĂƉƉĞĂƌƐ ƚŽ ƚŚĞĐĞůů ƚŽĂůǁĂǇƐďĞŝŶ ƚŚĞ  ‘ŽĨĨ ? ƐƚĂƚĞ ?dŚŝƐŝƐďĞĐĂƵƐĞ the glutamic acid 
residue has a negative side chain, therefore acts as if it is already phosphorylated. To 
generate these mutants here, the commercially available Quik Change kit (Qiagen) was 
used along with the primers descried in table 3.1 to mutate the Threonine 56 amino acid to 
an alanine (Ala56 eEF2) or glutamic acid (Glu56 eEF2) residue. The Thr56Ala mutant was 
thus generated in the Ppc3.1V5 plasmid backbone and the Thr56Glu in in the FRT plasmid 
backbone. The only difference between these was the single amino acid change compared 
to the wild type eEF2, this being confirmed by sequencing of the resulting construct. Using 
these two mutants and the wild type eEF2 it was then possible to begin investigating the 




































Table 3.1 Primers used to clone, sub-clone and mutate human and Chinese hamster elongation factor 2 
(eEF2) sequences.  eEF2 sequences for cloning into pc.1V5 were primed from human and Chinese 
hamster cDNA generated from HELA and Chinese hamster ovary cells (CHO) respectively. The Thr56Ala 
point mutation was achieved using the pc3.1V5 with an inserted CHO eEF2 wild type sequence, to 
generate an eEF2 Thr56Ala mutant inserted in the PC3.1V5 vector. 
For insertion of eEF2 into FRT, the Chinese hamster eEF2 sequences were sub cloned from the pc3.1 + 
eEF2 vectors, with and without the V5 tag, using the primers described in the FRT se ction of the table. 
Point mutation of Thr56Glu was achieved using the FRT + eEF2 wild type vector once it was constructed.  
PC3.1V5 
Forward Primers 
Hela BamH1 forward: tatggatcccactatggtgaacttcacggtagacc 
CHO NotI: tatgcggccgctgagaatccgtcgccaatg 
Reverse Primers 
Hela XhoI reverse Stop: atactcgagctacagtttgtccaggaagttgtcc 
Hela XhoI reverse V5: atactcgagtacagtttgtccaggaagttgtcc 
CHO XbaI stop: atatctagaacggatattctacagtttgtccaggaagttgtcc 
CHO XbaI V5: atatctagaacggatatttacagtttgtccaggaagttgtcc 
THr56Ala mutation primers 
CHO Ala56 sense ggtgagacacgcttcgccgacacccgcaaggacgaacag 
CHO Ala56 anti-sense ctgttcgtccttgcgggtgtcggcgaagcgtgtctcacc 
FRT 
Forward Primers  
 Stop Forward Kpn1 tatggtacctgagaatccgtcgccaatg 
V5 Forwards Pme1 tatgtttaaactgagaatccgtcgccaatggtg 
Reverse Primers 
 Stop Reverse Not1 atagcggccgcacggatattctacagtttgtccaggaagttgtcc  
V5 Reverse Pme1 ctgatcagcgggtttaaactcaatggtgatg 
Thr56Glu mutation  
Forwards ggtgagacacgcttcgaggacacccgcaaggacgaacag  

















































Figure 3.1 (a)(b) PCR colony screens of competent E.coli cells transformed with 
pc3.1V5 ligated with either (a) human or (b) Chinese hamster elongation factor 2, 





Initially, after the construction of the  FRT eEF2 V5 vactor, the C-terminal V5 reporter tag 
was found to not be expressed I.e. not giving a signal on blots or in immunoflorescences 
experiments when probed for using antibodies specific for the V5 tag. Therefore the V5 tag 
was attached to the N- terminus of eEF2, to determine if the physical location of the V5 tag 
was effecting its expression. Elongation factor 2 was therefore cloned into an FRT vector 
with a N-terminal V5 tag using the primers shown in table 3.2.  
 
Sequencing of the NV5 FRT eEF2 wild type vector was confirmed using commercial 
sequencing. Later it was found that both the NV5 and CV5 tagged eEF2 had an unexpected 
error within their sequencing. Within the CV5 tagged eEF2 the sequence between the 
deleted stop codon at the end of the eEF2 sequence   and the V5 tag had another stop 
codon inserted during cloning, preventing the expression of the V5 tag. In the NV5 FRT eEF2 
vector, the sequence between the N-V5 tag and the start of eEF2 was out of frame by one 
nucleotide preventing the translation of eEF2 with an N-terminal V5 tag. To remedy these 
problems, the Quik Change lighting mutagenesis kit and primers  (Table 3.2) was used on 
ƚŚĞs ?ƐƚŽƉĐŽĚŽŶŵƵƚĂƚĞĚƚŽĂ ‘ŶŽŶ-ƐƚŽƉ ?ĐŽĚŽŶ ?ĂŶĚĂƐŝŶŐůĞŶƵĐůĞŽƚŝĚĞĚĞůĞƚŝŽŶǁŝƚŚŝŶ
the sequence between the NV5 and the eEF2 sequence allowed for the expression of eEF2 
















CV5 Fwd ggacaacttcctggacaaactgtacatatccgttctagagggc 
Rev gccctctagaacggatatgtacagtttgtccaggaagttgtcc 
NV5 Fwd cgattctacgcgtaccgtcactatggtgaacttcacggtagacc 
Rev ggtctaccgtgaagttcaccatagtgacggtacgcgtagaatcg 
 
Table 3.2  Primers used for construction and mutation of FRT vectors for expression of eEF2 
with  either an N-terminal or a C-terminal tagged elongation factor 2.   
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3.2.1.2 Investigating the Effect of Transient eEF2 Over-Expression in CHO Cells 
The constructs generated in section 3.2.1.1 above were used to transiently over-express 
eEF2 or the mutants in a model CHOK1 system. As described above, the constructs were 
generated in a vector with a read through the stop codon to a V5 tag on the C-terminal end. 
This allows detection of the recombinant material from the construct but not the 
endogenous material by using an anti-V5 antibody. Initially the human WT, eEF2 construct 
was transfected into the CHOK1 cells to check that expression of the recombinant eEF2 
could be achieved; cell lysates were collected 24 and 48 h post-transfection. The resulting 
lysates were then analysed by SDS-PAGE and subsequent western blot analysis using an 
anti-V5 antibody undertaken and are shown in Figure 3.3 below.  
 
 
Figure 3.3 SDS-PAGE and western blot analysis of CHOK1 cells following transfection with 
wild-type eEF2 with a C-terminal V5-tag 24 and 48 h post-transfection. Vector = control 
empty vector, gene = eEF2 V5 tagged wild-type containing construct, (-) = not transfected, 
(+) = transfected. The left hand image shows a Coomassie blue stained image of all samples 
loaded, the right-hand image shows the western blot with the anti-V5 antibody. 
 
The Coomassie stain of the cell lysates showed very similar banding patterns and protein 
content across the lanes (Figure 3.3) confirming that equal protein load was used from the 
different samples. The fact that there were no obvious differences in the banding pattern 
suggests that the transfection of the cells and over-expression of WT eEF2 did not 
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detrimentally affect the cells. The western blot analysis confirmed the recombinant 
expression of human wild-type eEF2 at 24 and 48 h respectively (Fig 3.3). A band of the 
expected size was observed at ~100 kDa at both the 24 and 48 h time points; however at 
the 48 h time point there was also a much higher band in the gel suggesting the presence of 
aggregate eEF2. In both lanes there was a band the size of a dimer that was more intense in 
the 48 h sample (Fig 3.3). These data confirm the over-expression of eEF2 but that as time 
progresses aggregate dimer and aggregate material appears to form. 
 
Eventually the Chinese hamster sequence was inserted into the pc3.1V5 vector (Figure 
3.1b), and the Thr56 residue mutated to Ala56 using the Quik change kit (Aligent) and 
primers described in table 3.1. The pc3.1V5 CHO eEF2 wild type and Ala56 mutant were 
then transfected into CHOK1 adherent cells, cell lysates were collected 24 and 48 hours 
post transfection and analysis via western blotting for total and phosphorylated eEF2 
undertaken (Figure3.4). Consistent loading of the SDS-gels for the western blotting analysis 
was achieved using a Bradford assay to confirm equal amounts of protein were loaded. The 
analysis showed no change in total levels of eEF2 over 48 hours between the control cells 
and those transfected with the eEF2 WT and Ala56 mutant. The levels of phosphorylation 
after 24 hours of the Ala56 mutant transfected samples appeared to be slightly reduced 
compared to the plasmid control and the wild type samples, but after 48 hours the levels of 
phosphorylation appear to be uniform across all of the samples.   
 
The initial decrease in phosphorylation of eEF2 after 24 hours post transfection could be 
due to stress imposed upon the cell by the transfection reagents; or as the phosphorylation 
levels are only decreased in the samples that were transfected with eEF2, it is possible that 
over expression of eEF2 causes a reduction in phosphorylation of both the endogenous and 
exogenous eEF2. However, this reduction in phosphorylation in the Ala56 samples suggests 
that the Ala56 mutant is effective at reducing the phosphorylation of eEF2; and that the 
CHO eEF2 is being expressed as a monomer at the correct size. The over expression of the 
pc3.1 V5 CHO eEF2 WT and Ala56 mutant appears to be short lived, only lasting around 24-















In addition to confirming expression of the human wild-type eEF2 by Western analysis, 
immunofluorescence was also undertaken using the anti -V5 antibody to detect the 
recombinant eEF2 and DAPI staining to visualise the nucleus (Figure 3.5). As expected, for 
the control and empty plasmid samples no recombinant eEF2 was detected using the anti-
V5 antibody. However, where the pcDNA3.1V5 tagged wild-type eEF2 construct was 
transfected into CHOK1 cells eEF2 was detected (Figure 3.5). The immunofluorescence 
analysis showed the eEF2 to be present in the cytosol as expected and the transfection 
efficiency or number of cells expressing eEF2 24 hour post-transfection was approximately 
20-30% (see Figure 3.5 for example). There was no direct evidence of aggregates in these 
images although it would be difficult to tell this from these images and the previous 





24 h 48 h




Figure 3.4 Western blot analysis of CHOK1 cells transfected with 2µg PC3.1V5 CHO eEF2 
wild type or PC3.1V5 CHO eEF2 Ala56 mutant, 24 and 48 hours post transfection. Cn= 
control lysates, P= empty PC3.1V5 vector, WT= PC3.1V5 CHO eEF2 wild type, ALA= 
PC3.1V5 CHO eEF2 Ala56 mutant.  
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Figure 3.5 Immunofluorescence of CHOK1 cells 24 h post-translation with the human wild-
type V5-tagged eEF2 construct. Blue = DAPI stain for nucleus, Red = V5 antibody stain. 
Control = transfection agents only transfected (no DNA), Plasmid = empty pcDNA3.1 
plasmid with no gene sequence, Gene = eEF2 wild-type containing pcDNA3.1V5 construct. 
Combined shows an overlay of the V5 and DAPI stains. 
 
Although the cellular protein composition did not appear to change upon transfection and 
expression of human wild-type eEF2 (see Figure 3.4 above), a longer time period was 
investigated post-transfection to determine if there was any effect on cellular growth in the 
transient transfections over a 96 hour period. These studies showed that there was no 
change in the cellular growth or viability profiles when CHOK1 cells were transfected with 
the wild-type human eEF2 construct (Figure 3.6). Both the control and eEF2 WT constructs 
when transfected gave comparable growth profiles suggesting that the expression of the 
exogenous V5-tagged eEF2 (in 20-30% of cells) was not detrimental to the cells, even if 




Figure 3.6 Growth profiling of CHOK1 cells transiently transfected with 2µg of pcDNA3.1V5 
human eEF2 (insert) (red) or the empty pcDNA3.1V5 vector (control) (blue). n=2  
 
The growth profile experiment was then also repeated with the CHO derived wild-type eEF2 
and CHO eEF2 Ala56 mutant to determine if the inability to phosphorylate the exogenous 
eEF2 in transfected cells influenced the cell growth or viability. Again, the expression of the 
eEF2 Ala56 mutant did not appear to have any adverse effect upon the cellular growth or 
viability of the CHOK1 cells (Figure 3.7). This may be due to the cellular transfection rate 
being too low to have a significant impact, that the transfected cells compensate for the 
additional eEF2 by down regulating its activity by phosphorylation in the case of the wild 
type (but this would not be possible with the eEF2 Ala56 mutant), that the endogenous 
eEF2 is down regulated to compensate for the recombinant eEF2 being produced, or that 
the over expressed WT/Ala56 constructs ,or total eEF2 including the endogenous material, 
are being degraded and turned over to regulate and maintain homeostasis of the 






Figure 3.7 Growth profiling of CHOK1 cells transiently transfected with 2µg of empty 
pcDNA3.1V5 vector (plasmid), pcDNA3.1V5 CHO eEF2 (WT) construct, or the pcDNA3.1V5 
CHO Ala56 mutant construct (mut). The data shows the total and viable cell numbers 













3.2.1.3 Investigating the Effect of Transient Over-Expression of Wild Type CHO eEF2 and 
Mutants of eEF2 on Recombinant Protein Expression using Firefly Luciferase as a Reporter 
Gene 
To determine if the transient expression of eEF2 has any effect on recombinant protein 
expression from CHO cells a CHO cell line stably expressing the reporter gene firefly 
luciferase, CHOK1D6, was used. The amount of firefly luciferase being expressed at any one 
time can be rapidly assessed by measuring the amount of light produced when an 
activating substrate of firefly luciferase is present. In this way whether the over-expression 
of eEF2 or the mutants influences recombinant expression can be determined. It is noted 
that firefly luciferase is widely used as a reporter gene for such studies (Masterton et al. 
2010) but is also a cytosolic protein whilst most biotherapeutic recombinant proteins, 
certainly those expressed from mammalian cells, are secreted proteins.  
 
CHOK1D6 cells were therefore transiently transfected with either the empty pcDNA3.1 
vector, a vector containing the eGFP gene, the pcDNA3.1 vector containing the wild-type 
eEF2 construct or the Ala56 mutated eEF2 construct. The resulting firefly luciferase activity 
48 h post-transfection is reported in Figure 3.8. The transfection of the CHOK1D6 cells with 
the CHO eEF2 constructs resulted in no appreciable increase in luciferase expression 48 h 
post-transfection compared to the transfection reagent, pcDNA3.1 empty vector and eGFP 
control vectors (see Figure 3.8). This may reflect the low levels of over-expression achieved 
as demonstrated previously and discussed in the previous sections. This also may reflect 
the cells ability to tightly regulate the amounts of eEF2 in the cell or poor transient over-
expression or a combination of both. In order to better assess the influence of eEF2 
manipulation on CHO cell phenotypes, the production of stably over-expressing eEF2 cell 









Figure 3.8 Firefly luciferase expression (shown as Light counts per second (LCPS)) per cell in 
CHOK1D6 cells 48 hours post transient transfection with 2 µg of CHO eEF2 constructs. TR, 
Cells treated with transfection regent only; PC 3.1, empty pcDNA3.1 V5 vector; GFP, eGFP 
vector; WT eEF2, wild type eEF2 in pcDNA3.1 V5 vector; Mut eEF2, Thr56Ala eEF2 mutant in 
pcDNA3.1 V5 vector. n=6, Wt eEF2 and Mut eEF2 p>0.05 compared to TR control  
 
3.2.2 Generation and Investigation of Stably Over-Expressing Chinese Hamster eEF2 in 
CHO Cell Lines  
Due to the low expression or transfection efficiency of the eEF2 constructs when 
transfected into CHO cells, the generation of cell lines stably expressing the various 
constructs was investigated, these being the CHO eEF2 WT, Thr56Ala, Thr56Glu and 
eEF2WT with a C/N terminus V5 tag. To generate stable cell lines the commercially 
available CHO Flp-In system (Invitrogen) was used. This system uses a recombinase site 
placed into the host CHO cell genome, in which the corresponding FRT cloning and 
expression vector can be stably integrated into the host cell rapidly and stable integration 













Figure 3.9 Schematic depicting the stable integration of the FRT construct of 
interest into the FRT site of the CHOK1 FRT host to generate stable expressing 







3.2.2.1 Subcloning of the eEF2 gene sequences from the pcDNA3.1 plasmid into the FRT 
cloning vector and generation of stably expressing cell lines 
In order to sub-clone the various eEF2 constructs from the pcDNA3.1 vector into the FRT 
cloning vector, the primers listed in Table 3.1 were used to PCR amplify the different eEF2 
sequences plus the V5 tag from the pcDNA3.1 vector. Bands of the expected size were 
obtained as confirmed by agarose gel electrophoresis, gel purified and then digested with 
the appropriate restriction enzymes and ligated into the FRT vector that had also been 
digested with the appropriate restriction enzymes. Following transformation, colonies 
containing the inserts of interest were confirmed by PCR screening with the primers used to 
amplify the insert of interest and a positive colony confirmed by commercially available 
sequencing for each construct (appendix 7.4).  
 
In addition to generating the FRT constructs to generate these stable cell lines, CHO eEF2 
WT FRT vectors were also generated to transiently express exogenous e EF2 with a V5 
reporter at the C- and N- terminus, in case the presence of the tag at either end influences 
the activity of eEF2. Using the presence of the V5 tag the exogenous eEF2 can be detected 
by western blotting and immunofluorescence to confirm the expression and location within 
the cell of the exogenous eEF2 in the CHO Flp-In cell lines. In this way the exogenous eEF2 
only is detected and not the endogenous and naturally expressed eEF2. Initially to confirm 
that these constructs were transient expressed in the CHO Flp-In host cells, transient over-
expression of these constructs was undertaken. 
 
Figure 3.10 Western blot analysis 24 and 48 hour post-transient transfection of 2 ʅg of 
either N-V5 or C-V5 V5 tagged eEF2 in FRT vector in CHO Flp-In cells. T.R, Transfection 
reagent control; C-V5, C-terminus V5 eEF2; N-V5, N-terminus V5 eEF2. eEF2 = total eEF2 in 
cell (both endogenous and exogenous), eEF2V5 = V5 tagged blot for V5 tagged eEF2. A 
tubulin loading control is shown. 
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The data shown in Figure 3.10 confirmed that the V5 tagged FRT eEF2 constructs were 
expressed in the CHO FRT host cell line both 24 and 48 h post-transfection. There were a 
number of interesting observations from these data. Firstly, and as expected, there  was no 
signal in the control transfection reagent V5 blot. Further, the C-terminal tagged eEF2 gave 
a much higher signal than the N-terminal V5 tagged eEF2 suggesting that the presence of 
the V5 tag on the terminal can influence either the amount of protein produced or the 
stability of the recombinant eEF2. It is possible that the C-terminal V5 tag stabilises the 
eEF2 and hence could result in higher amounts of material being observed or that the N -
terminal tag destabilises the eEF2 protein and hence this is turned over faster. Alternatively, 
the tag at either end could influence the protein synthesis rate. It was also interesting to 
note that although the C-terminal V5 tagged eEF2 protein was well expressed as 
determined by western blot analysis, there was little elevation in the overall (total) 
ĂŵŽƵŶƚƐŽĨĞ& ?ŽďƐĞƌǀĞĚ ?&ŝŐƵƌĞ ? ? ? ? ? ?dŚŝƐƐƵŐŐĞƐƚƐƚŚĂƚƚŚĞĐĞůůĐĂŶ ‘ƐĞŶƐĞ ?ƚŚĞĂŵŽƵŶƚ
of eEF2 present in the cell and regulates this to maintain a more-or-less constant amount. 
This regulation could only be achieved by reducing the amount of endogenously expressed 
eEF2 or by changing the turnover of eEF2 as the cell cannot directly control the synthesis 
rate of the exogenous material. These data all suggest careful control of eEF2 amounts by 
the cell. In addition to the western blot analysis of the transient expression of the C/N 
terminus V5 eEF2, immunofluorescence analysis was also undertaken (Figure 3.11). As 
expected endogenous eEF2 was observed in the cytosol of cells. In those transfected with 
the V5 eEF2 tagged constructs, the immunofluorescence data again showed more cells 
expressing higher amounts with the C-terminal tagged eEF2 than the N-terminal in 
agreement with the western blot analysis. There were also fewer cells in the eEF2 N -
terminal tagged samples suggesting that this was not as well tolerated as the C-terminal 
exogenous material (Figure 3.11). These data combined suggest that the exogenous C-
terminal V5 tagged eEF2 was better expressed in the CHO FRT cells than the N-terminal V5 





Figure 3.11 Combined immunofluorescent images of a 24 hour transient transfection of  0.8 
ʅg of either N-V5 or C-V5 V5 tagged eEF2 in FRT vector in CHO Flp-In cells. Green, 
endogenous eEF2; Red, anti-V5. Each image shows an overlay of the green and red and 
hence yellow results from yellow and red overlay.  Cells, untreated cells; TR, cells treated 
with transfection reagent only; Cv5, cells transfected with FRT eEF2 with a C-terminus V5 










Once all the FRT vectors with the CHO eEF2 WT, Thr56Ala, and Thr56Glu were constructed 
and confirmed by sequencing (Appendix 7.4), these were used to generate stably 
expressing CHOK1 FRT cell lines following the instructions in the manual. Three polyclonal 
cell lines for experimentation were generated, one for each construct, these being the CHO 
eEF2WT, Thr56Ala, and Thr56Glu mutants. Alongside the generation of these eEF2 over-
expressing cell lines, the parental CHO cell line (Host cell line) and a cell line containing an 
empty FRT vector (FRT, not containing a gene of interest) were also constructed as controls. 
The reason for generating stable pools and not clonal cell lines was that although the 
generation of cell lines in this way should allow for cells expressing the same amount of 
recombinant mRNA (transcriptional activity the same), there may be different translational 
limitations in different cells that mean varying amounts of recombinant eEF2 are expressed 
in different cells lines. As such, a polyclonal pool of cells was maintained to determine if this 
ǁĂƐƚŚĞĐĂƐĞĂŶĚƚŽĞŶƐƵƌĞƚŚĞ ‘ĂǀĞƌĂŐĞ ?Ğ& ?ŽǀĞƌ-expression was being investigated. 
 
3.2.2.2 Characterisation of the eEF2 Protein Levels in the Stable eEF2 Expressing CHO FRT 
Poly-clonal Cell Lines 
Once the stably expressing eEF2 FRT CHO Flp-In polyclonal cell lines were established it was 
necessary to confirm expression of the exogenous eEF2. Initially this was achieved by 
western blotting of the CHO WT eEF2 stably expressing pools with either a C-terminal or N-
terminal V5 tag. The resulting blot data is shown in Figure 3.12. Interestingly, V5 labelled 
exogenous eEF2 was observed in both the C-terminal and N-terminal V5 tagged eEF2 
polyclonal cell lines, and possibly the amount of expression was marginally higher in the N-
terminally tagged samples (Figure 3.12). This is in direct contrast to the transient results 
reported above where there was much less expression of the N-terminally V5 tagged eEF2 
construct. This suggests that those cells that have survived the stable cell line generation 
and selection process are able to tolerate the N-terminally V5 tagged version of eEF2 as 





Figure 3.12 Western blot analysis of cell lysates collected from CHO Flp-In stable cell lines 
expressing either the empty FRT vector, human WT eEF2 with a C-terminus V5 tag or eEF2 
with a N-terminus V5 tag. Alpha tubulin (TAT) is shown as a loading control. FRT, stable cell 
line expressing the empty FRT vector; CV5, stable cell line expressing eEF2 with C-terminus 
V5 tag; NV5, stable cell lines expressing eEF2 with N-terminus V5 tag. 
 
In addition to the western analysis, immunofluorescence analysis was undertaken again for 
the expression of exogenous V5 tagged eEF2 (Figures 3.13 and 3.14 bel ow). These data 
showed that all cells were expressing the recombinant exogenous V5 tagged eEF2 and that 
the N-terminal tagged eEF2 may express marginally more than the C-terminal in agreement 
with the western blot data again. When the C-terminal tagged V5 eEF2 polyclonal cell line 
was investigated in more detail, there was clearly V5 tagged exogenous eEF2 expressed in 
all cells and this overlaid with the total eEF2 in the cell (Figure 3.14). These stable cell lines 
therefore appear to tolerate the expression of endogenously V5 tagged eEF2 although the 
western blot analysis suggest that total eEF2 amounts are not increased, again suggesting 







Figure 3.13 Combined immunofluorescent images of CHO Flp-in cells stably expressing eEF2 
either N-V5 or C-V5 tagged 24 hours post seeding. Host = host FRT untransfected cell line; 
FRT stable = control FRT cell line containing empty FRT cloning vector; CV5 = C-terminal V5 
tagged eEF2 stable cell line; NV5 = N-terminal V5 tagged eEF2 stable cell line. Red= V5, 
Green= eEF2  
 
In addition to characterising the WT eEF2 V5 tagged polyclonal stable cell lines, western 
analyse was undertaken on cell lysates of the non-tagged stable cell line mutants and WT 
collected 24 h after cells were seeded into flasks when growth should be maximal. Western 
blot analysis was undertaken for the amount of total and phosphorylated eEF2 in each of 
the polyclonal cell lines generated, these being: the non-tagged version of the CHO wild-
type eEF2 stably expressing cell line, the Ala56 and Glu56 eEF2 mutants and the control FRT 
cell line containing an empty FRT vector (no exogenous gene). The initial western blot 
analysis suggested that the amount of total eEF2 was elevated in the stably expressing WT 
eEF2, Ala56eEF2 and Glu56eEF2 polyclonal cell lines compared to the host and FRT control 




Figure 3.14 Immunofluorescent images of stable CHO Flp-in cell line expressing eEF2 with a 
C-terminus V5 tag 24 hours post seeding. Green= total eEF2; Red= anti-V5 tag; overlay, total 
and V5 overlay. 
 
In order to determine if this elevation was real, the freeware ImageJ software was used to 
analysis the levels of total and phosphorylated eEF2 relaƚŝǀĞ ƚŽ ƚŚĞ ɲ-tubulin loading 
control for each sample, and then the levels in each cell line were expressed relative to the 
FRT control cells (Figure 3.15b). From this analysis the total level of eEF2 was reduced when 
the empty FRT vector was stably present in the CHO Flp-In cells. However, when the WT 
eEF2, Ala56 or Glu56 eEF2 mutant constructs were stably integrated into the CHO Flp-In cell 







The Ala56 eEF2 mutant cell line had the highest amount of total eEF2. The Glu56 eEF2 
mutant cell line also had elevated amounts of total eEF2 compared to the controls; the WT 
eEF2 cell line also had increased amounts of eEF2 but this increase was less than that 
observed for either of the mutants (see Figure 3.15b). Although there was an increase in 
total eEF2 amounts in these untagged eEF2 cell lines, the amount of phosphorylated eEF2 
was slightly reduced in the WT eEF2 cell line and reduced by almost 50% in the Glu56 eEF2 
cell line. This reduction in phosphorylation in the Glu56 cell line suggests that the cells 
could be compensating for the expression of the inactive Glu56 eEF2 by activating 
endogenous eEF2. The amount of phosphorylated eEF2 in the Ala56 eEF2 mutant cell line 
was similar to that of the FRT control, suggesting that the cells may compensate for the 
expression of the presence of the active and non-phosphorylatable Ala56 eEF2 by 
phosphorylating a larger amount of the endogenous eEF2 within the cell.  
 
These data suggest that the non-V5 tagged eEF2 WT and mutants were able to up-regulate 
eEF2 expression to a greater degree than the V5 tagged WT eEF2 and that eEF2 can be 
elevated in CHO Flp-In cells stably. Further, dependent upon the eEF2 mutant over-
expressed, the cells adjust the amount of eEF2 phosphorylated to compensate for 
inactive/activate additional eEF2, at least when the cells are in rapid growth phase and are 



















































































Figure 3.15 (a) Western blot analysis of stable CHO flp-in cell lines expressing the eEF2 variant 
lysates 24 hours after seeding cultures. (b)&(c) Densitometry analysis of total and phosphorylated 
eEF2 in each cell line relative to the loading control of alpha tubulin; the levels of each cell line 
were made relative to the FRT control cell line. HOST: CHO Flp-In parental cell line; FRT: CHO Flp-
In cells stably transfected with an empty FRT vector; WT: CHO Flp-In cells stably expressing wild 
type CHO eEF2; ALA: CHO Flp-In cells stably expressing CHO Thr56Ala CHO eEF2; GLU: CHO Flp-In 






3.2.2.3 Characterisation of eEF2 mRNA Levels in the Stable non-V5 tagged eEF2 Expressing 
CHO FRT Polyclonal Cell Lines 
As well as determining the over-expression of eEF2 at the protein level in the stable cell 
lines, the effect at the mRNA level was also determined. To do this, each cell line was 
cultured for 24 hours before extracting the total RNA and then using qRT-PCR the relative 
amount of total eEF2 mRNA was determined using the primers described in Table 3.3. 
mRNA levels of E-actin were also determined as a normaliser, assuming that these do not 
change. The resulting data is shown in Figure 3.16. All eEF2 mRNA amounts are shown 
relative to the FRT eEF2 mRNA levels. Despite the fact that the eEF2 protein amounts were 
elevated in the eEF2 WT, Ala56 and Glu56 mutant stable cell lines (see Figure 3.15), the 
eEF2 mRNA amounts were only raised to any extent in the Glu56 mutant cell line (see 
Figure 3.16). Therefore, only the eEF2 Glu56 mutant appears to have increased levels of 
ŵZE ?ƚŚŝƐŵĂǇďĞďĞĐĂƵƐĞƚŚĞĐĞůůƐĂƌĞĐŽŵƉĞŶƐĂƚŝŶŐĨŽƌƚŚĞƉƌŽĚƵĐƚŝŽŶŽĨ ‘ĚĞĂĐƚŝǀĂƚĞĚ ?
Thr56Glu eEF2 mutant by producing more endogenous eEF2 mRNA. . It also suggests that 
the cells modulate the total mRNA level to maintain this and this may be the mechanism by 
which protein amounts are maintained, even when over-expressing exogenous mRNA. 
When investigating the WT V5-tagged cell lines the V5 tagged protein is expressed although 
total amounts of protein were not elevated.  These data suggest that endogenous mRNA 
amounts may be down-regulated in response to exogenous mRNA amounts to try and 





Total eEF2 forward agtgtcgacaggactcaagg 
Total eEF2 reverse acataccggcccatcatcag 
ɴ-actin forward agctgagagggaaattgtgcg 
ɴ-actin reverse gcaacggaaccgctcatt 
 
Table 3.3 Primers used for the mRNA analysis of the stale eEF2 CHO Flp-In cell lines. 
A universal forward primer was used, on specific primers were used for analysis of 














Figure 3.16 qRT-PCR analysis of eEF2 mRNA amounts relative to the FRT control cell line in 
the various stably eEF2 expressing CHO FRT cell lines. Total mRNA was extracted from each 
cell 24 hours post seeding. HOST, parental CHO Flp-In cell line; FRT, CHO Flp-In cell line 
stably expressing an empty FRT vector; WT, CHO Flp-In cell line stably expressing wild type 
human eEF2; ALA, CHO Flp-In cell line stably expressing Thr56Ala eEF2 mutant; GLU, CHO 
Flp-In cell line stably expressing Thr56Glu eEF2 mutant. Error bars show one standard 
deviation of n=3 independent experiments. p>0.05 when comparing the Host, WT and ALA 
































3.2.3 Effect of Stable eEF2 and eEF2 Mutant Expression on CHO Cell Growth 
3.2.3.1 Growth of Stable eEF2 Expressing CHO FRT Cell Lines 
As described in the introduction to this thesis, elongation and eEF2 is a key control point of 
translation elongation and hence protein synthesis. For high recombinant protein 
producing cell lines it is ideal if a high cell concentration can be achieved, and/or the 
specific productivity (Qp) of each cell is increased W the more cells in the bioreactor 
producing a high amount of target protein results in a higher yield of recombinant protein. 
Therefore the ability to engineer cells to grow faster: to higher concentrations less time = 
less cost for a fermentation would be beneficial. Also with a greater Qp = higher 
recombinant protein titre per culture and therefore a reduction in the ratio of host cell 
protein to target protein, reducing the cost of downstream processing.  
 
As a cell must double its protein mass before it can divide (Foster 2013; Conlon & Raff 
2003) and elongation is a key control point of protein synthesis, the effects of whether the 
manipulation of eEF2 amounts or the expression of the mutant eEF2 molecules in the stably 
expressing CHO FRT cell lines influenced cell growth parameters was investigated. Further, 
temperature shift to a lower culture temperature is often used during bioprocessing (e.g. 
from 37 to 32
o
C) to prolong culture and increase recombinant protein yields, the effect at 
both these temperatures was investigated. At the lower temperature protein synthesis 
rates are usually decreased by approximately 50% compared to those observed at 37
o
C 
(Roobol et al. 2009). 
 
The growth profiles of each of the non-V5 tagged stably over-expressing CHO eEF2 cell lines 
was established using the commercial Xcellegence system (Roche) (Host, FRT, WT, Ala56 
mutant, Glu56 mutant cell lines) over a period of 7 days (Figure 3.17). This system uses 
impedance of an electronic current across the surface of the wells the cells are adhered to 
ŝŶŽƌĚĞƌƚŽŵĞĂƐƵƌĞƚŚĞ ‘ĐĞůůŝŶĚĞǆ ?ƌĞĨůĞĐƚŝŶŐƚŚĞŶƵŵďĞƌŽĨĐĞůůƐƉƌĞƐĞŶƚŽŶƚŚĞƐƵƌĨĂĐĞŽĨ
the well. Triplicate cultures for each cell line were setup and an impedance reading was 
recorded every 30 minutes. At 37°C the growth profiles for the host cell line and FRT 
control were very similar to each other, however the three cell lines expressing additional 
exogenous CHO eEF2 all grew faster than the control cell lines and reached a higher cell 
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index more rapidly (Figure 3.17). All of these three cell lines grew much more rapidly during 
the first 60-70 h of culture even though they all started from a more-or-less equivalent cell 
index. The fastest growing cell line that also reached the highest cell index was that over-
expressing the eEF2 Ala56 mutant that cannot be phosphorylated. This was the cell line 
that densitometry analysis of the western blots of total eEF2 amounts showed had the 
highest total eEF2 amounts (Figure 3.15). The eEF2 Glu56 and WT eEF2 cell lines grew with 
approximately the same profile although the Glu56 mutant declined earlier (Figure 3.17).  
 
When the same cell lines were cultured at 32
o
C instead of 37
o
C, again the Ala56 mutant 
grew to the highest cell index. The host actually initially grew the fastest but reached the 
lowest cell index of any of the cell lines (Figure 3.17). The Glu56 mutant and FRT control 
both grew the slowest but reached a similar cell index to that of the eEF2 WT ce ll line. 
These data together suggest that the stable expression of a the Ala56 eEF2 mutant in CHO 
Flp-In cells gives an advantage at both 37 and 32
o
C in terms of the cell growth, maximum 







Figure 3.17 Growth profiles of the stably expressing eEF2 CHO FRT cell lines generated 
using the Xcellegence system (Roche). Each cell line profile was generated in triplicate with 
readings taken every 30 minutes over a 7 day period at 37 or 32
o
C. Host, parental CHO Flp-
In cell line; FRT, CHO Flp-In cell line stably expressing the empty FRT vector; WT,  CHO Flp-In 
cell line stably expressing wild type human eEF2; ALA, CHO Flp-In cell line stably expressing 
the Thr56Ala eEF2 mutant; GLU, CHO Flp-In cell lines stably expressing the Thr56Glu eEF2 
mutant. Each profile represents the average of triplicate growth curves.   
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3.2.3.2 Effect of the Presence of Rapamycin on the Growth of the Stable eEF2 Expressing 
CHO FRT Cell Lines  
Elongation factor 2 is indirectly regulated by mTOR (mammalian target of rapamycin), as 
described in the introduction chapter of this thesis. When mTOR is active eEF2 is not 
phosphorylated at the Thr56 residue because the kinase that phosphorylates eEF2 (eEF2K) 
is inactivated. However, when mTOR is inactivated, as in the presence of rapamycin, eEF2K 
is active and eEF2 becomes phosphorylated and inactivated. Therefore, the effect of the 
addition of 10 nM rapapmycin, enough to partially inhibit mTOR as shown in other studies 
(Raje et al. 2004; Lee & Lee 2012; Leontieva et al. 2012), on cell growth in the stably 
expressing CHO eEF2 cell lines was investigated.  
 
In order to investigate the growth profiles of the different cell lines in the presence of 
rapamycin, once again the Xcellegence system was used to culture the cell lines: FRT, WT 
eEF2, Ala56 mutant and the Glu56 mutant in 10 nM rapamycin over 7 days. As the 
rapamycin is prepared and added in DMSO, the same volume of DMSO without rapamycin 
was used as the control conditions. The resulting growth profiles are shown in Figures 3.18 
and 3.19. The growth profiles of each cell line were similar in that the presence of the 
rapamycin generally slowed the growth of the cell lines compared to the DMSO controls. 
The presence of the rapamycin therefore appears to have reduced the cells growth such 
that the maximum cell index is achieved ~48 hours later than in the presence of DMSO 
alone. Aside from the reduced growth rate, the FRT, WT and ALA cell lines exhibited similar 





Figure 3.18 Growth profiles of CHO Flp-In cells stably expressing eEF2 constructs in 
triplicate using the Xcellegence system over 7 days. Cells were either grown in the presence 
of 10 nM rapapmycin in DMSO or in DMSO alone. DMSO, cells grown in the presence of 
DMSO only; RAP: cells grown in the presence of 10 nM rapamycin; FRT, CHO Flp-In cells 
stably expressing the empty FRT vector; WT, CHO Flp-In cells stably expressing wild type 
eEF2; ALA, CHO Flp-In cells stably expressing Thr56Ala eEF2; Glu, CHO Flp-In cells stably 






Figure 3.19 Growth profiles of the CHO Flp-In cells stably expressing eEF2 constructs in 
triplicate using the Xcellegence system over 7 days. In either DMSO alone (upper panel) of 
in DMSO + 10 nM rapamycin (lower panel). RAP: cells grown in the presence of 10 nM 
rapamycin; FRT, CHO Flp-In cells stably expressing the empty FRT vector; WT, CHO Flp-In 
cells stably expressing wild type eEF2; ALA, CHO Flp-In cells stably expressing Thr56Ala 
eEF2; Glu, CHO Flp-In cells stably expressing Thr56Glu eEF2; RAP media: media with 10 nM 
rapamycin without cells present. Each curve is the average of three replicate cultures. 
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3.2.4 Influence of Stable CHO WT eEF2 and eEF2 Mutant Expression on Recombinant 
Protein Production in CHO FRT Cell Lines 
 
3.2.4.1 Effect of Stable Expression of Non-V5-Tagged eEF2 WT and Mutants in CHO Cells 
on Transient Firefly Luciferase Expression 
In order to investigate any effect of expressing the non-tagged version of CHO WT eEF2 or 
the mutant Ala56 or Glu56 eEF2 on recombinant protein expression from the CHO Flp-In 
cell lines, transient transfection and expression of firefly luciferase from these cell lines was 
investigated. In the early experiments of this chapter, transient expression of eEF2 on 
stable firefly expression was investigated but the lack of eEF2 transfection and expression 
made it difficult to draw conclusions from these studies although it did appear that over-
expression of eEF2 did enhance luciferase expression. In this experiment, the stable cells all 
express the eEF2 WT or mutants as appropriate and assuming that luciferase transfection is 
equal across the cell lines it should be more evident if there is an effect of eEF2 expression 
on luciferase expression. Therefore, the firefly luciferase construct pGL3 (commercially 
available from Promega) was transfected into each cell line and the luciferase expression 
determined 48 h post-transfection. Figure 3.20 reports on the total light counts per second 
or total luciferase expression in each sample 48 h post-transfection. 
 
When the firefly luciferase pGL3 construct was transient transfected into the CHO FRT 
control or stably expressing WT eEF2 cell lines the total luciferase expression observed was 
more-or-less the same (Figure 3.20). A small but detectable increase in total luciferase 
expression was observed when the pGL3 construct was transfected into the stably 
expressing Glu56 eEF2 cell line above that of the FRT control. However, when the pGL3 
construct was transfected into the stably expressing Ala56 eEF2 mutant an approximate 3-
fold increase in the total amount of luciferase activity was observed (Figure 3.20). These 
data suggest that the total transient luciferase expression obtainable from the stably 
expressing Ala56 eEF2 cell line dramatically enhanced the luciferase expression compared 
to the control. In addition to the total luciferase expression detected, the luciferase 
expression was normalised for cell number to determine the luciferase activity per cell 
(Figure 3.21). Once again the CHO FRT and stably expressing WT eEF2 cell lines gave similar 
cell specific productivities (amount of luciferase produced per cell). However the amount of 
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luciferase produced per cell was approximately 50% higher in both the Ala56 and Glu56 
eEF2 cell lines (Figure 3.21). This suggests that as the total amount of luciferase was the 
same in the Glu56 cell line compared to the control, there must be fewer Glu56 cells 
producing the same amount of total protein. The Ala56 mutant must have both of these: 
more cells each producing more luciferase, resulting in the approximate 3-fold increase in 
total luciferase observed. Together these data confirm that over expression of the eEF2 
Ala56 mutant confers an advantage for the transient expression of firefly luciferase above 













Figure 3.20 Total transient firefly luciferase expression from the FRT control and stably 
expressing eEF2 cell lines 48 h post-transfection. Hcon, FRT cell line transfected without 
luciferase DNA; FRT, CHO Flp-In cells stably expressing the empty FRT vector; WT, CHO Flp-
In cells stably expressing wild type eEF2; ALA, CHO Flp-In cells stably expressing Thr56Ala 
eEF2; Glu, CHO Flp-In cells stably expressing Thr56Glu eEF2. Error bars represent standard 
deviation from n=4 independent experiments. p<0.05 when comparing the FRT control 































Figure 3.21 Transient firefly luciferase expression per cell from the FRT control and stably 
expressing eEF2 cell lines 48 h post-transfection. Hcon, FRT cell line transfected without 
luciferase DNA; FRT, CHO Flp-In cells stably expressing the empty FRT vector; WT, CHO Flp-
In cells stably expressing wild type eEF2; ALA, CHO Flp-In cells stably expressing Thr56Ala 
eEF2; Glu, CHO Flp-In cells stably expressing Thr56Glu eEF2. Error bars represent standard 
deviation from n=4 independent experiments. p<0.05 when comparing the FRT control 
values to the ALA or GLU values. 
 
3.2.4.2 Effect of Stable Expression of V5-Tagged eEF2 WT and Mutants in CHO Cells on 
Transient Firefly Luciferase Expression 
In addition to investigating the effect of stable expression of the untagged eEF2 and 
mutants on firefly luciferase expression, any effect of stably expressing the V5-tagged eEF2 
in CHO cells on recombinant firefly luciferase expression was also investigated. For this 
experiment, 1 µg of the firefly luciferase pGL3 was transfected into the CHO FRT control cell 
line and the stably expressing C-terminal and N-terminal V5-tagged eEF2 CHO cell lines; the 
luciferase activity determined 48 h post-transfection. In both the N- and C-terminal V5-
tagged eEF2 cell lines there was a 2-3-fold increase in the total luciferase expression above 
that observed in the FRT control cell line (Figure 3.22). This increase was not previously 
observed when the WT untagged eEF2 cell line was transfected with the pGL3 and hence 























luciferase expression. The reason for this is not clear from this data, or whether this is a 
direct effect of eEF2 and elongation or via some other unknown mechanism.  
 
Figure 3.22 Total transient firefly luciferase expression from stable CHO Flp-In cell lines 
expressing eEF2 with either a V5 tag at the C-terminus (Cv5) or the N-terminus (Nv5), 
transiently transfected with a pGL3 firefly construct. Light counts per a second (LCPS) were 
measured 48 hours post transfection. FRT = control cell line. Error bars represent standard 
deviation from n=4 independent experiments. p<0.05 when comparing Cv5 or Nv5 values to 
the FRT control. 
 
3.2.5 Effect of Stable eEF2 Expression in CHO FRT Cells on Protein Fidelity 
The data shown in this chapter suggests that the stable expression of an eEF2 Ala56 mutant 
in CHO cells can result in increased firefly luciferase expression. However, increased 
expression and particularly polypeptide elongation could come with a cost of increased 
amino acid mis-incorporation compromising protein fidelity. To investigate this two mutant 
variants of the pGL3 firefly luciferase were kindly provided by Dr Anne Roobol; an R218S 
mutant which causes the luciferase molecule to lose its activity and an R218STOP mutant 
which results in a truncated luciferase protein with no activity (Conn & Qian 2014). 
Luciferase activity from these mutants is therefore only observed upon mis-translation or a 















When these constructs were transfected into the FRT CHO control cell line, or stably 
expressing WT eEF2 and mutant Ala56 and Glu56 eEF2 cell lines there was very low 
luciferase activity 48 h post-transfection indicative of very low infidelity. In the stably 
expressing WT eEF2 cell line there was actually a slight decrease in luciferase expression 
compared to the FRT control cell line suggesting an increase in fidelity in this cell line 
(Figure 3.23). There was little difference in the expression from the Glu56 mutant cell line 
compared to the FRT control. However, in the Ala56 mutant there was a small but 
noticeable increase in luciferase expression compared to the FRT control cell line for both 
constructs, indicating a very small loss in protein fidelity. However,  this small increase is 
more than offset by the fact that this cell line gives the highest total luciferase expression 
by approximately 3-fold as shown in Figure 3.20. This may therefore not actually represent 
a true increase in infidelity but rather reflect the increased amount of luciferase expressed 
and as such could well be considered as an increase in fidelity (i.e. may expect a 3-fold 






































Figure 3.23 CHO Flp-In cell lines stably expressing eEF2 constructs, transiently transfected with 
mutant firefly luciferase constructs. R218S firefly luciferase mutant and R218STOP fire luciferase 
mutant. Lysates were taken 48 hours post transfection; light counts per a second (LCPS) were 
measured and normalised to total protein per a sample. FRT, CHO Flp-In cell line stably 
expressing the empty FRT vector; WT, CHO Flp-In cell line stably expressing wild eEF2; ALA, CHO 
Flp-In cell line stably expressing Thr56Ala eEF2; GLU, CHO Flp-In cell line stably expressing 
Thr56Glu eEF2. n=3, When comparing the R>S WT values to the R>S values, p<0.05. 
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3.3 Conclusions and Summary Statements from this Chapter 
The main findings of this and subsequent chapters are discussed together in detail in the 
discussion chapter (chapter 6) of this thesis. Here the main findings are summarised.  
 
To summarise, it was found that due to the conserved nature of the amino acid eEF2 
sequence it was possible to use the human DNA sequence to express eEF2 (elongation 
factor 2) constructs in adherent CHOK1 cells, which was confirmed by western blot analysis, 
but transient expression of the human eEF2 in the CHOK1 cells did not affect their growth 
in culture. Transient expression of wild type and Thr56Ala eEF2 in CHOK1 cells appears to 
effect the short term (24-48 hours) phosphorylation of eEF2; but it does not appear to have 
an effect upon intra cellular recombinant protein production and cellular growth in culture 
over 96 hours. Immunofluorescence imaging of CHOK1 cells transfected with the eEF2 WT 
construct revealed that the translation efficiency of eEF2 in to the CHOK1 cells was only 20-
30%. Therefore the majority of the cells within culture were not expressing the eEF2 
constructs, skewing the results of the growth and western analysis of the transient 
experiments. Therefore to have all of the cells within the culture expressing the eEF2 
construct for an extended period of time required stable expression of the construct.   
 
Using the commercially available CHO Flp-In system (Invitrogen), CHO Flp-In cells stably 
expressing a variant of the CHO FRT eEF2 constructs (eeF2 WT or Thr56Ala or Thr56Glu) as 
well as a control cell line using an empty FRT vector were generated. Confirmation of the 
eEF2 constructs expression was confirmed via western blotting and immunofluorescence of 
an N- or C-terminal V5 reporter tag. 
 
Initial stable over expression of the wild type eEF2 construct showed a 2-fold increase in 
expression of eEF2 and a decrease in phosphorylation of eEF2 at the protein level; but the 
there was no change in the levels of total eEF2 mRNA expression. These data suggest that 
there is some form of regulation of eEF2 expression between translation of the eEF2 mRNA 
and its expression as a functional protein.  
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Stable expression of the Thr56Ala and Thr56Glu mutants had a greater effect upon eEF2 
expression resulting in a 3-5 fold increase in total eEF2 expression, however the 
phosphorylation of eEF2 was almost unchanged in the Ala56 cell line, whereas it was 
reduced in the Glu56 mutant cell line. This reflects the activity of the mutants, where the 
Thr56Ala mutant is considered to be continuously active; therefore phosphorylation of the 
endogenously expressed eEF2 is increased. The Thr56Glu cell line eEF2 mutant is 
considered to be continuously inactive; therefore the endogenous eEF2 must increase its 
activity to maintain protein expression, resulting in a reduction in eEF2 phosphorylation.  
 
Growth of the CHO Flp-In cells lines expressing the eEF2 mutants show that over expression 
of any of the eEF2 mutants resulted in a change in growth, but the Ala56 eEF2 mutant 
showed the biggest change in cellular growth, increasing the cell index and prolonging the 
cellular culture compared to the FRT control. When cultured with rampamycin the opposite 
was observed, when under the stress of rapamycin the Ala56 cell line was the first to enter 
the decline phase of cellular culture and the maximum cell number was reduced. These 
data suggest that although additional exogenous eEF2 is capable of increasing cellular 
growth, this leaves the cell less resistant or able to adapt to additional stress on the mTOR 
signalling pathway.  
 
Short term (48 hours) transient expression of recombinant firefly luciferase in the stable 
eEF2 cell lines revealed that the Thr56Ala mutant greatly increases the CHO cells total 
recombinant protein production. When normalised to cell number there was a change in 
luciferase levels the Ala56 and Glu56 cell lines that show a greater expression of luciferase 
compared to the Wt and FRT cell lines.  
 
With the over expression of eEF2 read through or mis-incorporation of amino acids during 
translation of polypeptides is a potential concern. Using a mutant luciferase it was possible 
to investigate if the mutant of eEF2 would cause additional errors in mRNA translation. It 
was determined that mutation of eEF2 to Ala56 or Glu56 had little negative effect upon the 
mis-incorporation of amino acids during translation. However, over expression of the wild 
type eEF2 construct decreased the mis-incorporation of amino acids. 
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Finally, the V5 reporter tag itself appeared to have a positive effect upon recombinant 
protein production, both the N-terminal and C-terminal V5 tag resulted in an increase In 
recombinant firefly luciferase production as seen in Figure 3.22.  The C-terminal V5 tag 
appears to be the more effective construct, as seen during transient immunofluorescence 
of the eEF2 WT V5 construct.  The reason for the increase in eEF2 activity/ recombinant 
protein production due to the addition of a V5 reporter tag is still unknown, it is possible 
that it stabilises eEF2s structure or ha some similar effect as the Ala mutation.  This is 






















Manipulation of the Kinase eEF2K and the Effect On Cell 




In the previous chapter the effect of (i) manipulating of elongation factor 2 (eEF2) amounts 
and (ii) the ability of exogenous eEF2 to be phosphorylated at Thr56 on CHO cell growth 
and reporter recombinant protein expression was investigated. These investigatinos were 
undertaken by the exogenous over-expression of either CHO WT eEF2, a non-
phosphorylatable Thr56Ala eEF2 mutant or a mimic of phosphorylated eEF2: Thr-Glu56 
eEF2. The results showed that the expression of the Ala56 mutant in particular offered 
advantages of better growth and higher recombinant protein expression as determined 
using a firefly luciferase reporter assay. One of the major disadvantages of this approach is 
that the endogenous CHO eEF2 is still present and thus the effect of manipulating the 
exogenous eEF2 is likely to be dampened by the endogenous material. 
 
 A more direct way of manipulating the endogenous eEF2 and its activity is to reduce or 
prevent its phosphorylation of the Thr56 residue by removing the kinase responsible, 
elongation factor 2 kinase (eEF2K). In this way it may be possible to prevent the slowing of 
elongation by phosphorylation of eEF2 although the cell may compensate for this by 
reducing the amount of total eEF2 produced. As such, the work described in this chapter 
focused upon investigating whether manipulation of eEF2K amounts in CHO cells could be 
used to reduce eEF2 Thr56 phosphorylation and if this subsequently influenced cell growth 
and recombinant protein expression from CHO cells. 
 
As described in the introduction chapter to this thesis, eEF2K is the key regulator eEF2, 
through phosphorylation of the threonine 56 amino acid residue. When eEF2 is 
phosphorylated by eEF2K it is inactivated and hence polypeptide elongation during 
translation is slowed. In other words, the inactivation of eEF2 halts global protein synthesis, 
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which in turn would reduce recombinant protein production. In the previous chapter 
(Chapter 3) it was shown that eEF2 regulation is a key component in determining 
recombinant protein production and its amount and activity within CHO cells affected the 
volume and quality of the recombinant protein produced.  
 
Elongation factor 2 kinase belongs to a super family of alpha kinases due to its active kinase 
site being an alpha helix instead of the more conventional beta sheet model ((Blakemore et 
al. 1998; Kenney et al. 2014); eEF2K has 2 structural domains: one at the N-terminus which 
has a calmodulin binding region and an alpha kinase region. At the C-terminus there are 
four alpha helical repeats, which have an unknown role but are believed to be involved with 
protein-protein interactions. Elongation factor 2 kinase is regulated by a number of other 
proteins including calmodulin, AMPK, mTORC1 and cAMPK (Kenney et al. 2014). Previous 
work has suggested and shown that manipulation of eEF2K and its activity has an effect on 
global protein expression (Kenney et al. 2014; Leprivier et al. 2013b; Heise et al. 2014). As 
eEF2K is the major regulator of eEF2, here the hypothesis that inactivation, 
knockdown/silencing of eEF2K results in increased/prolonged/enhanced CHO cell growth 




4.2.1 Development of a shRNA for the Knockdown of CHO eEF2K  
One method of modulating the amount of eEF2K in the cell and hence the phosphorylation 
of eEF2 is to reduce the amount of eEF2K in the cell by RNA silencing approaches. As such, 
the use of a short hairpin RNA (shRNA) approach for targeted silencing of eEF2K expression 
was utilised. In this way the amount of eEF2K in the cell can be reduced and subsequently 
the phosphorylation of eEF2 and eEF2s inactivation should be reduced. shRNAs work by 
generating a tight hairpin turn that supress mRNA translation of the target mRNA via RNA 
interference (RNAi) which reduces its expression, in this case expression of eEF2K. shRNAs 
are usually delivered via plasmid based systems which offers an advantage over the use of 
chemically synthesised siRNAs, that are directly transfected into cells, in that shRNA 
harbouring plasmids can be amplified in bacteria and also used to generate stably 
expressing shRNA cell lines where knockdown should be constitutive.  
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The shRNAs work by being transcribed in the nucleus after transfection and the resulting 
hairpin is a mimic of a pri-ŵŝĐƌŽZEƚŚĂƚŝƐƉƌŽĐĞƐƐĞĚŝŶƚŚĞŶƵĐůĞƵƐďǇƌŽƐŚĂ ?dŚŝƐ ‘ƉƌĞ-
ƐŚZE ?ŝƐƚŚĞŶƚƌĂŶƐƉŽƌƚĞĚŝŶƚŽƚŚĞĐǇƚŽƐŽůďǇĞǆƉŽƌƚŝŶ-5 where it is further processed by 
Dicer and loaded into the RNA-induced silencing complex (Z/^  ? ?dŚĞƐŚZEƚŚĞŶƐŝůĞŶĐĞ ?Ɛ
the expression of the mRNA either by repressing translation of the target to which it is 
complementary or the targeted mRNA is cleaved, again resulting in silencing. 
 
A shRNA targeting eEF2K was therefore developed for use in this investigation. To do this 
the commercially available Gene Clip U1 Hairpin system (Promega) was used (Figure 4.1a) 
to investigate the effects of eEF2K knockdown upon recombinant protein production and 
cellular growth in CHO cells. In order to develop the eEF2K targeting shRNA, 
oligonucleotides for construction of the hairpin were designed based upon siRNA 









The oligonucleotides were annealed together then ligated into the pGeneClip U1 plasmid 
before being transformed into competent E.coli cells. The presence of the hairpin insert in 
the resulting colonies was then confirmed by undertaking a digestion with the  restriction 
enzyme PstI on minipreps of selected colonies (Figure 4.1b). When the hairpin is 
successfully inserted it causes a new restriction site to be constructed, therefore if the 
insert is present two bands are observed upon PstI digestion and only one when the insert 
is not present. As shown in figure 4.1b, in 4 of the colonies screened by this method two 
bands were observed at the expected sizes giving preliminary confirmation that the hairpin 
had been inserted correctly. In order to further confirm the correct insert and sequence 
was present, commercial sequencing of the hairpin constructs was undertaken which 




Oligo A tctcctcatgcctgcaaccggatttctcgagaaatccggttgcaggcatgagct 
Oligo B ctgcagctcatgcctgcaaccggatttctcgagaaatccggttgcaggcatgag 
 
Table 4.1 Oligonucleotides used to construct the eEF2K shRNA hairpin using the 

















































Figure 4.1 (a) Schematic depicting the pGeneClip U1 cloning system. 
Two oligonucleotides, designed as a short hairpin, that have been 
annealed together are inserted into the commercial pGeneClip
TM
 
vector. Once inserted, the newly constructed vector is screened using 
a Pst I digest restriction. If inserted correctly the annealed 
oligonucleotides result in a second Pst I digest site, allowing for quick 
screening of the ligated insert and vector. 
 
(a) (b) 
(b) Screening of constructs for the presence of the eEF2K silencing hairpin by restriction digest with the PstI 
restriction enzyme. Agarose gel analysis shows four positive constructs had the short hair pin oligonucleutodies 
inserted into the pGeneClip
TM
 vector by production of 2 bands at 3209 bp and 1402 bp. These construct where 
later confirmed with commercial sequencing.  
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4.2.2 The effect of transient transfection of the eEF2K shRNA into CHO Cells 
 
4.2.2.1 Does Transient Transfection of the eEF2K shRNA into CHO Cells Reduce eEF2K 
Expression and Subsequently Reduce eEF2 Phosphorylation? 
In order to determine if the eEF2K shRNA was expressed and resulted in knockdown of 
eEF2K at the protein level in CHO cells, transient transfection was undertaken into the 
CHOK1 Flp-In host cell line. To achieve this both 0.5 and 1 Pg of the shRNA plasmid was 
transfected into 6 well plates containing the CHOK1 Flp-In host cell line as described in the 
methods chapter and cell lysates collected 24 and 48 h post-transfection. A control 
containing just the transfection reagents was also undertaken and lysates collected at the 
same time points.  
 
The lysates were then examined for eEF2K levels by western blot analysis probing with an 
anti-eEF2K antibody. A loading control blot was also undertaken. The results of these blots 
are shown in Figure 4.2. The western analysis showed that there was good knockdown of 
eEF2K compared to the control when using 1 Pg of the shRNA plasmid 24 h post-
transfection (Figure 4.2). The effect was still present but not to the same extent at 48 h as 
there appeared to be less eEF2K even in the control sample. The knockdown was not as 
obvious in the 0.5 Pg sample at 24 h post-transfection but still present. The short-term 
knockdown may partially reflect the regulation and rapid turnover of eEF2K, which has 
been reported to have a half-life of around 6 hours (Arora et al. 2005; Wiseman et al. 2013). 
Regardless, the 24 h 1 Pg data confirmed that a high level of eEF2K knockdown could be 
achieved at least transiently in CHO cells using the eEF2K shRNA. 
 
Once it had been established that the eEF2K shRNA could give a high amount of eEF2K 
protein knockdown, the same cell lysates were probed by western blotting for total eEF2 
and phosphorylated eEF2 levels. The blot for these targets showed that the levels of total 
eEF2 did not change in response to the knockdown of eEF2K (Figure 4.2). However, there 
was a very distinct and large reduction in the amounts of phosphorylated eEF2 in the 1 Pg 
knockdown sample 24 h post-transfection (Figure 4.2). These data confirm that the 
knockdown of eEF2K was sufficient to reduce the ability of eEF2K to phosphorylated eEF2 
and hence inactive eEF2. There was still an effect upon eEF2 phosphorylation levels 48 
hours post transfection compared to the control samples. In the 0.5 Pg transfected samples 
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there was still a reduction in phosphorylated eEF2 24 h post-transfection but this was not 
as dramatic as transfecting 1 Pg of the shRNA. Once again there did appear to be an effect 
on eEF2 phosphorylation 48 h post-transfection in the 0.5 Pg samples but reduced eEF2 
phosphorylation compared to the 1 Pg sample (Figure 4.2). Together these data show that 
the shRNA was able to silence eEF2K expression at the protein level and that this 
subsequently reduced the observed phosphorylation of eEF2 in the CHO Flp-In host cell 
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Figure 4.2 Western blot analysis of the knockdown of eEF2K using the shRNA plasmid generated 
in this study and the subsequent effect on total and phosphorylated eEF2 levels in CHO Flp-In 
parental cells. These blots confirm the knockdown of eEF2K 24 hours post transfection of 1ug of 
the eEF2K shRNA; this is corroborated by the reduction of eEF2 phosporylation in the same 
sample and that levels of total eEF2 are unchanged. eEF2K: elongation factor 2 kinase, eEF2-T: 




4.2.3 The Effect of Transient eEF2K Knockdown On Recombinant Protein Expression 
 
4.2.3.1 Effect of Transient eEF2K Knockdown upon Stable Firefly Luciferase Expression 
from CHO Cells 
Once it had been established that the shRNA eEF2K targeting plasmid could successfully 
knockdown endogenous CHO eEF2K it was used to assess whether transient knockdown of 
eEF2K had any effect on CHO cells capability of achieving recombinant protein production. 
This was initially investigated using the cytosolic firefly luciferase reporter gene. To achieve 
this, the CHOK1D6 cell line that stably expresses firefly luciferase were transfected with 1 
Pg of the eEF2K shRNA in 24 well plates as described in the methods section. Control 
experiments with transfection reagent only and the cells only with no additions were also 
undertaken. 24 hours post-transfection the firefly luciferase expression was determined in 
the different samples as light count per second (LCPS). The resulting data is presented in 
Figure 4.4.  This data shows that the cells transfected with the eEF2K shRNA produced a 
much higher amount of luciferase per cell than in the controls, the amount of expression 
being approximately 5-fold higher (Figure 4.4). 
 
As the transient knockdown of the eEF2K had such a pronounced effect on the stable firefly 
luciferase expression, the effect of a co-transfection of the eEF2 constructs used in Chapter 
3 and the eEF2K shRNA on firefly luciferase expression was investigated. In doing this it is 
noted that the major effect of over-expressing eEF2 reported in chapter 3 was in the stably 
expressing Ala56 cell line and that the transient over-expression had less to no effect. To 
investigate this transient co-expression of the eEF2 and shRNA eEF2K knockdown plasmid, 
the CHOK1D6 cells were initially transfected cells with the different eEF2 constructs 
described in Chapter 3 (eEF2 WT, eEF2 Thr56Ala, eEF2 Thr56Glu) and 24 hours post-
transfection the eEF2 WT transfected cells were transfected again with the eEF2K shRNA 
targeting plasmid to silence eEF2K activity. Then 24 hours post the 2nd transfection the 
amount of luciferase produced from each sample was determined. The results from this 
experiment are shown in Figure 4.5. From these data it appears that in the stably 
expressing firefly luciferase cell line that the knockdown of eEF2K has a greater effect upon 
recombinant firefly luciferase protein production than mutation of eEF2 that cannot be 
phosphorylated. This would be expected as the transient eEF2 manipulation reported in 
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chapter 3 showed little effect on luciferase expression (as opposed to stable expression of 
the Ala56 mutant).  
 
Further, when the mutant Thr56Ala eEF2 is transfected into the cells, endogenous eEF2 is 
still expressed and can be phosphorylated by the cell to control elongation as described in 
the introduction to this cell. In the samples where the WT eEF2 was over-expressed and 
eEF2K was knocked down there appeared to be a decrease in luciferase expression (Figure 
4.5) compared to the knockdown. Co-transfections are likely to result in additionally stress 
upon the cell as opposed to a single transfection and this may also explain why less 
luciferase expression was observed as compared to the knockdown alone (Figure 4.5). 
These data confirm that the transient knockdown of eEF2K enhances firefly luciferase 






































Figure 4.4 Expression of firefly luciferase measured as LCPS (Light counts per a second) from 
CHOK1D6 cells 48 hours post transfection of 1µg eEF2K shRNA (KD). Control samples of 
CHOK1D6 cells were treated with transfection reagent (TR) and others incubated without any 
treatment. Knockdown of eEF2K resulted in a 5-fold increase of LCPS expression and 
therefore luciferase production. Readings were taken in n=4 and averages and standard 



















































Figure 4.5 Determination of firefly luciferase activity via measurement of LCPS (Light counts 
per a second) in CHOK1D6 cells stably expressing firefly luciferase 48 hours post transfection 
of wild type eEF2 (WT), Thr56Ala eEF2 (ALA), Thr56Glu eEF2 (GLU)or eEF2K shRNA (KD). 24 
hours post transfection of the wild type eEF2, a sample of CHOK1D6 cells were transfected 
again with 1µg eEF2K shRNA and then incubated for a further 24 hours (WT/KD). n=6, p<0.05 
when comparing the GLU, KD and WT/KD values against the WT values.      
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4.2.3.2 Effect of Transient eEF2K Knockdown upon Stable Gaussia Luciferase Expression 
from CHO Cells 
The transient knockdown of eEF2K was shown to be able to enhance cytosolic firefly 
luciferase expression; however biotherapeutic proteins expressed from mammalian cells 
are secreted proteins therefore the effect of the eEF2K knockdown upon the production of 
secreted proteins are of more interest industrially. As a model secreted protein gaussia 
luciferase was chosen as this can be rapidly assayed like firefly luciferase and stably 
expressing CHO cells were available for investigation. Further, previously studies have used 
this to determine the effect of manipulation of gene expression in CHO cells on secreted 
recombinant protein productivity (Jossé et al. 2010). One disadvantage of using gaussia 
luciferase is that the molecule itself appears to be less stable than firefly luciferase and this 
must be considered when interpreting expression data. The expression of gaussia luciferase 
was therefore determined by western blotting instead of an activity assay as used in the 
case of the firefly luciferase protein. 
 
Two cell lines stably expressing gaussia luciferase available in the laboratory at Kent (cell 
line 12 and cell line 14) were transiently transfected with 1 µg of the eEF2K targeting shRNA 
and left for 24 hours before both supernatant and cell lysates were collected from control 
and knockdown samples. The resulting supernatant and cell lysates were then analysed by 
western blot analysis for total and phosphorylated eEF2, eEF2K and gaussia luciferase. This 
experiment was repeated twice. As can be seen in western blot data shown in figure 4.6a 
and 4.6c, gaussia luciferase was detected in the supernatant of all samples. For intracellular 
ĂŶĂůǇƐŝƐŽĨĞ& ? ĂŶĚ Ğ& ?< ƚŚĞɲ-tubulin loading suggested that less protein had been 
loaded in the knockdown cell lysate samples (Figure 4.6a and 4.6c). As all cell lysates were 
collected with a set volume of lysis buffer, this suggest that there were less cells in the 
knockdown samples which may be due to the knockdown or could be due to cell seeding 
ĚŝĨĨĞƌĞŶĐĞƐ ?ƐƐƵĐŚ ?ƚŚĞŐĂƵƐƐŝĂůƵĐŝĨĞƌĂƐĞĞǆƉƌĞƐƐŝŽŶǁĂƐƚŚĞƌĞĨŽƌĞŶŽƌŵĂůŝƐĞĚƚŽƚŚĞɲ-
tubulin bands as an estimate to normalise to total protein or total cell amount. This is 
discussed more below (Figure 4.6). There was little or no gaussia luciferase expression 
detected in the cell lysates (Figure 4.6).  
 
As described above, the western blot data shown in figures 4.6 showed less tubulin in the 
knockdown samples indicative of a lower protein load, presumably due to fewer cells. 
Therefore, it was necessary to consider this when determining the level of knockdown in 
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the cells and hence densitometry analysis was undertaken (Figure 4.6b and 4.6d). The blots 
suggested a knockdown of eEF2K even with a reduced tubulin band and the densitometry 
analysis confirmed this (Figure 4.6b and 4.6d). There was also a decrease in the amount of 
eEF2 phosphorylation.  The total amount of guassia luciferase present in the supernatant 
was reduced in eEF2K knockdown samples as the same amount of supernatant was loaded 
from each sample (Figure 4.6). However, when the amount of luciferase was normalised to 
the tubulin loading control for the amount of cells, cells transfected with the eEF2K shRNA 
generally produced more gaussia luciferase compared to the control cells (untreated or 
treated with transfection reagent only). This was particularly true for cell line 12 but less 
pronounced for cell line 14 (see figure 4.6).  
 
These data together suggest that knockdown of eEF2K influenced the total cellular protein 
amount (e.g. cell biomass generated over the time course) but that the amount of gaussia 
luciferase generated was increased on a total protein biomass basis upon eEF2K knockdown. 
Further, there was a cell line specific effect suggesting that the knockdown of eEF2K may 
have a different level of effect on different cells, probably due to a different balance in the 
amount of eEF2K, eEF2 and other translation factors. This has important implications for 
potential cell line engineering strategies by manipulation of eEF2K. Firstly, if the knockdown 
of eEF2K does reduce biomass then this is not desirable, as it will potentially limit target 
recombinant protein and cell biomass amounts. Secondly, from the results in this chapter 
so far, transient manipulation of eEF2K does appear to enhance recombinant protein 
expression but that this effect in stably expressing cell lines may be cell line specific and 
therefore not predictable.  
 
It is noted that knockdown of eEF2K was attempted in the stably over-expressing eEF2 
Ala56 mutant as the work in chapter 3 had shown this to have the most effect on cell 
growth and recombinant protein production. However, when knockdown was attempted in 
this stable cell line all cells died and the knockdown was not tolerated. This suggests that in 
the cell line the knockdown is lethal to the cell, possibly because it results not only in a 
reduced ability to phosphorylate endogenous eEF2 but the exogenous, non-
phosphorylatable eEF2 is also present. This in all likelihood results in elevated levels of eEF2 
that is not phosphorylated and the work in the previous chapter suggested that eEF2 levels 
are controlled by the cell to be maintained at a buffered level. The effect of the knockdown 






































Figure 4.6 (a)(c) Western blot analysis of two CHO Flp-In cell lines stably expressing gaussia luciferase (12 
and 14) 24 hours post transfection of 1 µg eEF2K shRNA (KD) or treatment with transfection reagents 
(TR). Duplicate supernatant samples were probed for secreted gaussia luciferase and lysates of the 
corresponding CHO Flp-In cell lines were probed for gaussia luciferase (lysate), levels of total (eEFF2 T)  
and phosphorylated (eEF2 P) elongation factor, elongation factor 2 kinase (eEF2 K) ,anĚĂůƉŚĂƚƵďƵůŝŶ ?ɲ-
Tubulin) as a loading control. Due to the unequal loading of the samples densitometry analysis was 
undertaken; relative levels of gaussia luciferase, eEF2 and eEF2K levels were calculated (relative to alpha 
tubulin) (b)(d). Blots (a) and anaylsis (c) ŚĂǀĞĚƵƉůŝĐĂƚĞƐĂŵƉůĞƐŽĨƚŚĞĐŽŶƚƌŽůƐĂŵƉůĞ ‘ĐĞůůƐ ? PƵŶƚƌĞĂƚĞĚ
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4.2.4 Transient Knockdown of eEF2K in CHO Cells upon Leucine Depletion in the Culture 
Media 
As described in the introduction chapter of this thesis, eEF2K activity is controlled via mTOR 
signalling which keeps eEF2K activity low when mTOR is active. However, upon nutrient 
depravation, particularly leucine depravation, mTOR signalling is impaired (Lynch 2001; 
Gran & Cameron-Smith 2011; Proud 2004) and eEF2K activity is increased to slow 
translation elongation. The effect of leucine depletion upon eEF2K knockdown in CHO cells 
was therefore investigated using the CHO gaussia luciferase 14 expressing cell line. 
 
 To undertake this, eEF2K was knocked down in cell line 14 for 24 hours and then the cells 
placed in leucine depleted media (LD media) for 24 hours and cell lysates and supernatant 
collected. Control samples where eEF2K was not knocked down were also generated. 
Western blot analysis of the cell lysates for eEF2K, total eEF2, phosphorylated eEF2 and 
ŐĂƵƐƐŝĂůƵĐŝĨĞƌĂƐĞĂƌĞƐŚŽǁŶŝŶ&ŝŐƵƌĞ ? ? ?Ă ?ďůŽƚĨ ƌ ɲ -tubulin was also undertaken as a 
loading control. As described above, the tubulin loading was less in the knockdown cells; 
therefore densitometry analysis was undertaken on the bands and is shown in Figure 4.7b.  
 
The densitometry data suggested that there had been little knockdown of the eEF2K in the 
samples (see Figure 4.7b) although the phosphorylation of eEF2 was decreased. The cells 
with transfection reagent only also had decreased phosphorylation of eEF2 although not to 
the same extent as the samples transfected with the eEF2K shRNA knockdown plasmid. 
There was no difference in the total amount of eEF2 between the different samples. It is 
difficult to determine how eEF2 phosphorylation levels were down when eEF2K levels were 
not in the knockdown samples. It may be that the amounts of eEF2K were difficult to 
normalise with the tubulin and an over-representation of the amount of eEF2K present 
resulted. Alternatively, it is possible that due to the leucine depletion even though eEF2K 
was being knocked down, the cell responded to this to increase the eEF2K amounts in 
response under the leucine deficient conditions so that the eEF2K amounts were more-or-
less the same as the control samples. However, this would not account for a reduction in 
phosphorylation of eEF2. Finally, although the normalised amount of gaussia luciferase in 
the supernatant appeared increased over the controls, the total amount detected was 






















Figure 4.7 (a) Western blot 
analysis of CHO Flp-In cells 
stably expressing gaussia 
luciferase (cell line 14) 
transfected with 1 µg eEF2K 
shRNA and incubate for 24 
hours, then incubated in 
leucine depleted media for a 
further 24 hours, after which 
supernatant and lysate were 
collected. Supernatant were 
probed for secreted gaussia 
luciferase and lysates of the 
corresponding CHO Flp-In cell 
lines were probed for gaussia 
luciferase (lysate), levels of 
total (eEFF2 T) and 
phosphorylated (eEF2 P) 
elongation factor, elongation 
factor 2 kinase (eEF2 K), and 
ĂůƉŚĂ ƚƵďƵůŝŶ  ?ɲ-Tubulin) as a 
loading control.  KD = cells 
transfected with 1 µg eEF2K 
shRNA, TR = cells treated with 
transfection reagent, Cell s= 
untransfected cells.  (b)  
Densitometry analysis of the 
relative levels of gaussia 
luciferase, total and 
phosphorylated eEF2 and 
eEF2K levels were calculated 
ƌĞůĂƚŝǀĞ ƚŽ ƚŚĞ ɲ-Tubulin 






4.2.5 Calcium Flux in the ER and eEF2K Knockdown 
As described in the introduction chapter of this thesis, eEF2K has several regulators, one of 
these being calmodulin. The activity of calmodulin is responsive to calcium ions, therefore 
the control of eEF2K activity may respond to calcium flux levels. Although the tools to 
investigate   a direct link were not available, changes in calcium amounts in the ER could be 
monitored using a calcium fluorescence based probe in stable cells available in the 
laboratory. Specifically, for this experiment, HEK Flp-In cells stably expressing a FRET 
genetically encoded calcium sensor that reports as a fluorescent indicator of calcium ion 
concentration in the ER was used (Palmer & Tsien 2006).  
 
The FRET molecule consists of two arms with a CFP donor which has an excitation at 440 
nm and emission at 480 nm, as well as a YFP acceptor arm which has an emission of 535 nm, 
with a calcium binding pocket between the arms.  When excited by a laser at 440 nm and 
calcium is not bound, only the CFP donor emits a signal. However, when calcium binds in 
the calcium binding pocket this results in a conformation change that means the CFP donor 
and YFP acceptor arms become close to each other, causing the excitation e nergy to 
transfer to the YFP acceptor resulting in emission at 535 nm. Previous work in the 
laboratory at Kent has shown that during mild cold-shock of these HEK cells, calcium ions 
are released from the ER into the cytosol and hence there is a loss of the YFP signal and 
increase in CFP. This translocation of calcium ions from the ER to the cytosol could activate 
eEF2K via calmodulin activation and subsequently increase phosphorylation of eEF2. 
Therefore, whether knockdown of eEF2K had any effect on the calcium ion redistribution 
upon mild cold-shock was investigated. It was not expected that this would be the case, but 
as mild cold-shock is often used for the production of recombinant proteins from 
mammalian cells (Thaisuchat et al. 2011; Roobol et al. 2009) it was important to confirm 
this if engineering of eEF2K knockdown was to be considered as an approach for generating 
host cells for recombinant protein production. 
  
HEK D1ER cells stably expressing the FRET molecule localised to the ER were therefore 
transfected with the eEF2K shRNA plasmid and then 24 hours post transfection cells were 
incubated at 37
o
C for a further 1 hour 20 minutes or at 32
o
C for 1 hour 20 minutes. The 
FRET in the cells was then observed using a confocal microscope to determine any 
differences in calcium ion concentrations in the ER under the different conditions. The 
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results are shown in Figure 4.15.  For samples maintained at 37
o
C, the initial most striking 
feature was a change in the morphology of the cells (see figure 4.8). Whilst the control cells 
ŚĂĚĂ ‘ƚǇƉŝĐĂů ?,<ĐĞůůŵŽƌƉŚŽůŽŐǇǁŝƚŚĂŶĞǆƚĞŶƐŝǀĞZŶĞƚǁŽƌŬĂŶĚĐǇƚŽƐŽů ?ƚŚĞĐĞůůƐƚŚĂƚ
had been transfected with the eEF2K targeting shRNA plasmid were more rounded and had 
a less extensive cytosol and ER network as determined from the fluorescence imaging.  
 
Further, there appeared to be less YFP expression and more CFP in the knockdown cells 
suggesting that the knockdown experiment had in some way interfered with calcium 
homeostasis in the ER (see figure 4.8), which was unexpected. The difference in the extent 
of the cytosol could explain the lower total protein amounts in the lysates of the gaussia 
expressing cells discussed in the previous section. The potential change in calcium 
distribution from the ER could only occur if the cell responds to the knockdown of eEF2K by 
releasing calcium from the ER to try and activate more eEF2K in response to the knockdown, 
such that control and slowing of protein synthesis occurs, or if the transfection and 
expression procedure somehow compromises the ER membrane integrity or calcium 
transporters across the ER so that calcium is released into the cytosol, reducing that in the 
ER and hence reducing the YFP signal. It is not obvious from these data, which, if ei ther, of 
these mechanisms is responsible for the observed effect. 
 
In the cold-shocked control samples there appeared to be very little difference in the 




C samples (Figure 4.8). However, once again 
there was a loss of the YFP signal in the eEF2K knocked down cells, suggesting a change in 
ER calcium amounts upon the knockdown procedure as in the 37
o
C knockdown samples. 
The general trend was for the loss of YFP signal to be greater at 32
o
C in the knockdown cells 
than that in the 37
o
C cells suggesting that temperature increased the effect observed. A 
hypothesis to explain these somewhat unexpected results is that the cell may try to adjust 
for reduced eEF2K levels, and hence a lack of ability to phosphorylate and inactivate eEF2, 
by modulating calcium amounts to try and activate eEF2K to provide an ability to continue 
controlling protein synthesis rates at the elongation stage via eEF2 phosphorylation. 




























Figure 4.8 Visualisation of live HEK (Human embryonic kidney cells) stably expressing FRET 
genetically encoded calcium sensor localized to the ER 25 h 20 minutes post a 24 hour   
transfection of 1 µg eEF2K shRNA (KD) or treated with transfection reagent (TR) and a 1 h 
20 minute cold shock (32°C), HEK cells that were not subjected to cold shocked were 
incubated at 37°C for the same length of time. The FRET molecule has two arms:  a CFP 
donor with excitation at 440 nm and emission at 480 nm and an YFP acceptor with emission 
of 535 nm, with a calcium binding pocket between the arms.  Excitation by a laser at 440 
nm, without calcium binding, the CFP donor emits a signal at 480 nm. With calcium binding 
a conformation change occurs that closes CFP donor and YFP acceptor together, causing the 
excitation energy to transfer to the YFP acceptor resulting in emission at 535 nm. False 
colour was assigned to both the CFP (Green) and YFP (Red). Compositions of the red and 
green images were made using the freeware tool ImageJ.  
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4.2.6 Generation of CHO Cells with Stable Knockdown of eEF2K and the Effect on Protein 
Synthesis and Cell Growth 
The work described in section 4.2.2 showed that eEF2K could be transiently knocked down 
in CHO cells resulting in reduced eEF2 phosphorylation and increased firefly luciferase 
expression. However, if such an approach was to be utilised in a biotechnological setting it 
would be necessary to generate stably knockdown eEF2K cell lines that exhibited the same 
effect. Whether stably knocked down eEF2K cell lines could be established, and the effect 
of this on cell growth and recombinant protein productivity, was therefore investigated. 
 
4.2.6.1 The Generation of CHO Cell Lines Stably expressing the eEF2K targeting shRNA 
Plasmid 
For construction of CHO cells stably expressing the eEF2K shRNA, the plasmid construct 
generated in the gene clip system could be used as this contains antibiotic selection for 
Puromycin. By application of the puromycin antibiotic, selection after transfection for the 
presence of the eEF2K shRNA would be possible to create stable cell lines expressing the 
eEF2 targeting shRNA. This was therefore achieved following the protocols provided with 
the Gene Clip kit to generate stable cell lines with puromycin resistance. The host cell line 
used was the CHO Flp-In parental cell lines. It is noted here that the recombinase targeting 
is not utilised in this approach as the shRNA was not on the appropriate vector nor was the 
plasmid with the recombinase co-transfected at the same time. This approach will lead to 
selection of random integration in the genome as is usually undertaken when generating 
recombinant cell lines and as such the resulting cells that survive would be expected to 
show different expression levels of the shRNA.  
 
To generate the stably eEF2K shRNA targeting expressing cells, the CHO Flp-In parental 
were cells were transfected with 1 Pg of the eEF2K shRNA as used in the transient 
expression studies previously described. 24 hours post-transfection the media was changed 
for selection media containing 10 µg/mL of the  pyromycin antibiotic. The cells were then 
cultured in this selection media for two weeks before use in experimentation. Initially upon 
addition of puromycin the majority of cells died as expected, but then colonies of cells that 
survived the selection began to emerge and a pool of cells was developed.  
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In order to determine if the eEF2K targeting shRNA selected cells had reduced eEF2K and 
phosphorylated eEF2-levels, western blotting for these targets was undertaken. Initially the 
pool of stable cells was cultured over a 96 h period with cell samples taken every 24 h for 
western blot analysis. In order to ensure equal amounts of protein were loaded for each 
cell lysate, the protein concentration in each sample was determined by Bradford analysis 
and then equal amounts of protein loaded into each well. The resulting blot is shown in 
Figure 4.9. The blot showed low amounts of the eEF2K present early in culture but that this 
increased as the culture progress and this was mirrored by an increase in phosphorylation 
of eEF2. 
 
 In order to ascertain if the amounts of eEF2K were reduced compared to the host a second 
experiment was run where the amounts in the host of each of these proteins was directly 
compared to the amounts in the eEF2K shRNA stable pool of cells (Figure 4.9). These data 
showed that there was a small reduction in the amount of eEF2K present in the knock down 
cell line and an associated delay in eEF2-phosphorylation but the effect was far less obvious 
than that observed in the transient studies described earlier. This suggests that cells with a 
more pronounced knockdown of eEF2K did not survive the selection process providing 
further evidence that knockdown of this kinase and the loss of control over translation 
elongation is not tolerated by CHO cells. Further, the fact that eEF2K expression is observed 
later in culture in the knockdown cells also suggest that these cells are able to up-regulate 
eEF2K expression to overcome the shRNA effect or that the shRNA is not highly/well 
expressed in these cells. However, as there was a small knockdown of eEF2K the stable pool 






































































Figure 4.9 (b) Repeat western blot analysis of the eEF2K knockdown stable cells lines 
(eEF2KD) and the CHO Flp-In parental cell line (Host) used in the construction of the 
eEF2KD cell line. Both cell lines were cultured for a period of 96 hours with cell lysates 
collected every 24 hours. The samples were then probed for levels of total and 
phosphorylated eEF2, eEF2K. Samples were also separated on an SDS-PAGE gel and 
stained with Coomassie brilliant blue as a loading control.   
Figure 4.9 (a) Western blot 
analysis of CHO cells selected for 
during construction of eEF2K 
knockdown stable cell lines. Stably 
expressing CHO cells were cultured 
for 96 hours with biological 
duplicate lysates taken every 24 
hours. The samples were then 
probed for levels of total and 
phosphorylated eEF2, eEF2K and 





4.2.6.2 Growth of the stable eEF2K shRNA cell lines  
To assess if there was any effect on the growth of the CHO cells stably expressing the eEF2K 
shRNA construct, the cells were seeded into T25 flasks whilst control cells were seeded at 
the same time. The growth profile cultures were set up in biological duplicate and the 
viable cell concentration determined in each flask over a four day period. The resulting 
growth profiles are shown in Figure 4.10. As can be seen in Figure 4.10, there was no 
appreciable difference in cell concentration or viability of the cells expressing the eEF2K 
shRNA when compared to the control cell line (CHO Flp-In parental cells) across the four-
days of culture. This is likely to reflect the fact that there was only a small knockdown in 
eEF2K amounts as determined by western blotting. It is also possible that a greater effect 
may have been observed at longer culture duration when nutrients become limiting and 
translation is slowed but this was not determined here. It is most likely that the small 

























































































Figure 4.10 The average viable cell number (a) and average cell viability (b) of CHO 
Flp-In parental cells (H) and the eEF2K shRNA stable cell lines (KD) over a period of 
4 days/96 hours. Cells were counted in biological duplicate, n=2 which were 






4.2.6.3 Use of 
35
S Metabolic Labelling of Nascent Polypeptides to Determine if Stable 
Over-Expression of the eEF2K Targeting shRNA Effects Global Protein Synthesis  
The western blot data on the stably generated eEF2K targeting shRNA suggested that those 
cells generated using the process did not exhibit a significant knockdown of eEF2K and 
hence there was not a major effect upon eEF2 phosphorylation as determined by western 
blot. Further, the growth curve data again suggested there was little difference between 
the host control and stably expressing eEF2K shRNA knockdown plasmid. To further 
investigate if there was any effect on protein synthesis in the eEF2K shRNA harbouring cells, 
35
S Met metabolic labelling studies were undertaken on the control host and knockdown 
cells. 
 
 For radiolabelling, the routine maintenance media was supplemented for 1770 kBq/ml Pro-
Mix L-[
35
S] cell labelling mix (GE Healthcare) then incubated for 1 h before cell lysates were 
collected to determine 
35
S incorporation over the 1 h period which would be indicative of 
protein synthesis. This process was used rather than changing to cysteine- and methionine-
deficient media as this in itself can result in stress to the cell and changes in protein 
synthesis. 
 
From the growth data of the eEF2K targeted shRNA stable CHO Flp-In cells, two time points 
were determined for the addition of the 
35
S isotope, 68 hours post-seeding of the cells 
when these were considered to be in the rapid growth phase of growth, and 120 hours 
post-seeding of the cells where the cells would be in the stationary phase of growth (see 
Figures 4.10). It was important to investigate both these potential time points as during 
rapid cell growth when there is also no nutrient limitations upon the cells, it would be 
expected that knockdown of eEF2K would have little effect on protein synthesis rates as 
protein synthesis would be at a maximum. However, when cell growth slows and nutrients 
become limiting protein synthesis might be expected to decrease and elongation slowed.  
 
The cell lysates were collect and separated by SDS-PAGE, the gels dried and then exposed 
to X-ray film for 5 hours. The resulting autoradiograph is shown in Figure 4.11. The 
autoradiographs showed the same banding patterns between the host and eEF2K shRNA 
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harbouring cells at both the 68 and 120 h time points. Whilst the banding intensity was 
more-or-less equivalent at the 120 h time point, indicating a similar level of protein 
synthesis between the two samples, there was a reduced banding intensity in the eEF2K 
knockdown samples (Figure 4.11). It was expected that the knockdown cell line would if 
anything show enhanced protein synthesis compared to the host cell line. However, it 
appears that the knockdown either has no effect or has a negative effect upon global 
protein synthesis. The growth curve data also showed a lower number of cells around 3 
days into culture in the eEF2K cells than the host, suggesting that protein synthesis and cell 
growth may be marginally compromised in these cells at this stage of culture. However, the 
lack of an obvious knockdown probably means that there is insufficient difference in eEF2K 
amounts between the control and shRNA harbouring cells to detect a difference in the 
protein synthesis. When cell lysate samples from these cell lines were probed by western 
blotting for eEF2K and eEF2 at 68 and 120 h of culture time points there was no obvious 
difference in the amounts of eEF2K or eEF2 phosphorylation (see Figure 4.12). 
Densitometry analysis of the western data suggested that eEF2 phosphorylation may have 
been elevated in the shRNA eEF2K harbouring cells compared to that observed in the host 













Fig 4.11 Lysates of CHO Flp-In 
parental cells (H) and the eEF2K 
shRNA stable cell lines (KD) 
cultured for 67 and 119 hours and 
then incubated with a 
35
S Met 
metabolic label in routine 
maintenance media for 1 hour. 
Lysates were separated by SDS-
page electrophoresis; the 
subsequent gel was then dried 
and exposed to x-ray film for 5 
hours. Gel loading was normalised 
using a Bradford assay to quantify 
















Figure 4.12 (a) Lysates of CHO Flp-In parental cells (h) and the eEF2K shRNA stable cell 
lines (kd) cultured for 68 and 120 hours analysed via western blotting, lysates were 
collected in conjunction with the 
35
S Met radiolabelling experiment. Cells were cultured 
without the addition of the 
35
S Met label. Lysates were probed for levels of total and 
ƉŚŽƐƉŚŽƌǇůĂƚĞĚĞ& ? ?Ğ& ?<ĂŶĚɴ-actin as a loading control. (b) Densitometry analysis 
ŽĨƚŚĞďĂŶĚŝŶƚĞŶƐŝƚŝĞƐǁĞƌĞŶŽƌŵĂůŝƐĞĚƚŽƚŚĞŝƌĐŽƌƌĞƐƉŽŶĚŝŶŐɴ-actin and relative levels 
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4.2.6.4 Effect of Stable eEFK shRNA Expression upon Recombinant Protein Production  
The work described earlier in this chapter where eEF2K was knocked down transiently 
showed this could result in enhanced firefly luciferase expression in CHO cells (see section 
4.2.3.1). Although the stable expression of the eEF2K shRNA appeared to result in the 
selection of cells whereby knockdown was limited compared to the control cells, it may be 
possible that the effect of the shRNAs knockdown was sufficient to alter the cellular protein 
production of the firefly luciferase reporter gene. To investigate this, the eEF2K shRNA cell 
lines were transiently transfected with the pGL3 firefly luciferase construct. 48 hours post 
transfection, light counts per second were measured as well as viable cell counts and from 
this the amount of luciferase (as determined by luciferase activity) per cell was calculated. 
The resulting firefly luciferase expression observed is reported in Figure 4.13.  There was no 
change in the firefly expression per cell produced from the stable eEF2K knockdown cells 
when compared to the CHO Flp-In parental cells used as a control  (Figure 4.13).  
 
These data collectively confirm that the knockdown of eEF2K by stably expressed eEF2K 
shRNA is not as potent as transient expression of the shRNA. It is likely that CHO cells are 
not capable of maintaining a higher level of stable shRNA expression, such as that observed 
in the transient experiments. If this is the case, it is likely that during the stable cell 
construction, those cells with higher expression of the shRNA eEF2K targeting hairpin are 
not able to survive the antibiotic selective pressure as well as the knockdown of eEF2K. 
Meanwhile, those cells that had a lower level of shRNA expression survived the antibiotic 
pressure as well as being able to maintain eEF2K levels and control of eEF2 over longer 






























Fig 4.13 Determination of firefly luciferase activity via measurement of LCPS (Light counts 
per a second) 48 hours post transfection of 2µg pGL3 firefly luciferase into CHO Flp-In 
parental cells (Host) and the eEF2K shRNA stable cell lines (KD); Cells were also treated with 
transfection reagent only (TR) as a control. Cell counts were taken in correspondence of the 















4.3 Conclusions and Summary Statements from this Chapter  
The data presented in this chapter shows that the transient expression of an shRNA plasmid 
targeted to eEF2K can be used to successfully knockdown eEF2K transiently and to prevent 
eEF2 phosphorylation. However, CHO cells do not appear to tolerate the knockdown of 
eEF2K stably or at only very low levels. This suggests that a sustained, high level of eEF2K 
knockdown is lethal to the cell; which would result in the loss of eEF2 regulation for 
extended period of time. It has been suggest by Ashour et al. (2014) in tumour cells eEF2K 
down regulation  results in in cellular death. This supports the data shown in this chapter 
that it is only possible to stably express a low level of eEF2K shRNA. Therefore if eEF2K is 
not present within the cell, the cell is more susceptible to pro-apoptotic signalling.  
 
The data in this chapter therefore suggests that any cells expressing high levels of the 
eEF2K shRNA would succumb to apoptosis/cell death during the antibiotic selection process 
of stable cell line production; as well as the cells that had not integrated the shRNA pl asmid. 
This would mean only a small pool of CHO cells that have integrated the eEF2K shRNA 
plasmid into their genome, allowing the cells to survive the antibiotic selection process, 
with a low eEF2K shRNA expression, would survive. A possible method to circumvent this 
would be to use an inducible expression system whereby expression of the shRNA could be 
ŝŶƚŚĞ ‘ŽĨĨ ?ŵŽĚĞƚŚĞŵĂũŽƌŝƚǇŽĨƚŚĞƚŝŵĞďƵƚƐǁŝƚĐŚĞĚƚŽ ‘ŽŶ ?ǁŚĞŶŝƚŵŝŐŚƚďĞŵŽƐƚƵƐĞĨƵů
later in culture 
 
Any effect of the stable expression of the eEF2K shRNA appears to be until only around 48 
hours after seeding of a culture, approximately the same length as the transient expression. 
Although the levels of eEF2K within the CHO Flp-In parental cell line are similar to that of 
the eEF2K knockdown cell line post 24 hours seeding, the rate at which eEF2K is expressed 
is reduced within the eEF2K knockdown cell line around 24 hours (Figure 4.9b). As the 
growth profile of the stable CHO Flp-In eEF2K knockdowns is similar to that of the original 
parental cell line (Figure 4.10), the delay of eEF2K expression is most likely due to the 
knockdown effects of the shRNA. It is likely that after the effects of the antibiotic selection 




Transient knockdown of eEF2K was shown to be a much more effective approach to 
knocking down eEF2K protein expression. The effect of the shRNA knockdown is only a 
short period of 24-48 hours, but with the majority of eEF2K protein expression suppressed 
over this period (Figure 4.2). This could in part be seen in the stable eEF2K knockdown cell 
lines as the eEF2K expression increase 72 hours post seeding (Figure 4.9), suggesting either 
the reduced effect of the antibiotic selection or an up regulation of  the eEF2K mRNA 
transcription and translation.  
 
Signalling to eEF2 in response to the transient transfection of the eEF2K shRNA appears to 
be at least partially mediated via the Ca
2+/
calmodulin/eEF2K axis. Live cellular imagining of 
HEK cells stabling expressing an ER localised FRET molecule that responds to Ca
2+
 (Figure 
4.8) showed an influx of Ca
2+
 out of the ER into the cystol 24 hours post transfection of 
eEF2K shRNA. Due to the reduced eEF2K expression, the cells appear to release calcium 
into the cystol in an attempt to activate calmodulin and in turn active eEF2K. These releases 
of calcium in to the cystol would also result in the activation/modulation of other proteins 
regulated by calcium such as the RAS GTPases (Aspenström 2004) and calcium dependant 
transcription factors (Fodor et al. 2013). Interestingly, visualisation of HEK cells revealed a 
change in cellular morphology upon eEF22K knockdown. Cells that had been transfected 
with the eEF2K shRNA were more rounded and the ER capacity reduced compared to those 
cells only treated with transfection reagent. 
 
Transient expression of the eEF2K shRNA into CHOK1D6 cells stably expressing firefly 
luciferase, a non-secreted protein, resulted in a 5-fold increase in luciferase expression 
(Figure 4.4) showing that a knockdown of eEF2K did increase the short term productivity of 
these cells. However, in the biopharmaceutical industry the therapeutic proteins are 
secreted from the cell therefore a similar transfection in two CHO Flp-In cell lines stably 





The effect of the shRNA appears to depend upon the activity and capacity of each cell line, 
as knockdown of eEF2K in cell line 14 only marginally increased the level of gaussia 
luciferase produced where as in cell line 12 there was little to no knockdown of eEF2K, but 
the levels of gaussia luciferase showed a greater increase in expression. The reason for this 
is not clear but collectively the results provide further evidence to support the idea that the 
up-regulation of elongation can increase recombinant protein production. 
 
When cell line 14 was put under nutrient stress by being cultured in leucine depleted media 
for 24 hours post transfection of eEF2K shRNA, the only change was the levels of eEF2 
phosphorylation (see figure 4.7) but levels of eEF2K remained similar to those of the control 
samples. It is possible that eEF2 activity has been increased due to the stress induced by the 
deprivation of leucine. Further, investigations into the levels of eEF2 and eEF2K mRNA as 
well as an extension of the time in culture before samples were collected could lead to a 
clearer picture of what is occurring under these conditions.  
 
When compared to the short term (48 hour) transient effects of over expression of wild 
type eEF2 and the Thr56Ala and Thr56Glu eEF2 mutants in CHOK1D6 cells that stably 
express firefly luciferase transient knockdown of eEF2K had a greater effect upon intra 
cellular protein production as shown in figure 4.5. When co-expressed with the wild type 
eEF2 the knockdown effect appears to be dismissed. It is possible that is due to the stress 
caused by a second transfection. When the eEF2K shRNA plasmid was transiently 
transfected into the stable eEF2 CHO Flp-In stable cell lines the cells did not survive. It 
would appear that the effects of the eEF2K shRNA and consistent over expression of eEF2 









Investigations into the Link between Mammalian Target of 
Rapamycin (mTOR) Signalling, eEF2K, eEF2 Phosphorylation 
and CHO Cell Growth and Recombinant Protein Productivity 
 
5.1 Introduction  
The mammalian target of rapamycin (mTOR) is considered a master regulator of 
intracellular processes, such as protein and lipid synthesis, autophagy and cellular 
metabolism (Laplante & Sabatini 2009b).  There are two known complexes of mTOR: 
mTORC1 and mTORC2 (mTOR complex 1/2). In this chapter the investigation was focused 
on the manipulation of mTORC1 via signalling pathways and the effects of this manipulation 
upon protein synthesis.  
 
As outlined in the introduction to this thesis, the development of mammalian cell lines for 
high level expression of recombinant proteins has progressed such that cell line 
construction projects now routinely produce cell lines that are capable of delivering gram 
per litre yields of product in fed-batch cultures. In previous decades, such yields were 
unheard of whereby titres of 50-100 mg/L were the norm. The improvement of protein 
yield has largely been the result of improved expression vectors, development of medium 
and feeding optimisation, and advanced screening techniques that have dramatically 
improved the viable cell concentrations obtained in the bioreactor and reduced the time 
taken to produce stable production cell lines (Hacker et al. 2009; Wurm 2004). Despite such 
improvements, key areas remain that require further development in an industrial sense to 
reduce the timelines/cost of generating cell lines and improve the cell specific and 
volumetric productivities. One approach to addressing these issues is via engineering of 
cellular systems utilising the ever-improving understanding of the biology of cell growth 
and recombinant protein synthesis, folding, assembly and secretion. With regard to this, 
the manipulation of the mTOR pathway, a master regulator of protein synthesis, ribosome 
biogenesis and cell proliferation, has recently been reported to influence cell growth and 
recombinant protein synthesis from mammalian cells (Dreesen & Fussenegger 2011b). 
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Protein synthesis and ribosome biogenesis are key determinants of cellular biomass and 
protein productivity. However, the roles that these signalling pathway plays in these 
phenotypes, and whether it can be manipulated to enhance them, have yet to be fully 
elucidated. The studies described here investigated the role of mTOR signalling in 
determining the cellular phenotype of recombinant mammalian cell lines and whether this 
signalling system, and the environmental cues to which it responds, may be manipulated to 




Figure 5.1 Simple schematic of mTORC1 signalling in mammalian cells. Grey lines denote 
processes that are not fully understood. 
 
In the previous chapters of this thesis, the investigation was focused on elongation factor 2 
(eEF2) and its regulator, elongation factor 2 kinase (eEF2K). mTORC1 regulates protein 
synthesis via S6K kinase, which regulates eEF2K (see Figure 5.1), in this way eEF2K is 
controlled by mTORC1. When mTORC1 signalling is attenuated, such as under conditions of 
amino acid starvation, eEF2K is activated as mTORC1 inactivation of eEF2K, via S6k kinase, is 
removed and hence eEF2K can phosphorylate eEF2, inactivating it and slowing elongation 
(see Figure 5.1). mTORC1 also regulates initiation of translation via eukaryotic initiation 
factor 4E (eIF4E). mTORC1 mediation of translation is achieved through the binding of 
raptor to ribosomal S6 protein kinase 1 (S6K1) and eukaryotic initiation factor 4E binding 
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protein 1 (4E-BP1), which recruits these substrates to be phosphorylated by mTOR. When 
hypophosphorylated, 4E-BP1 acts as a translational repressor by binding to eIF4E (Figure 
5.1), preventing it interacting with eIF4G to promote ribosome recruitment to the mRNA; 
eIF4E also binds directly to thĞŵZE ?Ɛ ? ?-cap structure. By directly phosphorylating 4E-BP1 






), mTORC1 promotes its dissociation from eIF4E 
allowing the formation of the eIF4F complex and the initiation of cap-dependent translation 
(Fingar et al. 2002). 
 
In this manner mTORC1 signalling directly controls protein synthesis and manipulation of 
the mTOR pathways has been shown to increase cellular proliferation, size and protein 
synthesis and reduce cell death (Dreesen & Fussenegger 2011b; Fingar et al. 2002; 
Schneider et al. 2008). There are now a number of studies that describe (i) how improved 
media composition and feeding can increase cell biomass of recombinant cell lines (Wurm 
2004), (ii) that amino acid deprivation, osmolarity and general culture stress influence 
recombinant protein production from mammalian cells (Han et al. 2010), (iii) that mRNA 
translation can limit recombinant protein synthesis from mammalian cells  ?K ?ĂůůĂŐŚĂŶĞƚĂů ?
2010; Khoo & Al-Rubeai 2009) (iv) that ribosome biogenesis can be manipulated to improve 
recombinant protein expression (Santoro et al. 2009)(vi) that chaperones play a key role in 
antibody biogenesis (Feige et al. 2009; Vanhove et al. 2001), and (vii) that mTOR related 
processes correlated with recombinant protein production (Chong et al. 2009; Dreesen & 
Fussenegger 2011b). Despite these studies, the precise role that mTOR signalling plays in 
determining doubling time, proliferation and recombinant protein synthesis has not been 
defined. Therefore, here it was investigated whether an increase or manipulation of mTOR 
activity in CHO cells producing recombinant protein cells results in an increase in protein 





5.2.1 Investigation of the Relationship between mTOR Signalling and Recombinant 
Protein Production in Recombinant CHO Cell Lines  
In order to investigate any relationship between mTOR signalling and recombinant protein 
production during batch culture of CHO cells, two CHO suspension cell lines with different 
monoclonal antibody (mAb) productivities CHO High producer (CHOHP): regarded as high 
productivity - 560 mg/L in batch shake flasks, CHO Low producer (CHOLP): regarded as low 
productivity  W 170 mg/L in batch shake flasks) were initially cultured in CD-CHO media and 
cell pellets harvested during culture for analysis of protein target amounts by western blot. 
The growth data from these cultures is shown in Figure 5.2.  The growth curves for the 
CHOHP and CHOLP cell lines (Figure 5.2) show that the cell viability begins to decline after 
seven days of growth.  Therefore lysates of both cell lines between days 4-7 were prepared 
and probed for total and phosphorylated eEF2 and total eEF2K amounts. The subsequent 
blot analysis suggested that there was no obvious change in the amounts of these factors 
present, or the phosphorylation status of eEF2, across this section of the time course or 
between the cell lines (Figure 5.3). In order to allow comparisons between the cell lines and 
time points, the total amount of protein loaded was normalised by a Bradford assay and 
the same total number of cells were lysed. These data suggest that at least across the time 
course investigated for these two cell lines, there was little difference in the control of 





























































































Figure 5.2 Growth curve data showing viable cell concentration and cell viability of the 
recombinant CHO high producer and CHO low producer cell lines expressing a model 











In order to further investigate any potential relationship between the recombinant CHO cell 
lines ability to produce recombinant monoclonal antibody (mAb) and translation elongation 
ƐƚĂƚƵƐĚĞƚĞƌŵŝŶĞďǇĞ& ?ĂŶĚĞ& ?<ůĞǀĞůƐ ?ĂǁŝĚĞƌƉĂŶĞůŽĨŵď ‘ƉƌŽĚƵĐĞƌ ‘,KĐĞůůůŝŶĞƐ
with a range of mAb titres over a batch culture were therefore investigated. The range of 
antibody yields from these cell lines in a batch culture were from 240 to 690 mg/ml. The 
CHO cell lines investigated were labelled as H1, H2, M1, M2, L1 and L2 (High prouder 1 & 2, 
Mid producer 1 & 2 and Low producer 1 & 2) which had antibody productivities of 691, 541, 
415, 372, 272 and 244 mg/L each in a batch culture when harvested on the same day (10 
days of batch culture). Cell lysates were collected on days 6 and 8 of culture when the cells 
were in early stationary and late stationary phase, where the majority of antibody 
production occurred. These samples were then probed for total eEF2 and phosphorylated 
eEF2 and eEF2K, the resulting blots are shown in Figure 5.4. From the western analysis 
alone there was no obvious trend in the change of either of these proteins or the 






 Figure 5.3 Western blot analysis of eEF2, phosphorylated eEF2 (eEF2-P) and eEF2K on days 
4, 5 ,6 and 7 of batch culture for the CHO High producer and CHO low producer 
recombinant cell lines expressing a model monoclonal antibody. Lane 1 and 2 = day 4 
samples, lane 3 and 4 = day 5 samples, lane 5 = day 6 sample, lane 6= day 7 sample, lane 7 
and 8= day 4 samples, lane 9 and 10= day 5 samples, lane 11 and 12= day 6 samples, lane 


























Although an equal amount of protein was loaded for analysis from each sample as 
ĚĞƚĞƌŵŝŶĞĚƵƐŝŶŐĂƌĂĚĨŽƌĚĂƐƐĂǇ ?ƚŚĞɲ-tubulin control blot suggested different protein 
loading and therefore densitometry analysis was undertaken on the images and the 
amounƚ ŽĨĞĂĐŚ ďĂŶĚ ŶŽƌŵĂůŝƐĞĚ ƚŽ ƚŚĞ ɲ-tubulin loading control to determine if this 
revealed any relationship between these band intensities and culture productivity. The 
densitometry analysis confirmed the results of the initial study looking at the CHOHP and 
CHOLP cell lines; that the levels of total and phosphorylated eEF2 did not relate to a 
recombinant cell lines capacity for mAb production (Figure 5.5). Between day 6 and day 8 
levels of total eEF2 appeared to reduce slightly across most of the cell lines,  with cell lines 
H2 and L2 being the exception with a larger decrease in eEF2 levels. Phosphorylation of 
eEF2 generally increased from day 6 to day 8, which was expected, as eEF2 phosphorylation 
 
Figure 5.4 Western blot analysis of eEF2, phosphorylated eEF2 (eEF2-P) 
and eEF2K on days 6 (A) and 8 (B) during batch culture of a panel of 
recombinant CHO cell lines expressing different amounts of a model 
monoclonal antibody. Lane 1 and 2 = High level producing ce ll line 1, 
Lane 3 and 4= High level producing cell line 2, Lane 5 and 6= Mid level 
producing cell line 1, Lane 7 and 8= Mid level producing cell line 2, Lane 
9 and 10= Low level producing cell line 1, Lane 11 and 12= Low level 





increases over time in cell culture due to nutrient deprivation and increases in culture 
stress. Levels of eEF2K were difficult to detect but remained relatively constant throughout 
culture (Figure 5.5). These data suggest that the amounts of eEF2 and eEF2K are tightly 
controlled by the cell but do not underpin the recombinant capability of a CHO cell for 
producing monoclonal antibody. This agrees with the data in the previous chapters 
whereby the over-expression of eEF2 or knockdown of eEF2K was difficult in stable cell 
lines, once again suggesting that if the regulation of these crucial elongation control points 
































































Figure 5.5 Densitometry analysis of the western blots images shown in Figure 5.4. 
Analysis was undertaken using the ImageJ freeware. The density of each band was 
determined and then normalised to the tubulin loading control to compare 
expression of each target on the different days of culture in the different CHO 
antibody producing cell lines. H1 and H2= high producing cell lines 1 and 2, M1 and 
M2= Mid producing cell lines 1 and 2, L1 and L2= Low producing cell lines 1 and 2. 
eEF2T 
   
eEF2P eEF2K 
   
eEF2P eEF2K eEF2T 
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5.2.2 Investigating changes in mTOR signalling throughout culture in a host CHO cell line 
using mRNA profiling 
As described in the introduction to this thesis and this chapter, eEF2K and hence 
phosphorylation of eEF2 is controlled by mTOR signalling, particularly in response to 
nutrient depravation. Further, several reports have now suggested that mTOR signalling 
may play a role in the control of CHO cell growth and properties that underpin the ability to 
generate/produce recombinant protein from these cells. A wider study to investigate how 
mTOR signalling changes throughout batch culture was therefore undertaken using the 
commercially available mTOR Signaling RT
2
 Profiler PCR Array from QIAGEN. The array used 
was a panel of primers designed to allow the profiling of the expression of 84 genes in the 
mTOR signalling pathway. This includes profiling of mTORC1 and mTORC2 complexes, 
positive and negative regulators of each of these complexes, mTOR downstream effectors, 
and genes involved in other cellular processes related to mTOR signalling. De tails of all 
genes in the array are provided in Appendix 7.6. As there are many inputs/outputs into and 
out of the mTOR signalling pathway, it was envisaged that using this screening approach 
additional targets may be identified for the manipulation and control of mTOR signalling.  
 
The monetary cost of these arrays allowed the ability to only undertake repeat experiments 
on two samples. The CHO Flp In parental cell line was chosen as the cell line to profile as it 
had been used extensively in Chapter 3 and  4. CHO cell lysates were therefore collected 68 
h and 120 h post-seeding of a culture when the cells would be in exponential growth or 
stationary phase. The total RNA was then extracted from these cell lysates and used for the 
qRT-PCR array screening. The ƐĐƌĞĞŶƐ ǁĞƌĞ ƌƵŶ ĂĐĐŽƌĚŝŶŐ ƚŽ ƚŚĞ ŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ
instructions and then the data analysed following the manual instructions provided by the 
manufacturer and the Excel spreadsheet provided by Qiagen. Using these data and the 
house keeping gene normalises provided on the array plate, a fold-change in expression 
was calculated for each of the genes at the mRNA level between the 120 and 68 h time 
points. The resulting calculations from this (the Excel Spreadsheet) are shown in Appendix 
7.6.2. The fold-change reported here (see Table 5.1) is calculated using the crossing point 
threshold normalised to the control expression and the equation: 
 
Fold-Change = (2^(- Delta Delta Ct)) in the normalized gene expression (2^(- Delta 
Ct)) in the Test Sample divided the normalized gene expression (2^(- Delta Ct)) in 
the Control Sample.  
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The fold-regulation or change represents fold-change results in a biologically meaningful 
way; where the fold-change values greater than 1 indicate a positive or an up-regulation, 
and the fold-regulation is equal to the fold-change. Fold-change values less than 1 indicate 
a negative or down-regulation. In addition to the fold-change, the software also comments 
ŽŶƚŚĞƌĞůŝĂďŝůŝƚǇŽĨƚŚĞĚĂƚĂ ?tŚĞƌĞ ‘ŽŬĂǇ ?ŝƐƉůĂĐĞĚŝŶƚŚĞĐŽŵŵĞŶƚƐďŽǆ ?ŵĞĂŶŝŶŐƚhat the 
data is considered reliable and robust; comments A-C (see Appendix 7.6.2) generally mean 
that a higher number of replicate results should be run to be confident in the data. For the 
purposes of this investigation only genes where the data confidence was okay and a fold-
change greater than 2 was observed were considered. The genes that were found to meet 
these criteria are listed in Table 5.1 below. 
 
The data from the comparison of the mTOR screen at 68 and 120 h of growth showed that 
all genes, that meet the criteria except for one (Hsp90ab1) were up-regulated at 120 h 
compared to 68 h. This suggests that at 120 h the cells were responding to changes in 
ŐƌŽǁƚŚĐŽŶĚŝƚŝŽŶƐďƵƚǁĞƌĞŶŽƚŝŶĂ  ‘ĐƌŝƚŝĐĂů ? ƐƚĂƚĞƐƵĐŚ ƚŚĂƚŐůŽďĂůŐĞŶĞĞǆƉƌĞƐƐŝŽŶǁĂƐ
being down-regulated. None of the genes involved in autophagy or energy stress were 
differentially regulated to the extent of those above >2-fold; again suggesting that at the 
120 h time point the cell was not sufficiently stressed compared to the 68 h time point to 
result in the up-regulation of genes involved in these responses/processes. 
 
Interestingly, there were both positive (e.g. Akt1/2 and Rag A/C) and negative up-stream 
regulators (e.g. Pten and Lkbkb) of both mTORC1 and mTORC2 up-regulated at the 120 h 
time point relative to that observed at the 68 h time point. This suggests that at 120 h of 
culture, control of mTOR signalling by the cell was important. Further, the majority of these 
changes were up-regulation of positive regulators suggesting that the first responses to any 
stress later in culture is to try and maintain mTOR signalling (and thus protein synthesis) in 
order for the cell to continue growing and synthesising protein. The maintenance of mTOR 
signalling allows the downstream effectors to be maintained as well. This balance is 
obviously a crucial point for cell survival and the ability to continue producing recombinant 
protein and suggests that the engineering of upstream regulators of mTOR may allow the 
extended performance of cells. This of course would need to be further investigated by 
manipulating the amounts of those targets identified here to see if this did indeed give the 




Table 5.1 mTOR related genes shown to be differentially regulated up- or down by >2-fold at the 
mRNA level between 120 and 68 h of batch culture of the CHO host FRT cell  line using the 
commercially available mTOR Signaling RT
2
 Profiler PCR Array from QIAGEN. A  Wve fold-change 
means a decrease in mRNA expression at 120 h compared to 68 h, a +ve fold-change means and 













Akt1 2.82  mTORC1/C2 +ve 
regulator 
   
Akt2 2.86  mTORC1/C2 +ve 
regulator 
   
Cab39I 3.62  mTORC1/C2  
-ve regulator 
   
Gsk3b 2.78   mTORC2 +ve 
regulator 
  
Hras1  2.98  mTORC1 +ve 
regulator 
   
Lkbkb 2.84  mTORC1/C2  
-ve regulator 
   
mTOR** 2.92 mTORC1  
mTORC2  
    





Ppp2ca 2.90   mTORC1  
-ve regulator 
Translation  





Pten 2.24  mTORC1  
-ve regulator 
   












Rps6kb1  2.78   mTORC1/C2 
+ve regulator 
Translation  
Rptor 3.15 mTORC1      
Rraga 2.28  mTORC +ve 
regulator 
 Amino acid 
response 
 
RRagc 3.11  mTORC +ve 
regulator 
 Amino acid 
response 
 
Sgk1  3.57   mTORC2 +ve 
regulator 
  
Vegfa 2.37   mTORC1 +ve 
regulator 
Angiogenesis  
Vegfb 2.67   mTORC1 +ve 
regulator 
Angiogenesis  
Actb 2.11    Cytoskeleton  
Hsp90a
b1 
-4.39     Heat shock 
protein 





5.2.3 The Effects of adding Phosphatidic acid (PA) or Phorbol Myristate acetate (PMA) to 
CHO Cells, eEF2 Phosphorylation and Recombinant Protein Production 
Another direct way to try and influence mTOR signalling is to add molecules to the cell 
culture supernatant that can act upon the mTOR pathway. A number of such molecules 
have now been identified, although many of these can also in/activate other pathways as 
well and therefore it can be difficult to determine if any effects observed are related to 
mTOR signalling or due to other, off-target, effects. Despite this, the addition of such 
molecules to cell cultures and observation of the ensuring response(s) can be useful, 
particularly if investigating the effect on specific targets such as eEF2 phosphorylation and 
recombinant protein synthesis.  
 
A number of molecules are known to activate the mTOR pathway and enhance cell growth 
or protein production (Xu et al. 2004; Hagland et al. 2013; Hayashi & Proud 2007; Avila-
Flores et al. 2005; Roux et al. 2004; Dreesen & Fussenegger 2011b). A study into the 
literature around the mTOR pathways and the mTOR RNA panel revealed that there were 
several small molecules that can directly/indirectly activate mTOR. Two of these molecules 
were selected for further experimental study, based upon their availability and activity 
within the mTOR pathway. These molecules were phosphatidic acid (PA) and phorbol 
myristate acetate (PMA). Figure 5.6 below shows where and how these molecules elicit a 
response on the mTOR pathway. 
 
PA directly interacts with/activates mTOR within the cytosol of the cell; therefore addition 
of PA could provide artificial activation of mTOR. PA can directly activate mTORC1 after 
being produced from a number of sources, such as phosphatidylcholine. On-the-other-hand, 
PMA is known to promote cell growth through the mTOR and MAP kinase pathways, via 
activation of protein kinase C (Roux et al. 2004). Both of these were therefore investigated 
































5.2.3.1 The Effects of Adding Phosphatidic acid (PA) to CHO Cells, eEF2 Phosphorylation 
and Recombinant Protein Production 
The initial investigations were to add PA to a recombinant CHO cell lines expressing a model 
monoclonal antibody. For this, the cell line CHOHP described and used in section 5.2.1 was 
utilised. The PA molecule used in these experiments was derived from egg yolk lectin, it is 
therefore safe to handle and easy to acquire. As PA activates mTOR within the cystol, it is 
necessary for it to be taken up through the plasma membrane. The PA was added on day 4 
of a culture of CHOHP cells and then samples taken 24 and 48 h post-addition for analysis of 
mTOR, eEF2, eEF2-phospho and eEF2K amounts in the cell lysates. A total of 100µM of PA 
(in a buffer of 150mM NaCl, 10mM Tris-HCL pH 8) was added to each culture and controls 





































Recruits mTORC1 to 














Figure 5.6 Schematic of mTOR signalling showing where and how Phosphatidic acid (PA) or 
Phorbol Myristate acetate (PMA) act and potentially elicit a cellular response. Highlighted 
with purple outlines. 
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et al. 2009; Lim et al. 2003) to the CHO suspension cells on did not result in any major 
changes to the levels of mTOR, eEF2K and eEF2 observed (Figure 5.7). This is most likely due 
to PA needing to cross the cellular membrane, either PA was not able to cross the 
membrane due to the hydrophobicity of the PA molecule or the concentration was not high 




















As PA is most likely difficult to deliver through the cellular membrane, this is likely to pose a 
significant barrier for the treatment to be effective. Addition of a precursor of PA could be 
more effective in mTOR activation or genetic manipulation of Phospholipase (PLD)/ 
diacylglycerol kinase (DAGK)/ Lysophosphatidic acid acyltransferase-beta (LPAAT).  
Unfortunately, due to time restrictions and availability of DAG these experiments were not 






Figure 5.7 Western blot analysis of eEF2, phosphorylated eEF2, eEF2K, mTOR, 4EBP-1 and 
phosphorylated 4EBP-1 in the CHO high producer samples taken at 0, 24, and 48 h after 
addition of 100µM PA on day 4 of culture. E-actin is shown as a loading control. 
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5.2.3.2 The Effects of Adding Phorbol Myristate Acetate (PMA) to CHO Cells and 
Subsequent Recombinant Protein Production 
In addition to investigating the effect of PA on CHO cells, PMA (phorbol myristate acetate) 
was also investigated. PMA is a class 2 drug, known for its tumorigenic properties (Roux et 
al. 2004). It is known to promote cell growth through the mTOR and MAP kinase pathways, 
via activation of protein kinase C (see Figure 5.6). As PMA is capable of passing through the 
cellular membrane it was likely to provide a more efficient method of experimentation on 
these signalling pathways and any effect on recombinant protein expression. PMA 
indirectly activates mTOR via activation of PKC (protein kinase C), which actives RS6K 
(Ribosomal S6 Kinase), which inhibits the Tsc1/Tsc2 (tuberous sclerosis) complex and 
therefore allows for Rheb (Ras homolog enriched in brain) to become active and activate 
mTOR (see Figure 5.6).  
 
Previous research into PMA activity has shown that a 100 nM concentration is enough to 
elicit an effect in cells (Roux et al. 2004; Aeder et al. 2004). Therefore based upon this, 
CHOK1D6 cells stably expressing firefly luciferase were treated with 0.5-5 PM PMA and 24 
hours post PMA treatment the luciferase expression was determined. As the PMA is 
delivered in DMSO, cells where DMSO alone had been added were used as a control for 
each concentration of the drug investigated. The resulting luciferase expression for each 
sample is shown in Figure 5.8. This data showed that as the amount of DMSO added was 
increased, an increase in firefly luciferase expression was also observed, suggesting that the 
addition of the DMSO resulted in an increase in recombinant protein expression 
independent of the PMA. However, the PMA also appeared to further enhance the increase 
in recombinant firefly luciferase expression observed (Figure 5.8). In order to determine the 
effect of the PMA alone, the luciferase expression in the PMA samples was expressed as a 
percentage of the control DMSO samples and is shown in Figure 5.8. This showed that even 
at a concentration of 0.5 PM there was an approximately 150% increase in firefly luciferase 
ĞǆƉƌĞƐƐŝŽŶ ? dŚĞ  ‘ŐƌĞĂƚĞƐƚ ? ƌĞƐƉŽŶƐĞ ĨƌŽŵ ƚŚĞ WD ƌĞůĂƚŝǀĞ ƚŽ ƚŚĞ D^K ĐŽŶƚƌŽů ǁĂƐ
observed at a concentration of 2 PM PMA (approximately 325% of the DMSO control) and 
at 5 PM this was reduced to approximately 200% of the control. The actual highest amount 
of firefly luciferase was observed in the 5 PM sample but the amount of DMSO here 








































Figure 5.8 (a) Expression of firefly luciferase measured in light counts per a second 
(LCPS) from CHOK1D6 cells 24 hour post addition of 0.5-5 µM PMA or the equivalent 
volume of DMSO, n=4, p<0.05 when comparing the DMSO values against the PMA 
values at 2 µM and 5 µM PMA (b) The percentage increase of LCPS between the 





The addition of DMSO and PMA therefore appeared to have an effect on recombinant 
firefly luciferase expression, with 2 PM PMA giving the greatest response due to addition of 
PMA. A second experiment was therefore undertaken whereby 2 PM PMA in DMSO was 
added to the CHO recombinant monoclonal antibody producing cell lines CHOHP and 
CHOLP described in section 5.2.1 and the effect on recombinant antibody production, eEF2 
phosphorylation and mTOR determined.  The 2 PM PMA was added on day 6 of culture and 
samples taken 24 and 48 h post addition for both western blot analysis and analysis of 
secreted antibody in the supernatant. The western blot analysis from these samples is 































































Figure 5.9 Western 
blot analysis of (a) 
total eEF2 and 
phosphorylated 
eEF2 in the high 
producing CHO cell 
and low producing 
CHO cell samples 
taken at 0, 24, and 
48 h after addition 
of PMA on day 4 of 
culture. P= Cells 
treated with 2 
µMPMA, C= Cells 
treated with DMSO, 
eEF2-T= total eEF2, 
eEF2-P= 
Phosphorylated 
eEF2 (b) Western 
blot analysis of 
mTOR and eEF2K in 
the same samples. 
H.P= High producer, 
L.P= Low producer. 
(c) Densitometry 
analysis of the 
banding pattern of 
mTOR and eEF2K in 
the high and low 
producer cell lines, 
normalising the 
band intensities to 









The western blot data of the CHO recombinant cell lines expressing a monoclonal antibody 
showed that PMA did reduce the amount of phosphorylated eEF2 observed in samples 
compared to the control samples (eEF2-P levels) but not the total levels of eEF2 (Figure 5.9). 
This shows that PMA can influence eEF2 phosphorylation by addition to the supernatant of 
cells, but that the reduction in eEF2 phosphorylation was much less than that observed 
upon eEF2K knockdown reported in Chapter 4. Western blot data for the e EF2K and mTOR 
ƐĂŵƉůĞƐǁĞƌĞŶŽƌŵĂůŝƐĞĚƚŽƚŚĞůĞǀĞůƐŽĨɲ-tubulin, the loading control, via densitometry 
analysis due to the fluctuation of tubulin between samples. The analysis showed that eEF2K 
and mTOR levels decrease in the high producer cell line over 48 hours. The low producer 
ĐĞůůůŝŶĞƐƐŚŽǁĂ ‘ƐƉŝŬĞ ?ŽĨŵdKZĂŶĚĞ& ?<ůĞǀĞůƐ ? ?ŚŽƵƌƐƉŽƐƚWDƚƌĞĂƚŵĞŶƚǁŝƚŚĞ& ?<
levels slightly elevated and the mTOR levels increased by approximately 50%. This increase 
of mTOR activity coincides with the decrease of eEF2 phosphorylation, therefore it 
suggested that the addition of PMA has influenced mTOR activity, which in turn reduces 
eEF2K activity, in spite of the slight increase of eEF2K levels which result in a decrease of 
eEF2 phosphorylation.   
 
In order to determine whether this change in eEF2 phosphorylation and mTOR levels across 
the 48 h time course when PMA was added influenced antibody amounts in the 
supernatant from the recombinant CHO cells, the amount of antibody in the supernatant 
over the 48 hour time course was analysed by ELISA. The resulting data is shown in Figure 
5.10 where the amounts are relative to that observed at the time when the PMA was added 
(0 hours, 0 h). In the lower producing CHO cell line there was an almost 4.5-fold increase in 
the amount of antibody in the supernatant 48 h post-addition of the PMA compared to the 
0 h time point that was not reflected in the DMSO control (Figure 5.10).  Such an increase 
was not observed in the higher producing cell line. These data suggest that in the  low 
producing cell line the PMA is able to elicit a response that overcomes a potential limiting 
block(s) in this cell line that is not present in the high producing cell line. There was little 
difference in the total eEF2 and phosphorylated eEF2 amounts between these cell lines 
when initially investigated, suggesting that although phosphorylation is reduced this is not 
the key response that results in the observed increase in antibody production from the low 
producing cell line. It is interesting that this response is only observed in the low producing 
cell line. Thus, whatever the mechanism by which PMA results in increased antibody 
production from the low producing cell line might not be limiting in the high producing cell 
lines. Further investigations into identifying this might provide biomarkers for the 
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identification of high and low producing cell lines. Unfortunately there was not time to 























In addition to the analysis of eEF2 phosphorylation, mTOR and antibody production over 
the 48 h period post-PMA addition to the CHOHP and CHOLP cell lines, the viable cell 
concentration and viable cell number was followed. The resulting growth data is shown in 
Figure 5.11 below. Overall the PMA did not have any major effect upon the CHOHP cell 
viability or number and therefore the lack of an increase in antibody concentration was not 
due to cell death. The CHOLP cells did show a small decrease in viable cell  numbers on days 
7 and 8 relative to that when the PMA was added on day 6. This might suggest these cells 
ǁĞƌĞŵŽƌĞ ‘ƐƚƌĞƐƐĞĚ ?ďǇƚŚĞĂĚĚŝƚŝŽŶŽĨƚŚĞWD ?ƉŽƐƐŝďůǇƌĞƐƵůƚŝŶŐŝŶŝŶĚƵĐƚŝŽŶŽĨƐƚƌĞƐƐ
responses that might account for the increase in antibody concentration observed. Once 






























Figure 5.10 Antibody concentrations in the supernatant of CHOHP and CHOLP cells 24 and 48 h 
after the addition of PMA to the cultures on day 6 of culture. Concentrations are shown relative 
to those on day 6 when the PMA was added. HP= High producer, LP= Low producer P = PMA 
addition, C = control DMSO addition. n=3, student t-test shows that at 48 hours in the LP 
difference between the P and C samples are p<0.05. Base levels (ng/ul/cell) at 0h were LP C: 






































Figure 5.11 Total viable cell numbers (viable cells/ml) and culture viabilities in the CHOHP 
(HP) and CHOLP (LP) cultures at the time of, 24 hours and 48 hours post addition of 2 PM 
PMA to cultures. P= addition of 2 PM PMA, C= Control cell, incubated with the equivalent 
volume of DMSO.  
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5.2.3.3 The Effects of Adding Phorbol Myristate Acetate (PMA) to CHO Cell Growth 
As PMA was shown to be effective at increasing CHOK1D6 cell firefly luciferase recombinant 
protein production and a lower producing antibody producing cell line ?s productivity, 
further investigation into how PMA addition might influence the growth and proliferation 
of CHO cells across a longer time period was undertaken. Further, the addition of PMA and 
the mTOR inhibitor rapamycin were added separately and together to CHO cells. Using the 
Xcellegence system (Roche) described in earlier chapters and the host CHO Flp In cell line. 
The cells were cultured in the presence of either 2 PM PMA, 10 nM rapamycin or both. The 
cells were cultured at 37
o
C for 136 hours and electrical impedance measured every 30 
minutes to follow cell growth. The resulting growth profiles are shown in Figure 5.12 below.  
 
The addition of 10 nM rapamycin resulted in the CHO cells entering into decline phase after 
100 hours of culture whilst the cells grown in the presence of 2 PM PMA maintained lag 
phase for another  ~24 hours. These cells also grew to a much higher cell index suggesting 
higher cell numbers in the presence of PMA. Cells that were grown in the presence of both 
rapamycin and PMA showed slower growth initially but reached the higher cell index (or 
electrical impedance) observed in the PMA alone samples and were maintained in the 
stationary phase of growth. Surprisingly, cells grown in the presence of a double dose  of a 
singular molecule showed different profiles. A 4 PM dose of PMA appeared to result in 
almost complete cell death and 20 nM rapamycin resulted in an unexpected increase in the 
initial cellular proliferation and the cell index reached the same level as the cells grown in 
the presence of PMA but entered into decline phase of growth around 100 hours post -
seeding (Figure 5.12). 
 
One of the objectives of the simultaneous treatment of the CHO cells using rapamycin, a 
known mTOR inhibitor, and PMA was to try and determine if the PMA effect was via mTOR 
or another pathway. The result from the 20 nM rapamycin grown cells was not as expected 
and suggests this initiates some other response that results in enhanced cell proliferation. 
The PMA alone did result in a higher cell index being obtained, suggesting increased cell 
proliferation or a longer growth period before nutrient depletion was sensed, possibly 
through an mTOR mechanism. However, from these data alone it is not possible to 
























5.2.4 Investigating mTOR Signalling in CHO Cells Stably Expressing eEF2 Mutants in 
Leucine Depleted Media  
As described earlier in this thesis, it is well established that mTOR signalling is sensitive to 
intracellular nutrient concentrations and levels of amino acids; one of the responses to 
nutrient depletion is mTOR regulated attenuation of protein synthesis. It has been 
demonstrated that mTOR is particularly sensitive to leucine concentrations or availability 
(Gran & Cameron-Smith 2011; Proud 2002). In order to investigate mTOR signalling further, 
and how this might influence recombinant protein synthesis, the CHO Flp-In cells over 
expressing eEF2 mutants (WT: wild type; ALA: Thr56Ala mutation; GLU: Thr56Glu mutation) 
detailed in Chapter 3 were cultured in leucine depleted media over a short period of time 
(24 h) and targets of mTOR signalling investigated. The Ala mutant should always be in 
the  ?ŽŶ ?ƉŽƐŝƚŝŽŶĂƐŝƚĐĂŶŶŽƚďĞƉŚŽƐƉŚŽƌǇůĂƚĞĚĂŶĚƚŚĞƌĞĨŽƌĞŝŶĂĐƚŝǀĂƚĞĚ ?ǁŚŝůƐƚƚŚĞ'ůƵ
mutant is a phosphorylation mimic and hence should be inactive. 
 
 
Figure 5.12 Growth profiles of the CHO Flp-in host cell line in the presence or absence of 
PMA, rapamycin or both determined using the commercially available Xcellegence culturing 
system (Roche). n=2 
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In order to investigate mTOR and recombinant protein synthesis in the CHO eEF2 over-
expressing cell lines, two experiments were undertaken. In the first, the cell lines were 
grown in either leucine efficient (leucine present in the media) or leucine depleted media 
for 24 h and then cell pellets collected and lysates prepared for the analysis of total and 
phosphorylated eEF2, eEF2K and mTOR. In a second experiment, the CHO Flp-In eEF2 
mutants were transiently transfected with a firefly luciferase plasmid, 6 hours post 
transfection the media was changed and the cells were then incubated in leucine depleted 
media for 24 hours before the firefly luciferase expression from each cell line was 
determined and compared. 
 
Surprisingly, there was no significant difference in the levels of total and phosphorylated 
eEF2 and eEF2K between the cell lines in the presence or absence of leucine (Figure 5.13). It 
would have been expected that depleted leucine would result in increased eEF2 
phosphorylation after 24 h but this was not observed. However, the cells incubated in the 
leucine depleted media showed a decline in mTOR expression compared to those cultured 
in the regular media (Figure 5.13). There was once again no observable difference between 
the control and eEF2 over-expressing cell lines suggesting that this did not influence the 
response to leucine depravation. 
 
When firefly luciferase was transiently expressed in the different cell lines in the leucine 
depleted media, there was actually a reduction in the firefly luciferase expression in the 
Ala56 and Glu56 eEF2 mutant cell lines compared to the control and WT over-expressing 
cell lines (Figure 5.14). This is in direct contrast to the results reported in chapter 3 where 
the Ala stably expressing cell line was able to produce more luciferase in the presence of 
leucine. In the eEF2 over-expressing WT cell line there appeared to be a similar amount of 
luciferase expression as in the FRT control cell lines. The reasons for this are not clear as the 
blot data in the absence of leucine and firefly shown in Figure 5.13 show similar amounts of 
eEF2 and phosphorylated eEF2. The removal of leucine must therefore result in a greater 
impact upon firefly luciferase expression in the Ala56 and Glu56 eEF2 cell lines than that in 
the other two cell lines, presumably due to the presence of the exogenous eEF2. It is 
possible that in the CHO Ala56 eEF2 mutant stable cell line, as the eEF2 Thr56Ala mutant is 
considered to be constantly active, the cell takes other measures to slow protein 
production such as the prevention of translation initiation via eIF2D, eiF3 and 4EBP-1 






































Figure 5.13 Western blot analysis of 
cell lysates from the stably 
expressing eEF2WT, eEF2Thr56Ala 
and eEF2 Thr56Glu mutants after 
growing for 24 h in the presence or 
absence of the amino acid leucine. 
The blots shows total and 
phosphorylated eEF2, eEF2K and 
mTOR levels in the different cell lines 
in + or  W leucine media. H= CHO Flp-
In parental cells, F= CHO Flp-In cells 
stably trasfected with an empty FRT 
vector, W= CHO Flp-In cells stably 
expressing wild type eEF2, A= CHO 
Flp-In cells stably expressing 
Thr56Ala eEF2 mutant, G= CHO Flp-In 
cells stably expressing Thr56Glu 
eEF2mutant. 
 
Figure 5.14 Transient firefly luciferase expression measured as light counts per a second (LCPS) 
normalised to total protein from CHO Flp-In cells in the stably expressing empty FRT vector 
(FRT), wild type eEF2 (WT), Thr56Ala eEF2 (ALA) and Thr56Glu eEF2 (GLU) mutants for 24h post 
transfection of the pGL3 firefly luciferase construct (FF) or incubation with the equivalent 
volumes of transfection reagent (TR), incubated in leucine depleted media. n=3, error bars show 
one standard deviation.   
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5.2.5 Investigation of mTOR and Translation Initiation Factors in HEK Cells  
It has been established in this thesis that manipulation of elongation via over-expression of 
eEF2 or knockdown of eEF2K can result in enhanced recombinant protein synthesis and 
enhanced growth rate in CHO cells. Other studies have shown that by manipulating mTOR 
signalling translation elongation is controlled and hence protein synthesis rates. However, 
translation itself is made up of initiation, elongation, termination and a ribosome recycling 
step. Therefore before elongation can occur, mRNA translation initiation has to take place 
first. Reports have shown that mTOR regulates translation initiation as well as elongation, 
largely through the phosphorylation of 4E-binding protein, 4E-BP1 (Fingar et al. 2002; 
Gibbons et al. 2009). However, a more recent study has suggested that the phosphorylation 
of eIF3i might occur in an mTOR dependent manner and this could also influence 
translation initiation (Roobol et al. 2014). In order to investigate if cells over-expressing 
eIF3i are mTOR sensitive, HEK cell lines stably over-expressing eIF3i or eIF3h were 
investigated and the amounts of eEF2, eEF2K and cellular growth investigated to determine 
if there was a link between the over-expression of these initiation factors and elongation 
control. The eIf3h cell line was included as this is not thought to be mTOR sensitive. 
 
HEK (Human Embryonic Kidney) Flp-In cell lines (Invitrogen) each separately stably 
expressing either eIF3iV5, eIF3hV5 (both have a c-terminus V5 reporter tag) or eIF3h, were 
used to investigate the effect of stable initiation factor over expression. These cell lines 
were kindly provided by Dr Anne Roobol, University of Kent. This system is the same system 
used to create the stable eEF2 CHO mutants presented in chapter 3 except HEK cells were 
used as the mammalian host cell. For initial characterisation of these cell lines (FRT HEK 
control, eIF3i-V5 tagged, eIF3h-V5 tagged, eIF3h (no tag)) they were grown and after 24 and 
48 h of growth in static adherent culture, cell lysates were generated for western blotting. 
The lysates were analysed via western bottling for total and phosphorylated eEF2, eEF2K 
and the presence of the V5 tag (Figure 5.15). Subsequently, densitometry analysis was 
undertaken on blots and the results are shown in Figure 5.16.  
 
The V5 probe blot confirmed that the HEK cells were over-expressing the eIF3iV5 and 
eIF3hV5 tagged initiation factors (Figure 5.15). From this we assume that the eFI3h HEK cell 
line is also stably over-expressing this subunit although without an antibody for eIF3h it was 
not possible to confirm this. The western blot and densitometry data showed that 24 hours 
after seeding the cells, the levels of eEF2 across the cell lines did not appear to differ to a 
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great extent. However, the level of eEF2 phosphorylation and eEF2K did appear to be 
elevated compared to the FRT control. On the other hand, after 48 hours the levels of eEF2 
were dropped slightly in the eIF3 over-expressing cell lines relative to the control, and 
whilst the phosphorylation of eEF2 in the eIF3iV5 and eIF3h cell lines was similar, the 
eIF3hV5 cell line appeared to have a slightly elevated level of eEF2 phosphorylation. This 
could suggest that the presence of the V5 tag on the eIF3h subunit could be causing an 
artificial rise in eEF2 phosphorylation. Interestingly, the levels of eEF2K were also drastically 
decreased at the 48 h time point compared to that of the control cell line in each of the 
eIF3 expressing cell lines in contrast to that observed at the 24 h time point (see Figure 
5.16). This may account for the decrease in eEF2 phosphorylation observed. The eEF2K 
levels may be reduced in response to the cells requirements: the HEK cells will  have been 
entering into the log phase of growth, during this time eEF2 is very active and therefore 
deactivation by phosphorylation is not required. However, the question remains why this 
would be more pronounced in the eIF3 expressing cell lines than the  control cell line. One 
explanation would be if there was enhanced protein synthesis and growth in the eIF3 over-




















Figure 5.15 Western blot analysis of cell lysates from HEK Flp In cells stably 
expressing eIF3iV5, eIF3hV5, eIF3h and FRT control cell lines 24 and 48 h after 
seeding of cells. Cell lysates were probed for the presence of a V5 tag, eEF2, 







































Figure 5.16 (a) Densitometry analysis of the western blots present in figure 5.15. Levels of 
ƚŽƚĂů Ğ& ?  ?ƚŽƚĂů ? ? ƉŚŽƐƉŚŽƌǇůĂƚĞĚ Ğ& ?  ?WŚŽƐ ? ĂŶĚĞ& ?<  ?ŬŝŶĂƐĞ ? ǁĞƌĞ ŶŽƌŵĂůŝƐĞ ƚŽɲ-
tubulin. Samples were collected from HEK Flp-In cells stably expressing eIF3iV5, eIF3hV5, 
eIF3h and a FRT control cell lines, 24 and 48 h post seeding. (b) Levels of total eEF2, 





To investigate whether the over-expression of the eIF3 subunits offered a growth 
advantage over the control cell line and if there was a possible link that mTOR signalling 
was in any way related to the effects that the eIF3 over expression had upon cellular 
growth of the HEK Flp-In cells, HEK cells stably expressing the eIF3 mutants as well as HEK 
cells expressing an empty FRT vector were cultured in 10 nM rapamycin or the equivalent 
volume of DMSO over 136 hours.  
 
The growth curves were generated using the Xcelligence system (Roche) previously 
described and the resulting data is shown in Figure 5.17. These data show that the HEK cells 
are more sensitive to the presence of DMSO and rapamycin than the CHO cells previously 
investigated. The eIF3iV5 and the eIF3h cells cultured in DMSO showed a greater sensitivity 
to DMSO than the FRT and eIF3hV5 cell lines. In the FRT and eIF3hV5 cell lines the lag phase 
of growth was dramatically extended. When the cell lines were grown in the presence of 
rapamycin all of the cells showed little growth and long extended lag times. After 120 h of 
culture there was only growth from the eIF3hV5 and FRT host cell line. These data suggest 
that the over-expression of eIF3hV5 confers some sort of protective effect against 
rapamycin in the HEK cells but over expression of eIF3h and eIF3iV5 does not. Why this is 
not observed in the untagged eIF3h cell line is not clear although over-expression of eIF3h 
in this cell line could not be confirmed. Due to the sensitivity of the HEK cells to DMSO and 
rapamycin it was not possible to determine from these data if any mTOR related effects are 
















































Figure 5.17 Growth profiles of the HEK293 FRT control host cell line, and HEK FRT cell lines stably over-
expressing eIF3iV5, eIF3hV5 and eIF3h in the presence of DMSO over seven days. 
 
Figure 5.18 Growth profiles of the HEK293 FRT control host cell line, and HEK FRT cell lines stably over-




5.3 Conclusions and Summary Statements from this Chapter 
The findings of this chapter are discussed in detail in Chapter 6 but the main findings of this 
chapter are summarised here. The study of the CHO cell lines with varying recombinant 
monoclonal antibody protein production capacities revealed that levels of total and 
phosphorylated eEF2 do not appear to change in correlation with the mAb titre. This data 
suggest that eEF2 activity is tightly regulated across cell lines and is not directly related to 
recombinant protein secretion in these industrially used CHO cell lines  
 
When qRT-PCR analysis was used to investigated changes in mTOR signalling over time 
during culture of a model host CHO cell line, the majority of the changes detected in the 
mTOR qRT-PCR panel were up-regulation of +ve mTOR regulators. These data  suggest that 
the first response to stress later in culture is to try and maintain mTOR signalling (and thus 
protein synthesis) in order for the cell to continue growing and synthesising protein. The 
maintenance of mTOR signalling allows the downstream effectors to be maintained as well. 
This balance is obviously a crucial point for cell survival and the ability to continue 
producing recombinant protein. However, the addition of PA to the media during culture, 
to enhance mTOR activity, did not appear to have an effect upon CHO cells. This is probably 
either due to the hydrophobicity of the PA molecule or the concentration was not enough 
to elicit a response from the cells/ mTOR pathways. On-the-other-hand, addition of 0.5-
5µM PMA to adherent CHO cells increased the production of recombinant firefly luciferase 
and 2 µM PMA appeared to elicit the largest response. Western blot analysis revealed that 
addition of PMA, at least in part, signals to eEF2K via mTOR. It is very likely that PMA signals 
to other pathways. 
 
The addition of 2 µM of PMA also increased mAb production in a low producer cell line but 
had no effect upon the mAb production from a high producing cell line. This data suggests 
that a limiting factor(s) in the terms of mAb production in the lower producing cell line was 
over come upon PMA addition, but why and what these limitations could be is unknown 
and would require further investigation. Addition of PMA to the CHO producer cells does 
not appear to effect the growth of the cells, with only a few percent between the viability 
of the cells treated with PMA and the control cells. Finally with regards to PMA, CHO Flp-In 
parental cells cultured with 2 µM PMA and 10nM rapamycin, showed that PMA recovers 
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the cells from the effects of rapamycin, strongly suggesting that PMA is, in part, influencing 
mTOR signalling.  
 
Cell lines stably expressing the eEF2 mutants constructed in chapter 3 (eEF2 wild type, eEF2 
Thr56Ala and eEF2 Thr56Glu) transiently transfected with firefly luciferase and 
subsequently cultured in leucine depleted media exhibited behaviour the opposite of what 
was observed in Chapter 3. When the stable eEF2 cell lines were transiently expressing 
firefly luciferase the Ala56 eEF2 mutant cell line expressed the highest levels of luciferase. 
Conversely, when cultured in the leucine deplete media, the Ala56 eEF2 mutant cell line 
expressed the least amount of firefly luciferase. The data could be explained by the fact 
that the Ala56 eEF2 mutants is continuously activity and when this cell line is put under 
nutrient stress and the cells are still expending resources the cell takes other actions to 
dampen/suppress protein expression; such as the slowing of translation initiation. Further 
investigation into this behaviour would be required to determine this if  it was the case.   
 
Experimentation with HEK cells over expressing eIF3 subunits i and h with a V5 tag, and h 
without a V5 tag were also undertaken. This was to determine if any links between over 
expression of these subunits and mTOR regulated initiation and elongation were present. 
48 hours post seeding the cells over expressing the eI3iV5 and 3h subunits showed a small 
increase in eEF2 phosphorylation, but the cells over expressing the eI3hV5 subunit showed 
a larger increase in eEF2 phosphorylation. The reason why the presence of the V5 tag 
results in an increase in eEF2 phosphorylation is unknown.  Over expression of the eIF3 
subunits appears to sensitise the HEK cells to the effects of rapamycin and DMSO, although 
the V5 tagged eIF3h subunit exhibits improved growth over its non-tagged counterpart, 











The data presented in the preceding chapters of this thesis describe a number of 
investigations into the role of polypeptide elongation and its control in Chinese hamster 
ovary cells and how this may impact upon recombinant protein production. Here an overall 
discussion of the results arising from these studies is provided. 
 
6.1 Polypeptide Elongation during mRNA Translation and Elongation Factor 2 (eEF2) 
Polypeptide elongation during protein synthesis on ribosomes is a key control point of gene 
expression and mRNA translation as described in the introduction chapter. Indeed, mRNA 
translation can limit recombinant protein synthesis from mammalian cells (Gustafsson et al. 
2004; Wang & Proud 2006; Schwanhäusser et al. 2011; Modrak-Wojcik et al. 2013) and 
ribosome biogenesis can be manipulated to improve recombinant protein expression 
(Santoro et al. 2009), demonstrating the importance of translational control in recombinant 
protein expression from mammalian expression systems. The elongation of polypeptides is 
regulated via elongation factor 2 (eEF2) and elongation factor 1A (eEF1A).  Phosphorylation 
of eEF2 at Thr
56
 inhibits its activity by inhibiting its binding to ribosomes. This 
phosphorylation is catalysed by eEF2K (Kaul et al. 2011; Browne & Proud 2002). Over 
expression of eEF2 and its subsequent mutation in mammalian cells has been shown to 
result in an increase in cellular growth and protein synthesis capacity (Nakamura et al. 
2009), therefore it was hypothesised that the manipulation of eEF2 in CHO cells could 
improve the cells ? capacity for recombinant protein production as well as extend the length 





6.1.1 Transient Expression of Human and Hamster eEF2 in CHO Cells 
The initial construction of expression vectors for the expression of human and Chinese 
hamster eEF2 was undertaken to allow the investigation into the effects of eEF2 in human 
or Chinese hamster ovary cell (CHO) expression systems, as both are used in the industrial 
setting. Further, although the sequences are highly homologous (see  Chapter 3), it is 
ƉŽƐƐŝďůĞƚŚĂƚƚŚĞŚƵŵĂŶĞ& ?ŵĂǇ ‘ďĞŚĂǀĞ ?ĚŝĨĨĞƌĞŶƚůǇŝŶƚŚĞ,KĐĞůůƚŚĂŶƚŚĞĞŶĚŽŐĞŶŽƵƐ
CHO sequence. For example, stability and turnover, or the ability for the human eEF2 to 
play its role in elongation may be compromised or enhanced in the CHO system relative to 
the endogenous Chinese hamster eEF2. 
 
Section 3.2.1.2 reports, that transient expression of the human eEF2 was possible in CHO 
cells when tagged at the C-terminal with a V5 reporter tag. Further, the expression of the 
human eEF2 form did not appear to affect the growth of the CHO cells or the regulation of 
the endogenous eEF2. As there did not appear to be any difference between the CHO and 
human exogenous eEF2 at the amino acid level; this suggests that the human eEF2 is either 
inactive or is not detrimental to the CHO cells homeostasis. As a result of these early 
experiments with human and hamster eEF2 sequences, it was decided that the majority of 
the work to be undertaken would focus upon investigations using the CHO cell expression 
system and the hamster eEF2 sequence, as CHO cells are considered the current gold 
standard mammalian expression system in the industrial setting (Kotsopoulou et al. 2010; 
Becerra et al. 2012).  
 
Mutants of eEF2 in which Thr
56
 had been converted to a non-phosphorylatable residue (Ala) 
were therefore generated and transiently express in the model systems to determine the 
influence on recombinant protein synthesis. Complementary to this, and as described 
further below, eEF2K was knocked down by shRNAi to determine the effect on general and 
recombinant protein synthesis. Transient over-expression of wild type Chinese hamster and 
the Thr56Ala eEF2 mutant in CHOK1 cells affected the short-term (24-48 hour) amount of 
phosphorylated eEF2 present but had no appreciable effect upon intra-cellular recombinant 
protein production or cell growth in culture over a 96 hour period. Immunofluorescence 
imaging of CHOK1 cells transfected with the eEF2 hamster WT construct revealed that the 
translation efficiency/exogenous expression of eEF2 in the CHOK1 cells was approximately 
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20-30%. Therefore, the majority of the cells within the culture were not expressing the 
exogenous eEF2 constructs and as such interpreting the results from the transient 
expression studies is difficult. Transient expression also subjects the cells to the stress of 
the transfection protocol itself that can result in short-term cell responses and each cell can 
be expressing different amounts of the exogenous gene due to being transfected with 
differing copies of the plasmid. As such, these approaches are not idea for determining the 
effect of eEF2 manipulation on cell growth and recombinant protein productivity. Therefore, 
in order to ensure all of the cells within the culture were expressing the exogenous eEF2 
constructs and at approximately the same amount for an extended period of time, CHO cell 
lines stably expressing the eEF2 constructs were generated.   
 
6.1.2 Stable Over-expression of Wild Type, Thr56Ala and Thr56Glu eEF2 Mutants in CHO 
Cells 
Using the commercially available CHO Flp-In system (Invitrogen), CHO Flp-In cell lines stably 
expressing either the wild-type or mutants of the CHO eEF2 constructs (eEF2 WT or 
Thr56Ala or Thr56Glu) as well as a control cell line using an empty FRT vector were 
constructed. Whilst the Ala mutant cannot be phosphorylated and hence should always be 
ŝŶƚŚĞ ‘ŽŶ ?ŽƌĂĐƚŝǀĞƐƚĂƚĞ ?ƚŚĞ'ůƵŵƵƚĂŶƚŝƐĂŵŝŵŝĐŽĨƉŚŽƐƉŚŽƌǇůĂƚĞĚdŚƌ ? ?ĂŶĚƐŚŽƵůĚ
ƚŚĞƌĞĨŽƌĞ ĂůǁĂǇƐ ďĞ ŝŶ ƚŚĞ  ‘ŽĨĨ ? ƐƚĂƚĞ ŝŶ ƚĞƌŵƐ ŽĨ ĞůŽŶŐation activity. Further, stable 
expression of eEF2 and the eEF2 mutant variants in CHO cells removed the stress of 
transfection reagents upon the cells used for the transfection of the eEF2 constructs , and 
allows for transient transfection of another construct, such as the reporter firefly luciferase 
pGL3 construct. This also allowed for a more representative assessment of the effects of 
eEF2 over-expression and subsequent mutations on the CHO cell population. A limitation of 
this system however is that while it makes it possible to stably express the eEF2 constructs 
in all CHO cells, it is not possible to eliminate or suppress the expression of the endogenous 
or naturally expressed eEF2 within the CHO Flp-In cells. As the constructs at most had a 2 
base pair mutation (from Thr to Ala or Glu), it was not possible to suppress the endogenous 
eEF2 via RNA silencing as it would also supress the exogenous eEF2 constructs that were 





To begin addressing this it could be possible to mutate the dipthamide H715 residue on the 
eEF2 constructs to render them immune to the effects of diphtheria toxin (Argüelles et al. 
2014; Abdel-Fattah et al. 2013) thereby culturing the CHO Flp-In cells with diphtheria toxin 
ǁŽƵůĚ ƌĞŶĚĞƌ ƚŚĞŶĂƚŝǀĞĞ& ? ŝŶĂĐƚŝǀĞĂŶĚ ƚŚĞ ‘ĨůŝƉƉĞĚŝŶ ?Ğ& ?ǁŽƵůĚďĞ ƚŚĞŽŶůǇĂĐƚŝǀĞ
eEF2 within the cells. This was not put into action because it has been previously observed 
that the dipthamide H715 residue is linked to the functionality of eEF2 (Argüelles et al. 
2014; Meeting et al. 2006; Kaul et al. 2011) and therefore by mutating it unknown effects 
and introduction of a second variable into the investigation would occur in addition to the 
mutation being directly investigated (e.g. Thr56 mutations). Further, using diphtheria toxin 
as a selective pressure would have an unknown effect upon the CHO Flp-In cells themselves. 
A further possible way to address this would be to silence the endogenous eEF2 by genome 
editing knockout technology in the stable cell lines to prevent endogenous eEF2 expression. 
This could be targeted to the chromosome location of the cell lines but is a long and time-
consuming process. The investigation into the expression of exogenous eEF2 and the 
Ala/Glu56 mutants was therefore undertaken with the knowledge that as well as 
expression of the exogenous eEF2 constructs there would as expression of the 
endogenous/native eEF2 that the cell might modulate in response to the exogenous 
material. 
 
6.1.2.1 Stable Over-Expression of Wild Type eEF2 and Thr56Ala and Thr56Glu eEF2 
Mutants Changes the Intra-Cellular eEF2 Amounts in CHO Flp-In Cells 
Western blot analysis and the subsequent densitometry analysis of these blots showed that 
stable over expression of the eEF2 constructs in the CHO Flip-In cells increased the amount 
of eEF2 present at the protein level (Figure 3.10). Conversely, the mRNA levels did not show 
any increase aside from the CHO Flp-In cell line stably expressing Thr56Glu eEF2 (Figure 
3.16).  Over-expression of the hamster wild type eEF2 construct resulted in a 2-fold 
increase in expression of eEF2 and a small decrease in phosphorylation of eEF2 at the 
protein level; but there was no change in the levels of total eEF2 mRNA expression. The 
over-expression of the exogenous eEF2 construct provides another transcript for the 
translation of eEF2, this transcript being transcribed from the CMV promoter in the 
expression plasmid whose control is not naturally linked to eEF2 expression in mammalian 
cells. This suggests that there is some form of regulation of eEF2 mRNA expression between 
translation of the eEF2 mRNA and its expression as a functional protein. It may be possible 
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ƚŚĂƚ ƚŚĞĐĞůů ĐĂŶ  ‘ƐĞŶƐĞ ? ƚŚĞĂŵŽƵŶƚŽĨĂǀĂŝůĂďůĞĞ& ?ƉƌŽƚĞŝŶĂŶĚ ?ŽƌŵZEĂŶĚŚĞŶĐĞ
reduce the promoter activity transcribing eEF2 to maintain the mRNA amounts at an 
acceptable amount to the cells. It is noted that no very high expressing eEF2 stable cell lines 
were obtained, suggesting these either do not survive or that the cell regulates eEF2 
amounts. The exogenous amount could be controlled via increased mRNA or protein 
turnover although this was not investigated in this study. 
 
Expression of the Thr56Ala eEF2 mutant resulted in a 5-fold increase in total eEF2 levels as 
determined from western analysis and densitometry, but as for the wild type construct, 
there was little change in the mRNA levels. The mutation of Thr56 to Ala56 on eEF2 results 
ŝŶ Ă  ‘ĐŽŶƚŝŶƵŽƵƐůǇ ĂĐƚŝǀĂƚĞ ? Ğ& ? ? ƚŚĞƌĞĨŽƌĞ ƚŽ ŵĂŝŶƚĂŝŶ ŚŽŵĞŽƐƚĂƐŝƐ ŽĨ Ğ& ? ĂŵŽƵŶƚƐ
within the cell it would require reduction of the levels of eEF2/increased protein turnover 
or regulation of transcription or translation initiation of the endogenous gene within the 
cells to compensate for the inability to control the Ala56 eEF2 mutant. What was observed 
from the densitometry analysis was unexpected in that the levels of total eEF2 increase but 
the levels of eEF2 phosphorylation were similar to that of the FRT control (it might be 
expected that phosphorylation of endogenous material would be increased to inactive this 
and compensate for the 56Ala expression).    
 
The relatively larger increase in the Ala56 eEF2 cell line eEF2 amounts can therefore, at 
least partly, be attributed to the continuous constitutive expression of the exogenous eEF2. 
Further, as the Ala56 eEF2 mutant is alǁĂǇƐ ‘ĂĐƚŝǀĞ ? ?ƚŚŝƐĐŽƵůĚƌĞƐƵůƚŝŶŵŽƌĞƉŽůǇpeptides 
being translated/elongated faster, including the Ala56 eEF2 itself. This may be particularly 
so if the exogenous eEF2 Ala56 transcript is highly abundant although the data suggests this 
is not the case.  The increased elongation would only be possible in a nutrient rich 
ĞŶǀŝƌŽŶŵĞŶƚĂƐƚŚĞĞůŽŶŐĂƚŝŽŶŽĨƉŽůǇƉĞƉƚŝĚĞƐŝƐĂŶ ‘ĞŶĞƌŐǇŚĞĂǀǇ ?ĚĞƉĞŶĚĞŶƚƉƌŽĐĞƐƐ ?^ĞĞ
section 1.7.1.3). However, once stressed by nutrient depravation it is likely that the cells 
would need to drastically reduce their eEF2 activity or become starved of nutrients or die. 




Overexpression of the Thr56Glu eEF2 mutant resulted in an increase in both eEF2 protein 
and mRNA expression and the increase of total eEF2 protein expression in the Glu56 cell 
line relates to the levels of eEF2 mRNA. This increase may be more tolerated by the cell as 
ƚŚĞ 'ůƵ ? ? Ğ& ? ŵƵƚĂŶƚ ŝƐ ĂŶ  ‘ŝŶĂĐƚŝǀĞ ? ŵƵƚĂŶƚ ĂŶĚ ŵĂǇ ďĞƐĞ Ŷ ĂƐ ůŝƚƚůĞ ŵŽƌĞ ƚŚĂŶ Ă
harmless recombinant protein. However, the eEF2 mutant may also compete for 
interaction with the ribosome with wild type eEF2 and hence one might argue that an 
increase in endogenous eEF2 might occur to counter balance the inactive exogenous 
material. Alternatively, the levels of phosphorylation of wild-type eEF2 may be decreased in 
an effort to compensate for the expression of the inactive Glu56 eEF2.  The data generated 
ĨƌŽŵƚŚŝƐ ƐƚƵĚǇǁĂƐŶŽƚĂďůĞ ƚŽĐŽŶĨŝƌŵǁŚĞƚŚĞƌĞŝƚŚĞƌŽĨ ƚŚĞƐĞƐĐĞŶĂƌŝŽ ?ƐŽĐĐƵƌƌĞĚĂŶĚ
once again this could be further investigated in the future. 
 
6.1.2.2 Stable Over-Expression of Wild Type eEF2 or the Thr56Ala and Thr56Glu eEF2 
Mutants Affects the Growth of the CHO Flp-In Cell Lines Expressing Them  
The cellular growth in culture of the CHO Flp-In cell lines stably expressing the different 
exogenous eEF2 constructs were investigated using an Xcellegence system developed by 
Roche. The system is advantageous for the measurement of growth of adherent cell lines. 
The system uses 12 well plates and measures electrical impedance of a current passed 
across the bottom each well. The current was passed through the wells every 30 minutes; 
this allowed for a measurement for each cell line (5 in total) in triplicate without disturbing 
the cells during the culture period. The disadvantage of this system i s that the passing of 
the current across the wells cannot account for the mass of the cells adhered to the 
surface; the system cannot distinguish single cells via the electrical impedance cause by the 
cells. 
 
At 37°C the growth of all of the CHO Flp-In cell lines expressing any of the eEF2 constructs 
was increased as determined using this instrument and hence it is assumed the 
proliferation of the cells, in early stages of log phase growth in culture. The cell line 
expressing the Ala56 eEF2 mutant showed the largest increase in growth/proliferation. This 
ŝƐ ƚŚĞ  ‘ĂĐƚŝǀĞ ?ŵƵƚĂŶƚ ?ŚŽǁĞǀĞƌƉĞƌŚĂƉƐƐƵƌƉƌŝƐŝŶŐůǇ ? ƚŚĞ'ůƵ ? ?Ğ& ?ĐĞůů ůŝŶĞĐŽŶƚĂŝŶŝŶŐ
mutant grew more rapidly than the other cells lines except the Ala56 mutant. This growth 
pattern coincides with the levels of eEF2 in the different cell lines, with the Ala56 eEF2 cell 
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line having the largest amount of eEF2, then the Glu56 eEF2 cell line, and lastly the wild 
type eEF2 cell line.  These data suggest that increasing eEF2 amounts impacts upon cell 
growth/proliferation, presumably this can occur faster when eEF2 is up-regulated as 
protein can be synthesised faster. This could come with compromised protein quality, 
something that was investigated later in the project. 
 
Interestingly, the Glu56 and wild type eEF2 cell lines each achieved a similar maximum cell 
number in culture, although the Glu56 cell line reached this a little earlier than the wild 
type cell line. The Ala56 cell line attained the highest maximum cell number and appeared 
ƚŽ ‘ŚŽůĚ ?ƚŚŝƐƉĞĂŬĐĞůl number for the longest time. Late in culture, it was the Glu56 eEF2 
cell line that began to decline in viability/cell number first, the wild type cell line follows the 
same decline as the FRT and parental (HOST) cell line; but the Ala56 eEF2 cell line showed a 
more sustained cell index.  These data collectively suggest that at 37°C in nutrient rich 
conditions over-expression of any of the eEF2 constructs confers a benefit to cellular 
proliferation. The Glu56 eEF2 mutation does not appear to have any negative effects until 
later in culture, were the cell culture appears to decline only a few hours before the wild 
type eEF2. Under mild cold-shock growth conditions (32°C) the Ala56 eEF2 mutation within 
the cell line appears to promote cellular proliferation and increase the maximum cell 
number attained whereas the over expression of the wild type eEF2 and Glu56 mutant eEF2 
only increase CHO cells proliferation, but the maximum cell number attained remained the 
same as the FRT control cell line. Interestingly, mild cold shock has been reported to slow 
protein synthesis and mRNA translation by approximately 50% (Roobol et al. 2009). The fact 
that the over-expression of the Ala56 eEF2 mutant, that cannot be inactivated by 
phosphorylation, appears to increase the growth of CHO cells at 32
o
C, suggests that it is 
polypeptide elongation that is one of the major limiting steps or control points limiting 
protein synthesis at such temperatures. This may therefore be a possible route to increase 
cell biomass at 32
o






From the data presented in this thesis with the stably expressing CHO cell lines it could 
therefore be suggested that when the cells are put under stress from lack of nutrients or 
reduced temperature, polypeptide elongation is slowed by reducing polypeptide elongation 
rates to preserve nutrients and energy. However, this can be negated to some extent by 
expressing more of a more active eEF2 in the form of the Ala56 eEF2 mutant. Although it is 
not possible to discern the levels of the over expressed exogenous eEF2 constructs from the 
native eEF2 within the cells from these experiments, it is clear that the over expression of 
eEF2 affects the growth of CHO cells and can be used to enhance CHO cell biomass or the 
speed at which this is achieved.  
 
6.1.2.3 Culturing of the Wild Type eEF2 or Thr56Ala and Thr56Glu eEF2 Mutants in CHO 
Flp-In Cells with 10 nM Rapamycin Changes the CHO Cells Response and Growth 
Rapamycin inhibits mTOR activity by binding to FKBP12 and this complex binds to mTOR 
reducing its activity (see section 1.9). mTOR regulates eEF2 via S6K1 that phosphorylates 
elongation factor 2 kinase (eEF2K) (Kenney et al. 2014). Therefore, the CHO Flp-In cells 
stably expressing the eEF2 variants were cultured in the presence of rapamycin to 
investigate any link between mTOR and whether over expression of eEF2 or the Thr56 eEF2 
mutant affects the growth of the cells. The CHO Flp-In cell lines were cultured over 7 days 
with 10 nM rapamycin using the Xcellegence system. The rampamycin used was dissolved 
in DMSO as a solvent, therefore the control cultures were cultured with the equivalent 
volume of DMSO. When cultured with DMSO/rapamycin the CHO Flp-In cells exhibit a 
different behaviour to that when they are cultured in nutrient rich conditions or under mild 
cold shock. DMSO exhibits an toxic  effect upon the cells (Stevens et al. 2014) and the eEF2 
stable cell lines appear to have a different reaction to that of cold shock. Rapamycin 
resulted in the proliferation rate of all of the cell lines to decrease in line with this 
inactivating mTOR, prolonging the log phase of growth by approximately 50 hours. 
Interestingly, all of the recombinant eEF2 cell lines attained the same maximum cell 
number as the DMSO control except the Glu56 eEF2 cell line which showed an increase in 
cell index from 3.5 to 5. One plausible explanation for this is that the rapamycin slows the 
proliferation of each of the cell lines, the Glu56 having some protection against this already 




6.1.2.4 Stable Over-Expression of Wild Type eEF2 or Thr56Ala and Thr56Glu eEF2 Mutants 
can Increase the Levels of Transient Recombinant Firefly Luciferase Expression 
Firefly luciferase is an intra-cellular expressed recombinant protein and is often used as a 
reporter to give an estimate of a cells capacity for recombinant protein expression 
(Masterton et al. 2010). The advantage of this system is that the protein is not secreted as 
for most therapeutic recombinant proteins and therefore the direct result of manipulation 
of translation can be investigated. For secretory proteins limitations in secretion could mask 
any effects on translation when elongation is manipulated. Therefore, transient expression 
of firefly luciferase from the CHO Flp-In cell lines stably expressing the eEF2 variants was 
investigated 48 hours post-transfection of the firefly luciferase (Figure 3.20). The over-
expression the Ala56 eEF2 mutant increased the CHO cells ability to generate recombinant 
protein production as determined from these luciferase assays. This suggests that the Ala56 
eEF2 cell line overcomes a limitation in elongation that restricts firefly luciferase expression 
from CHO cells.  
 
The Glu56 eEF2 cell line produced a similar total amount of luciferase compared to the FRT 
control and wild type eEF2 cell lines. The Glu56 cell line was shown to have around a 3-fold 
increase in eEF2 (see figure 3.15) and was the only cell line to show an increase in eEF2 
mRNA levels. However, the Glu56 cell line produced a higher amount of luciferase than the 
control on a per-cell basis and more-or-less the same amount on a per cell basis as the 
Ala56 mutant. This suggests that the fact luciferase levels were not increased in terms of 
total amounts in the Glu56 cell line was down to a biomass issue, reduced compared to that 
in the Ala56 cell line over the same time period.  
 
One potential issue mentioned above is that increased elongation and translation could 
result in more errors during translation. An experiment using mutant luciferase  was 
therefore undertaken to determine levels of read through and amino acid mis-
incorporation into the poly peptide during translation elongation (see figure 3.23). It was 
observed that the wild type eEF2 expressing cell line had a reduced level of read through 
and mis-incorporation during recombinant luciferase protein production compared to the 
control cells. It appears from these data that the wild type eEF2 engineered cell lines results 
in more accurate translation elongation. It has been observed that during an increase in 
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protein synthesis there usually is a loss of translation fidelity (Conn & Qian 2014). On-the-
other-hand, the read though appeared to be increased in the Ala56 eEF2 mutant expressing 
cell line when the total amount of read through is considered. However, when the amount 
of read through is considered as a proportion of the total amount of luciferase made, the 
amount of read through is actually reduced. Thus, the data suggests that increasing eEF2 
amounts can both increase the fidelity of recombinant protein produced and the yield. 
 
6.1.2.5 The Addition of the V5 Tag to Stably Expressed Wild Type eEF2 at the C- and N- 
Terminus Increases the Expression of Recombinant Firefly Luciferase 
The use of the V5 reporter tag was essential in this project as confirmation of the 
 ‘ĞǆƉƌĞƐƐŝŽŶ ? of the exogenous eEF2 in the CHO Flp-In cells. This allows the distinction 
between the native eEF2 within the CHO cells and the exogenous eEF2 constructs although 
as different antibodies are used this cannot tell us about the relative amounts of 
endogenous and exogenous eEF2. Western blot analysis and immunofluorescent imaging 
confirmed expression of a C- and N- terminus V5 tagged wild type eEF2 in the CHO Flp-In 
cells. Due to difficulty in constructing/expressing the V5 tagged eEF2 (see section 3.2.2.1) 
only the wild type eEF2 cell lines were constructed with the C/N-terminal V5 tag. 
Interestingly, transient transfection of firefly luciferase into the C-terminus V5 (Cv5) eEF2 
cell line and the N-terminus (Nv5) eEF2 cell line stable CHO Flp-In cell lines showed a 2- to 
3-fold increase in luciferase when compared to the FRT control cell line (Figure 3.22). 
Previously the transient expression of luciferase in the wild type eEF2 stable cell line 
showed a similar luciferase expression to the FRT cell line (it was the Ala56 mutant where 
an increase was observed). Therefore, the presence of the V5 tag appeared to influence the 
amount of recombinant material produced.  The reason why the addition of a V5 tag to a 
terminus of the eEF2 would influence recombinant luciferase expression is unclear.  
Possible explanations are that the V5 tag provides the eEF2 molecule with some sort of 
activity advantage in its interactions regarding polypeptide elongation. The V5 tag may 
change the conformation of eEF2s structure so that the domains of eEF2 are shifted to a 
ŵŽƌĞ ‘ĂĐƚŝǀĞ ?ƉŽƐŝƚŝŽŶ ?/ƚŝƐ also possible that the V5 tag enhances the interaction between 
eEF2 and the ribosome complex. An alternative may be that the V5 tag prevents eEF2K 
interacting with eEF2 and therefore preventing its phosphorylation and subsequent 
deactivation, although there was little evidence of changes in eEF2 phosphorylation in 
these samples.  
192 
 
6.2 The Effect of Silencing Elongation Factor 2 Kinase (eEF2K) upon eEF2 Activity and 
Recombinant Protein Production   
After investigation into the effects of eEF2 over-expression and mutation upon 
recombinant protein production from CHO cells, the regulator of eEF2, eEF2K was 
investigated. As eEF2K is the only known regulator of eEF2, manipulation of eEF2K to 
inactive this and prevent phosphorylation of the Thr56 residue and thus promote eEF2 
activity was investigated as a means of modulating CHO cell growth and recombinant 
protein production. As described in section 1.8.4, eEF2K phosphorylates eEF2 at the Thr56 
residue resulting in the inactivity of eEF2 and therefore the silencing of eEF2K via siRNA 
ǁŽƵůĚƉƌĞǀĞŶƚƚŚĞƉŚŽƐƉŚŽƌǇůĂƚŝŽŶŽĨĞ& ?ĂŶĚŵĂŝŶƚĂŝŶĞ& ?ŝŶĂŶ ‘ĂĐƚŝǀĞ ?ƐƚĂƚĞ ?&ƵƌƚŚĞƌ ?
the amount of phosphorylated eEF2 can therefore be used as a direct readout of eEF2K 
activity. 
 
6.2.1 Transient Knockdown of eEF2K via Transfection of an shRNA (short hairpin RNA) 
Plasmid Construct  
Construction of the eEF2K shRNA was achieved using the commercial kit Gene Clip U1 
Hairpin system (Promega). The oligo nucleotides designed for the hairpin were based upon 
a commercial, verified sequence provided by Sigma. As both the plasmid vector and the 
hairpin sequences were commercial available and the sequencing of the construct was 
verified it provided confidence that the hairpin would be effective at eEF2K silencing. 
 
6.2.1.1 Short-Term (48 hour) Transient Transfection of the eEF2K shRNA Reduces the 
Amounts and Activity of eEFK  
The results in Section 4.2.2 show that transient transfection of the eEF2K shRNA effectively 
knocked down eEF2K, as shown by western blot analysis. There was also an associated 
drastic decrease in phosphorylation of eEF2 while total eEF2 levels remained constant over 
the 48 hour time period (Figure 4.2). The shRNA was therefore successful in silencing eEF2K 
expression at least over the short term and was therefore used to investigate the effect of 




6.2.2 The Transient Knockdown of eEF2K Effects Recombinant Protein Production in CHO 
Cells 
The effect of transient knockdown of eEF2K on recombinant protein production was 
investigated using CHO cell lines stably expressing the reporters firefly or gauusa luciferase. 
Using both firefly and gaussia luciferase would give data on how the knockdown of eEF2K 
effects intra cellular protein production (Firefly luciferase is a intra cellular protein) and 
how it may effect production of a protein that is secreted from the cell (gaussia luciferase in 
secreted from the cells), which mirrors the majority of recombinant proteins produced in 
the industrial setting, certainly those expressed in mammalian cells. 
 
6.2.2.1 Transient Knockdown of eEF2K Increases Firefly Luciferase Expression and is more 
Effective than Transient Expression of eEF2 and Thr56 Mutant eEF2 
The transient knockdown of eEF2K, in CHOK1D6 cells stably expressing firefly luciferase 
resulted in a 5-fold increase in firefly luciferase production. Comparison against the 
transient transfection of the wild-type eEF2 shows that the knockdown of eEF2K is more 
effective at increasing firefly protein production. When cells were co transfected with wild 
type eEF2 and the eEF2K shRNA, the knockdown of eEF2K appeared to enhance the 
production of firefly luciferase the most.  This could reflect the low transfection 
rate/expression of eEF2 described in chapter 3. The enhanced effect of eEF2K knockdown 
over eEF2 expression probably reflects the fact that the knockdown of eEF2K targets all of 
the eEF2K within the cell, removing its ability to phosphorylated eEF2, resulting in a larger 
ƉŽƉƵůĂƚŝŽŶŽĨ ‘ĂĐƚŝǀĞ ?Ğ& ? ?ǆƉƌĞƐƐŝŽŶŽĨƚŚĞĞ& ?ĂŶĚŵƵƚĂŶƚƐ  does not remove the effect 
of endogenous eEF2 as described previously. Transfection of the eEF2K shRNA into the CHO 
Flp-In cells stably over expressing the eEF2 mutants was also investigated, however 24 
hours post transfection the CHO cells did not survive this. These data suggest that the loss 
of native eEF2K and the over expression of mutant eEF2 was a lethal combination to the 
cells.  Therefore, the cells must maintain some measure of eEF2 and hence polypeptide 
elongation control. These findings agree with other studies of various cancer cells that 




6.2.3 Transient Knockdown of eEF2K in CHO Cells Stably Expressing Gassiua Luciferase is 
Cell Line Dependant 
Two CHO Flp-In cell lines expressing gaussia luciferase (cell lines 12 and 14), each at a 
different level, were used to investigate the effect of eEF2K knockdown upon secreted 
recombinant protein expression. Western blotting of the gaussia luciferase produced was 
the preferred method of analysis for the gaussia protein instead of measurement via 
luminescence due to the instability of the gaussia protein activity. Both gaussia cell lines 
appeared to secrete similar quantities of gauissa luciferase, but when transfected with the 
eEF2K shRNA, cell line 12 showed an increase in gausssia secretion but an actual increase in 
eEF2K expression. The response from cell line 14, on average, was the opposite; with a 
decrease of eEF2K levels but only a marginal if any increase in gaussia expression. These 
data were observed across two independent experiments, showing that the effects of the 
eEF2K knockdown appear to be cell line specific.  
 
It is possible the transfection efficiencies between the two cell lines are different, therefore 
the level of eEF2K knockdown achieved is different. From the data presented it would 
appear that there is a positive correlation between the amounts of eEF2K and gaussia 
luciferase secretion. It is possible that through some unknown mechanism eEF2K influences 
secretion of guassia recombinant protein. One scenario by which this might occur is that if 
large amounts of luciferase are already made in these cells (e.g. cell line 12), there may be a 
limitation upon secretion or folding in the ER in the secretory pathway. Upregulation of 
eEF2K may actually result in a slowing of translation and entry of gaussia luciferase into the 
ER and secretory pathway which may result in more correctly folded and thus secreted 
material being produced. Further experimentation would need to be undertaken to confirm 
if this hypothesis is correct. 
 
The depletion of leucine during knockdown of eEF2K in the gaussia cell line 14 resulted in a 
decrease of phosphorylation of eEF2 as well as a small knockdown of eEF2K and increase in 
secreted gaussia luciferase. The depletion of leucine inactivates mTOR signalling which 
results in the activation of eEF2K and in turn the phosphorylation of eEF2, although 
culturing in leucine deplete media resulted in a decrease in eEF2 phosphorylation.  As the 
depletion of leucine inactivates mTOR, it is also possible that other pathways are 
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in/activated that could potentially result in the activation of eEF2K as eEF2K activity is 
controlled via other pathways (Lynch 2001; Suryawan et al. 2012). 
 
6.2.4 Transient Knockdown of eEF2K is Associated with a Calcium Ion Flux Across the ER 
Membrane 
Another regulator of eEF2K that is linked both directly and indirectly to mTOR is calmodulin  
(Browne & Proud 2004; Gulati et al. 2008). Calcium flux can activate eEF2K and, it was 
possible that by knocking down eEF2K the cell may change the intra cellular calcium flux to 
try and compensate for reduced eEF2K activity. Live cell imaging of HEK cells stably 
expressing a FRET reporter molecule of calcium in the ER was therefore used to visualise 
any change in intracellular calcium ion distribution upon transient knockdown of eEF2K by 
shRNA. These studies showed that a flux of calcium ions out of the ER into the cytoplasm of 
HEK cells transfected with the eEF2K shRNA occurred along with changes to the cellular 
morphology.  
 
The knockdown of eEF2K increased intracellular firefly recombinant protein production, as 
described in section 4.2.3.1 In response to eEF2K knockdown, the imaging undertaken here 
in HEK cells suggests that calcium is transported from the ER into the cytosol. This may 
activate calmodulin and any eEF2K. With an increase of calcium ions within the cytosol, 
activation of other pathways and the transcription of various genes may also be 
de/activated. In eukaryotic cells, the release of calcium ions into the cytosol is often 
undertaken in response to stress upon the cells (Egnatchik et al. 2014). Therefore, it is likely 
that the stress/burden of increased recombinant protein production and depletion of 
eEF2K and the loss of control of elongation contributes to a cellular response involving the 
flux of calcium from the ER into cytosol in order to try and compensate for this. Further 
evidence that the shRNA eEF2K transfected cells are under stress is provided by the fact 
that the cells show a rounder morphology and a smaller ER. The control cells had a larger 




6.2.5 Stable Expression of an eEF2K Targeting shRNA in Adherent CHO Cells  
The shRNA vector provided with the kit for construction of the eEF2K shRNA contains a 
selection marker for pyromycin antibiotic resistance allowing for a stable selection process 
in CHO cells for those expressing the eEF2K shRNA vector. Stable expression of the shRNA 
was appealing as it would allow for longer term experiments (4-7 days) and remove the 
inconsistences and stress of transient transfection. The stable  expression system relies 
upon random integration of the shRNA plasmid into the cells genome instead of the use of 
a recombinase site like the CHO Flp-In system. 
 
CHO cells stably expressing the shRNA plasmid did not show any change in their grow 
profile compared to control cells and when analysed by western blot the silencing of eEF2K 
was not as apparent as in the transient experiments. After 72 hours the level of eEF2 
phosphorylation was increased in the shRNA eEF2K cells compared to the control, 
suggesting that the knockdown of the eEF2K was only apparent during the first 48-72 h of 
growth of the stably expressing cell lines. Further, the fact that no cells with complete 
knockdown of eEF2K were isolated suggests that these were not able to survive, again 
providing further evidence that permanent eEF2K knockdown is toxic to cells. The initial 
transient experiments also suggested that the CHO cells could only sustain a minimal level 
of eEF2K expression over a short time period. When investigating protein synthesis in these 
cells by radiolabelling of nascent polypeptides, the resulting 
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S autoradiograph also 
showed a decrease in protein in the stable eEF2K shRNA CHO cells. This again suggests a 
reduction in protein synthetic capacity in these cells. This is an undesirable effect where 
recombinant protein production is concerned. However, an alternative to this might be to 
use an inducible knockdown system whereby a cell line could be generated where eEF2K 
expression could be silenced at a particular time in culture by inducing expression of an 
shRNA eEF2K knockdown sequence. In this way cells could normally be cultured without 
the expression of the eEF2K targeting hairpŝŶďĞŝŶŐƚƵƌŶĞĚ ‘ŽŶ ? ?ďƵƚǁŚĞŶŝƚǁĂƐďĞŶĞĨŝĐŝĂů
to switch on knockdown this could be induced. This may give a phenotype similar to that 
observed with the transient knockdown but further experiments would have to be 




6.3 Investigating Links between mTOR, eEF2 and Recombinant Protein Production  
Mammalian target of rapapmycin (mTOR) is known to be a regulator of global protein 
synthesis and its manipulation, via SGK1 regulation of eEF2K, has been shown to increase 
protein production as well as other process within the cells (Laplante & Sabatini 2012; 
Dreesen & Fussenegger 2011a). Therefore the potential links between mTOR and 
polypeptide elongation with respect to recombinant protein production were investigated. 
 
6.3.1 There is no Correlation between mAb Titre in CHO Suspension Cell Lines and Levels 
of eEF2 and eEF2K 
Over expression of mTOR and its dis-regulation have been shown to increase intracellular 
protein production within mammalian cells (Dreesen & Fussenegger 2011a). In the 
industrial setting there is a desire to find mammalian cells capable of producing high levels 
of recombinant proteins of appropriate quality (e.g. correctly folded, no mis-incorporation 
of amino acids), therefore whether there is a link between industrially constructed cell lines 
capability of monoclonal (mAb) secretion and their expression of eEF2 and its regulation 
was investigated. 
 
Initially two cell lines, a high mAb producer and a low producer, were used to investigate 
eEF2 and eEF2K amounts in these cell lines between days 4-7 of growth in batch culture, 
the period when the mAb production begins. The levels of eEF2 and eEF2K were more -or-
less consistent between the cell lines and across the days of culture sampled. Therefore, 
the investigation was opened up into a wider panel of cell lines consisting of 6 cell lines of 
varying mAb titre. For this wider mAb producer panel samples were taken at day 6 and day 
8 of batch culture. The samples were screened for eEF2 and eEF2K amounts using western 
blotting techniques and the resulting data analysed using densitometry software. The 
results of the day 6 and day 8 producer panel (Figure 5.4 and 5.5) revealed that there was 
no discernible correlation between eEF2 and eEF2K activity and the cell lines mAb titre 
levels. The levels of total eEF2 appear to remain relativity consistent between all of the cell 
lines while the levels of eEF2K varied only slightly. The levels of eEF2 phosphorylation 
appeared to relate to the levels of total eEF2 in the cell lines i.e. the more eEF2 the more 
phosphorylated eEF2 was detected.  
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These data show and agree with the data collected in the other experiments within this 
study as well as other studies (Kaul et al. 2011; Nakamura et al. 2009) in that eEF2 is tightly 
regulated within the cell and the analysis of the producer panel revels that eEF2 and eEF2K 
do not play a key role in the production of the secreted recombinant protein investigated 
here. This does not mean that changes to eEF2 and eEF2K cannot inf luence recombinant 
protein activity as the previous sections have demonstrated that this can be achieved, but 
confirms that the cell controls the amounts of these and elongation closely. Thus any 
strategy to manipulate this must be carefully constructed in order that the cell can survive 
such intervention. 
 
6.3.2 Changes in the Environment During Batch Culture are Reflected in Changes in mTOR 
Signalling and Reveals Possible Targets for Cell Engineering 
The investigation into mTOR signalling and possibly extrapolating a link between mTOR, 
eEF2 and recombinant protein production would require experimentation and investigation 
into several pathways at the protein and mRNA level, resulting in a lengthy and extensive 
work load. Therefore, the use of a commercially available mTOR mRNA array was used as a 
starting point to identify potential targets that could be manipulated to up-regulate mTOR 
signalling and/or eEF2 activity via mTOR.  
 
In order to undertake such studies, the RNA from two phases of adherent CHO cell growth 
were collected, during log growth phase and stationary phase, to discern which genes 
become up or down regulated once nutrients start to become limiting. These genes could 
then become a potential target for manipulation and subsequent enhancement of mTOR 
activity and recombinant protein production. When comparing the changes in the gene 
array between the log phase (68 hour) and stationary phase (120 hour) samples several 
positive and negative regulators, up and down stream of mTOR, were seen to be up 
regulated over 2-fold after 120 hours of growth compared to that at 68 hours of growth. 
The initial assumption to such a result is that mTOR activity is modulated within the cell 
with time and environmental conditions (e.g. nutrient availability) in order to maintain cell 
 ‘ŚĞĂůƚŚ ? ?dŚŝƐǀŝĞǁ ŝƐĐŽƌƌŽďŽƌĂƚĞĚ ŝŶƐĞǀĞƌĂů ƌĞǀŝĞǁƐŽĨ ƚŚĞŵdKZ ůŝƚĞƌĂƚƵƌĞƐƚĂƚŝŶŐ ƚŚĞ
complexity involved in the regulation of mTOR and the numerous input and outputs from 
the mTOR complexes (Laplante & Sabatini 2012; Laplante & Sabatini 2009b). The function 
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of each gene identified as being differentially regulated between the two time points is 
described in appendix 7.6 which was provided with the data analysis spreadsheet provided 
with the array plates. Ideally this experiment would be repeated at least once more, and 
undertaken with other sample time points.  
 
Several of the genes identified in the array panel are regulators of, or involved in, several 
pathways including AKT, which regulates several responses involving mTORC1 and MTOR2 
and response from insulin receptors (Zoncu et al. 2011). Therefore, mTORC1 manipulation 
itself may be a the most likely route to deliver global change and regulation or effectors of 
the global pathway. For this reason two small molecules that are activators of mTOR: 
phosphatidic acid (PA), which interacts with mTOR directly, stabilising the formation of the 
mTORC1 complex (Foster 2009; Roux et al. 2004) and phorbol myristate acetate (PMA), a 
tumor promoting small molecule which activates protein kinase C and subsequently mTOR 















6.3.2.1 Addition of Phosphatidic Acid (PA) to Cell Culture does not Effect mTOR Signalling 
in CHO Cells 
PA is known to interact with mTORC1/C2, stabilising the complex (Foster 2009; Foster 2007) 
therefore it was investigated whether the addition of PA to the cell culture media would 
increase mTOR activity. Although PA is essential to mTOR activity, it appears to require 
other signalling for mTOR activation(Foster 2009) but it was unknown if addition of further 
PA would increase mTOR signalling.  PA was therefore added to a culture of a high 
producing mAb CHO cell line on day 4 (mid log phase of growth) of culture and samples 
collected 48 hours post addition of PA and mTOR, eEF2 and eEF2K activity analysed via 
western blotting. The analysis of the samples revealed no changes in the levels of eEF2, 
eEF2K and mTOR 48 hours post incubation with PA. This lack of response to PA maybe 
because the PA molecule was not able to cross the lipid membrane of the cell. PA is derived 
from several intra cellular pre-cursors (see section 1.9.2.5). Further investigation of the 
manipulation mTOR via PA would require either the addition of the pre cursor elements of 
PA or genetic manipulation of the kinases such as phospholipase D (PLD) involved in its in 
vivo synthesis.  This could be a viable route for the investigation as PA interacts with mTOR 
directly and therefore could demonstrate that intracellular PA directly stimulates mTOR, 
whereas other methods inadvertently activate other regulatory pathways due to the 
complex mature of the mTOR pathway.  
 
6.3.2.2 Addition of Phorbol Myristate Acetate (PMA) to Cell Culture Changes mTOR 
Signalling and Increases Recombinant Protein Production in CHO in a Cell Line Dependant 
Manner  
PMA was also chosen to use in the project due to its known turmogenic properties coupled 
with studies that show mTOR is implicated in some cancers and activated by PMA. Further, 
unlike PA, PMA has been shown in other studies to induce a cellular response at a low 
concentration of 10 µM and is known to be able to cross the plasma membrane into the cell 
(Roux et al. 2004). The initial investigation with PMA was to investigate if it could increase 
cellular recombinant protein production over a 48-hour period, as well as determining a 
suitable concentration that was not toxic but elicited a response for use in future 
experiments. Using CHOK1D6 cells stably expressing firefly luciferase revealed that 
concentrations as little as 0.5 µM of PMA can elicit an increase in firefly luciferase 
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production (Figure 5.8) and 2 µM was the optimum concentration of PMA of those 
investigated. With this confirmation of PMAs ability to elicit an increase in protein 
production from CHO cells, the investigation was moved to mAb producing CHO cells. Using 
the same high and low producer CHO cell lines from previous experiments (section 5.2.1), 
the effect of PMA upon mAb production within these cells as well as PMAs effects upon 
mTOR, eEF2K and eEF2 signalling was investigated. The experiment was conducted over 
days 6-8 of batch culture, where the majority of mAb production occurs and therefore 
would have the most impact upon the cells protein production mechanisms. PMA was 
added to the culture on day 6 and samples taken 24 and 48 hours later.  
 
PMA activates protein kinase C (PKC), which in turn goes on to activate a number of 
different pathways within the cell including the Nox enzymes which produce reactive 
oxygen species (Kizub et al. 2014; Cosentino-Gomes et al. 2012) and additional pathways 
involved in cellular responses and regulation. PKC activates mTOR via activation of RS6K 
(Ribosomal S6 Kinase), which inhibits the Tsc1/Tsc2 (tuberous sclerosis) complex, which in 
turn allows for Ras homolog enriched in brain (Rheb) to activate mTOR. Analysis of cellular 
lysates (western blotting) and supernatant (ELISA assay) revealed that the effect of PMA 
was cell line specific. The ELISA data revealed that only the low producing cell line increased 
its mAb output post PMA treatment. This suggests that the lower producing cell line was 
limited by one of the mechanisms/pathways that PMA activates. It is not possible to know 
ǁŚĂƚůŝŵŝƚŝŶŐĨĂĐƚŽƌƐǁĞƌĞ ‘ŽǀĞƌĐŽŵĞ ?ǁŝƚŚŽƵƚĂŶŝŶ depth study of the pathways regulated 
by PKC. However, through the western blot analysis it is possible to determine if mTOR 
signalling was increased in the low producing cell line. This did indeed appear to be the case 
as evidenced by a reduction of eEF2 phosphorylation upon PMA addition as well as an 
increase in mTOR levels. These data suggest that in the high producing cell lines 
investigated, mTOR signalling was sufficient and not limiting. This further suggests that the 
cell line selection and development process either selects for cell lines with appropriate 
mTOR signalling or that high producing cell lines must not have limitations in mTOR 




6.3.2.3 Culturing of Cells with PMA and Rapamycin Recovers Cell Growth Over that Seen 
When adding Rapamycin Alone 
As described above, rapamycin is known to inhibit mTORC1 activity and reduce cellular 
growth (Fingar et al. 2002; Dowling et al. 2010). To determine if PMA could recover cellular 
growth during culture via promoting mTOR activity in the presence of rapamycin, CHO Flp-
In cells were incubated with rapamycin and/or PMA, over a 7 day period using the 
Xcellegence system (Roche). Surprisingly, cells that were incubated with 20 nM rapamycin 
showed enhanced cellular growth; it is not know why this occurred. It is possible that the 
concentration of rapamycin passed a sensory threshold that triggered a stress response 
within the cells that was not reached in the cells incubated with 10 nM rapamycin. A 
concentration of 4 µM PMA appeared to be lethal  to the CHO cells, suggesting over 
activation of mTOR results in cellular death. As expected, cells cultured with 10 nM 
rapamycin declined in cell viability early in the cell culture at 100 hours, were as when 
cultured in the presence of 2 µM PMA the cells recovered their growth and the culture 
appeared to have an extended stationary phase. This data further suggests that PMA, at 
least in part, elicits its responses in a mTOR-dependant manner. Further investigation of the 
cellular signalling occurring under these conditions by investigating the response of the 
different components of the signalling systems involved would allow the unravelling as to 
whether PMA signalling occurs largely in an mTOR dependant manner or via a number of 
different mechanisms.  
 
6.3.2.4 Depletion of Leucine Adversely Effects the Expression of Recombinant Proteins in 
CHO Flp-In Cells Stably Over-Expressing Wild Type or Mutant Thr56Ala or Thr56Glu eEF2 
Leucine has been shown to be a key signal of intra cellular amino acid levels to mTORC1 and 
modulate mTORC1 activity (see section 1.9.2.2). The CHO cell lines stably over expressing 
either wild type eEF2 or the Thr56Ala or Thr56Glu mutants were shown to increase the 
intra cellular recombinant protein levels of firefly luciferase. Cells were therefore incubated 
in leucine depleted media for 24 hours and cell lysates were collected to determine if this 
influenced mTOR signalling in these cell lines. Cells were also incubated for 48 hours in 
leucine depleted media for 48 hours post transient transfection of the pGL3 firefly 
luciferase construct. These experiments were conducted to determine how and if the 
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leucine depletion would affect mTOR signalling in the CHO cells, and if this signalling effects 
polypeptide elongation in the CHO cells over expressing the eEF2 variants. 
 
Western blot analysis revealed that there was little change in the amount of eEF2 
phosphorylation and eEF2K across the cell lines compared to the control cells, although 
there was a decrease in mTOR levels in the cells incubated in the leucine depleted media. 
Although expression of eEF2 and eEF2K were unchanged 24 hours post incubation in 
leucine depleted media, the firefly luciferase assay revealed that compared to previous 
assays (see figure 3.20) there was a reduction of firefly luciferase expression, with the Ala56 
eEF2 cell line showing the largest decrease compared to that of the control cell line. This 
contrasted the results under nutrient rich conditions where the Ala56 eEF2 cell line showed 
a 5-fold increase in total luciferase expression and 2-fold increase in the amount of 
luciferase made per cell. This suggests that the presence of the exogenous Ala56 eEF2 that 
cannot be phosphorylated and inactivated compromises the ability of the cells to respond 
to the severe conditions of total depletion of the amino acid leucine. This inability to slow 
elongation must therefore be over-compensated for by mechanisms to slow protein 
synthesis such as attenuation of translation elongation. Further studies could therefore 
investigate whether translation elongation is attenuated in these cells to a greater extent 
under these conditions than the control cells. 
 
6.4 Investigating if Over-Expression of eIF3 Subunits 3i and 3h in HEK Flp-In Cells Leads to 
Increased Cell Growth and Productivity. 
Before translation elongation can begin, mRNA translation must be initiated. Therefore 
there are direct links and controls between translation initiation and elongation, including 
mTOR signalling which regulates translation initiation as well as translation elongation 
(Wang & Proud 2006; Holz et al. 2005). mTOR regulates initiation via 2 key points, 4E 
binding protein 1 (4EBP1) and regulation of eIF3, both of which are essential to initiation of 
cap-ĚĞƉĞŶĚĂŶƚƚƌĂŶƐůĂƚŝŽŶ ?dŚĞƌĞĨŽƌĞ ?ĂƉŽƐƐŝďůĞůŝŶŬďĞƚǁĞĞŶ ‘ŵdKZ ?ƚƌĂŶƐůĂƚŝŽŶŝŶŝƚŝĂƚŝŽŶ
and elongation was investigated in HEK Flp-In cells stably over expressing eIF3 subunits 3h 
or 3h/3i with a C-terminus V5 tag. Cell lysate samples were analysed via western blotting 
for levels of eEF2 and eEF2K as an initial indication if over expression of these initiation 
subunits would influence elongation in these cells. The hypothesis was that if translation 
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initiation is enhanced then elongation may be as well to prevent ribosome traffic jams on 
the mRNA and keep elongation rates in line with translation initiation. 
 
After 24 hours of culture there was an observable difference between the three cell lines in 
terms of eEF2 amounts, but 48 hours into culture the expression of eEF2 was more -or-less 
the same in the cell lines and the only discernible difference was an increase in eEF2 
phosphorylation in the eIF3hV5 cell line. However, after 48 hours the levels of eEF2K were 
approximately half that of the FRT control cell line, this suggesting that the expression of 
the eIF3 subunits has a negative effect upon eEF2 activity and therefore the required eEF2K 
to regulate eEF2 is reduced. 
 
The HEK cells were cultured in 10 nM rapamycin over 7 days to observe, if any, effects the 
inhibition of mTOR has upon the over expression of the eIF3 subunits. Compared to the 
CHO cells, the HEK cells appear to be more sensitive to the effects of DMSO and rapamycin. 
Further, the over expression of eIF3iV5 and 3h appears to have a detrimental effect upon 
the cells survival, showing complete culture death when cultured with rapamycin and a 
severely delayed growth when cultured with DMSO. In previous experiments, where eEF2 
was tagged with a V5 reporter, cellular recombinant protein output was increased. Once 
again the data suggests that the V5 sequence influences cellular responses. The reason for 
this is unclear and would require extensive investigation, although the manipulation of the 
V5 tag alone could prove to be a potential method of enhancing cellular process at minimal 





6.5 General Conclusions  
This project set out to investigate the effects of over expression of eEF2 and the 
subsequent mutation of eEF2 Thr56 residue upon CHO cellular growth and recombinant 
protein production. Further, silencing of eEF2K using shRNA to reduce eEF2 
phosphorylation was undertaken and an investigation of the signalling of mTOR between 
CHO cells that have a different capacity for recombinant protein production as well as an 
investigation into the effects of small molecule activators of mTOR signalling and their 
effects upon the recombinant protein capacity of the cells.  
 
This project has shown that: 
1. Stable over expression of a Thr56Ala mutant eEF2 in CHO cells increases cellular growth 
and recombinant protein production although it alters the cells ability to respond to various 
environmental stresses including reduced temperature shift, osmotic stress and rapamycin . 
This would suggest that eEF2, both the non-phosphorylated and phosphorylated form, are 
integral to the survival of the cell.  
 
2. Stable knockout of eEF2K is not tolerated by CHO cells and some eEF2K must remain or 
cellular death results. eEF2K is the sole regulator of eEF2, and knockdown results in the loss 
of eEF2 control. A partial transient knockdown of eEF2K greatly improves the cells capacity 
for intra cellular recombinant protein production, although secretion of recombinant 
proteins is dependent on the cells capacity for secretion, which is not improved by the 
silencing of eEF2K. This shows that although polypeptides can be synthesised faster by 
knock down of eEF2K, there are still other limiting factors down stream of poly peptide 
elongation that limit a cells capacity for secreted recombinant protein production, such as 
post-translation modification (Feige & Buchner 2014) and transport of the recombinant 
protein from the ER to and through the golgi apparatus (Le Fourn et al. 2014; Idiris et al. 
2010) and out of the cell.  
 
3. Stable over expression of eEF2 and the transient knockdown of eEF2K is not tolerated by 
CHO cells, showing that the eEF2-eEF2K regulatory pathway is strictly controlled.  
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 ? ?dŚĞ  ‘ŵĂƐƚĞƌ ƌĞŐƵůĂƚŽƌ ?ŵdKZ ?ǁŚŝĐŚŝƐ ƌĞƐƉŽŶƐŝďůĞ ĨŽƌ ƐĞǀĞƌĂů ĐĞůůƵůĂƌƉƌŽĐĞƐƐ ƌĂŶŐŝŶŐ
from gene regulation (Cunningham et al. 2007), lipid synthesis (Laplante & Sabatini 2009a) 
and protein synthesis (Hayashi & Proud 2007), has been studied extensively since its 
discovery and it is still not fully understood as a regulator within the cell. However, small 
chemical additives may enhance mTOR signalling and be used to increase recombinant 
protein expression from CHO cells and be useful experimental tools. 
 
6.6 Concluding Remarks 
To conclude, this project has shown that manipulation of eEF2 and eEF2K activity within 
certain limitations can enhance cellular growth and recombinant protein production from 
CHO cells. This suggests further efforts to understand and manipulate this process should 
be taken to apply such knowledge in an industrial sense. However, limitations in secretory 
productivity of a cell may further limit potential advances from manipulation of elongation 
alone and hence engineering strategies that combine enhancing the cells secretory capacity 
with enhanced elongation may yield the largest increases in recombinant protein 
production. Inducible systems that allow the control of elongation may be required to over-
come the cells lack of ability to survive in the absence of eEF2K and elongation control. 
Such manipulations would shed further light on elongation control more widely in addition 
to its importance in recombinant protein synthesis from CHO cells. It may also be possible 
to manipulate the mTOR pathway to improve recombinant protein production via addition 
of small molecules on a cell-by-cell basis, but the effect of this manipulation will effect 
several pathways connected to mTOR and may be unpredictable. As such, new engineering 
approaches that allow the manipulation of both elongation and polypeptide synthesis 
combined with the secretory capacity of the cell are likely to yield new host cells with more 










7.1 Alignment of human and hamster elongation factor 2 DNA sequences using a web 
based alignment tool.  
 
Comparison of: 
(A) ./wwwtmp/.17214.1.seq human 2582 bp                                      
- 2582 nt 
(B) ./wwwtmp/.17214.2.seq hamster 2577 bp                                    
- 2577 nt 
 using matrix file: DNA (5/-4), gap-open/ext: -14/-4 E(limit)   0.05 
 
  87.3% identity in 2577 nt overlap (1-2577:1-2577); score: 9933 
E(10000):      0 
 
               10        20        30        40        50        60 
human  ATGGTGAACTTCACGGTAGACCAGATCCGCGCCATCATGGACAAGAAGGCCAACATCCGC 
       ::::::::::::::::::::::::::::: ::::: ::::::::::: :::::::::::  
hamste ATGGTGAACTTCACGGTAGACCAGATCCGTGCCATTATGGACAAGAAAGCCAACATCCGG 
               10        20        30        40        50        60 
 
               70        80        90       100       110       120 
human  AACATGTCTGTCATCGCCCACGTGGACCATGGCAAGTCCACGCTGACAGACTCCCTGGTG 
       :::::::: :::::::: ::::::::::: ::::::::::: ::::: :::::::::::: 
hamste AACATGTCAGTCATCGCTCACGTGGACCACGGCAAGTCCACACTGACGGACTCCCTGGTG 
               70        80        90       100       110       120 
 
              130       140       150       160       170       180 
human  TGCAAGGCGGGCATCATCGCCTCGGCCCGGGCCGGGGAGACACGCTTCACTGATACCCGG 
       ::::::::::: ::::::::::: ::  : ::::: :::::::::::::: :: :::::  
hamste TGCAAGGCGGGTATCATCGCCTCTGCAAGAGCCGGTGAGACACGCTTCACAGACACCCGC 
              130       140       150       160       170       180 
 
              190       200       210       220       230       240 
human  AAGGACGAGCAGGAGCGTTGCATCACCATCAAGTCAACTGCCATCTCCCTCTTCTACGAG 
       :::::::: :::::::: :::::::: :::::::: :: ::::::::::::::::: ::: 
hamste AAGGACGAACAGGAGCGCTGCATCACTATCAAGTCCACGGCCATCTCCCTCTTCTATGAG 
              190       200       210       220       230       240 
 
              250       260       270       280       290       300 
human  CTCTCGGAGAATGACTTGAACTTCATCAAGCAGAGCAAGGACGGTGCCGGCTTCCTCATC 
       ::::: ::::::::: ::::::::::::::::::::::::: ::  : ::::: :::::: 
hamste CTCTCTGAGAATGACCTGAACTTCATCAAGCAGAGCAAGGATGGATCTGGCTTTCTCATC 
              250       260       270       280       290       300 
 
              310       320       330       340       350       360 
human  AACCTCATTGACTCCCCCGGGCATGTCGACTTCTCCTCGGAGGTGACTGCTGCCCTCCGA 
       :::::::: ::::: :: :: ::::: :: :::::::: :::::::: ::::: :: ::  
hamste AACCTCATCGACTCTCCAGGCCATGTGGATTTCTCCTCAGAGGTGACAGCTGCACTTCGT 






              370       380       390       400       410       420 
human  GTCACCGATGGCGCATTGGTGGTGGTGGACTGCGTGTCAGGCGTGTGCGTGCAGACGGAG 
       ::::::::::: ::  : :::::::::::::: ::::: :: :::::::::::::: ::: 
hamste GTCACCGATGGAGCTCTTGTGGTGGTGGACTGTGTGTCTGGTGTGTGCGTGCAGACTGAG 




              430       440       450       460       470       480 
human  ACAGTGCTGCGGCAGGCCATTGCCGAGCGCATCAAGCCTGTGCTGATGATGAACAAGATG 
       :: :::::::::::::::::::::::::::::::::::::: ::::::::::: :::::: 
hamste ACCGTGCTGCGGCAGGCCATTGCCGAGCGCATCAAGCCTGTCCTGATGATGAATAAGATG 
              430       440       450       460       470       480 
 
              490       500       510       520       530       540 
human  GACCGCGCCCTGCTGGAGCTGCAGCTGGAGCCCGAGGAGCTCTACCAGACTTTCCAGCGC 
       ::::: :::::::: ::::::::::::::::: ::::: :: :::::::: ::::::::: 
hamste GACCGTGCCCTGCTTGAGCTGCAGCTGGAGCCTGAGGAACTATACCAGACCTTCCAGCGC 
              490       500       510       520       530       540 
 
              550       560       570       580       590       600 
human  ATCGTGGAGAACGTGAACGTCATCATCTCCACCTACGGCGAGGGCGAGAGCGGCCCCATG 
       :: :::::::: :: ::::::::::: :::::::: :::::::::::::: :: :::::: 
hamste ATTGTGGAGAATGTCAACGTCATCATTTCCACCTATGGCGAGGGCGAGAGTGGACCCATG 
              550       560       570       580       590       600 
 
              610       620       630       640       650       660 
human  GGCAACATCATGATCGATCCTGTCCTCGGTACCGTGGGCTTTGGGTCTGGCCTCCACGGG 
       :: :: :: ::::: :: :: ::::: :: :: ::::::::::: :::::::: :: ::  
hamste GGAAATATTATGATTGACCCCGTCCTGGGCACTGTGGGCTTTGGCTCTGGCCTGCATGGC 
              610       620       630       640       650       660 
 
              670       680       690       700       710       720 
human  TGGGCCTTCACCCTGAAGCAGTTTGCCGAGATGTATGTGGCCAAGTTCGCCGCCAAGGGG 
       ::::::::::: :::::::::::::: :::::::::::::: ::::: :: :: :::::  
hamste TGGGCCTTCACTCTGAAGCAGTTTGCGGAGATGTATGTGGCTAAGTTTGCAGCAAAGGGT 
              670       680       690       700       710       720 
 
              730       740       750       760       770       780 
human  GAGGGCCAGTTGGGGCCTGCCGAGCGGGCCAAGAAAGTAGAGGACATGATGAAGAAGCTG 
       ::::::::: :::::::::: ::::::::::::::::: :::::::::::::::::: :: 
hamste GAGGGCCAGCTGGGGCCTGCTGAGCGGGCCAAGAAAGTGGAGGACATGATGAAGAAGTTG 
              730       740       750       760       770       780 
 
              790       800       810       820       830       840 
human  TGGGGTGACAGGTACTTTGACCCAGCCAACGGCAAGTTCAGCAAGTCAGCCACCAGCCCC 
       ::::: ::  :::: ::::: :: ::::: ::::: ::::::::::: :: : ::::::  
hamste TGGGGAGATCGGTATTTTGATCCCGCCAATGGCAAATTCAGCAAGTCCGCTAACAGCCCT 
              790       800       810       820       830       840 
 
              850       860       870       880       890       900 
human  GAAGGGAAGAAGCTGCCACGCACCTTCTGCCAGCTGATCCTGGACCCCATCTTCAAGGTG 
       :: :::::::: :::::::::::::: :::::::: :::::::::::::::::::::::: 
hamste GATGGGAAGAAACTGCCACGCACCTTTTGCCAGCTCATCCTGGACCCCATCTTCAAGGTG 








              910       920       930       940       950       960 
human  TTTGATGCGATCATGAATTTCAAGAAAGAGGAGACAGCAAAACTGATAGAGAAACTGGAC 
       ::::: :: :::::::: ::::  :: :::::::: :: :: ::::: ::::: :::::  
hamste TTTGACGCCATCATGAACTTCAGAAAGGAGGAGACGGCCAAGCTGATTGAGAAGCTGGAT 
              910       920       930       940       950       960 
 
              970       980       990      1000      1010      1020 
human  ATCAAACTGGACAGCGAGGACAAGGACAAAGAAGGCAAACCCCTGCTGAAGGCTGTGATG 
       ::::: ::::::::::::::::: ::::: :: ::::: ::::::::::::::::::::: 
hamste ATCAAGCTGGACAGCGAGGACAAAGACAAGGAGGGCAAGCCCCTGCTGAAGGCTGTGATG 
              970       980       990      1000      1010      1020 
 
 
             1030      1040      1050      1060      1070      1080 
human  CGCCGCTGGCTGCCTGCCGGAGACGCCTTGTTGCAGATGATCACCATCCACCTGCCCTCC 
       ::::: :::::::: :: :: :::::: :: :::::::::: ::::::::::: :: ::: 
hamste CGCCGGTGGCTGCCCGCAGGGGACGCCCTGCTGCAGATGATAACCATCCACCTCCCTTCC 
             1030      1040      1050      1060      1070      1080 
 
             1090      1100      1110      1120      1130      1140 
human  CCTGTGACGGCCCAGAAGTACCGCTGCGAGCTCCTGTACGAGGGGCCCCCGGACGACGAG 
       :: :: :: :::::::: :::::::::::::: :: ::::::::::: :: :: :: ::: 
hamste CCCGTCACCGCCCAGAAATACCGCTGCGAGCTGCTCTACGAGGGGCCACCTGATGATGAG 
             1090      1100      1110      1120      1130      1140 
 
             1150      1160      1170      1180      1190      1200 
human  GCTGCCATGGGCATTAAAAGCTGTGACCCCAAAGGCCCTCTTATGATGTATATTTCCAAA 
       :: ::::::::::::::::::::::: ::::: :: :: ::::::::::: ::::::::  
hamste GCGGCCATGGGCATTAAAAGCTGTGATCCCAAGGGTCCCCTTATGATGTACATTTCCAAG 
             1150      1160      1170      1180      1190      1200 
 
             1210      1220      1230      1240      1250      1260 
human  ATGGTGCCAACCTCCGACAAAGGTCGGTTCTACGCCTTTGGACGAGTCTTCTCGGGGCTG 
       ::::::::::::::::::::::: :: ::::::::::::::  :::: ::::: ::: :  
hamste ATGGTGCCAACCTCCGACAAAGGCCGCTTCTACGCCTTTGGTAGAGTGTTCTCCGGGGTA 
             1210      1220      1230      1240      1250      1260 
 
             1270      1280      1290      1300      1310      1320 
human  GTCTCCACTGGCCTGAAGGTCAGGATCATGGGGCCCAACTATACCCCTGGGAAGAAGGAG 
       :: :: :: :: :: :::::: : :::::::: :::::::: :: ::::::::::::::: 
hamste GTGTCGACAGGACTCAAGGTCCGCATCATGGGCCCCAACTACACGCCTGGGAAGAAGGAG 
             1270      1280      1290      1300      1310      1320 
 
             1330      1340      1350      1360      1370      1380 
human  GACCTCTACCTGAAGCCAATCCAGAGAACAATCTTGATGATGGGCCGCTACGTGGAGCCC 
       :: :: ::::::::::: ::::::::::: ::: ::::::::::::: :: ::::::::  
hamste GAACTGTACCTGAAGCCCATCCAGAGAACCATCCTGATGATGGGCCGGTATGTGGAGCCA 
             1330      1340      1350      1360      1370      1380 
 
             1390      1400      1410      1420      1430      1440 
human  ATCGAGGATGTGCCTTGTGGGAACATTGTGGGCCTCGTGGGCGTGGACCAGTTCCTGGTG 
       :: ::::: ::::: :::::::::::::: :: :: :: :: :: :::::::: :::::: 
hamste ATTGAGGACGTGCCCTGTGGGAACATTGTCGGGCTGGTTGGTGTAGACCAGTTTCTGGTG 
             1390      1400      1410      1420      1430      1440 
 
             1450      1460      1470      1480      1490      1500 
human  AAGACGGGCACCATCACCACCTTCGAGCACGCGCACAACATGCGGGTGATGAAGTTCAGC 
       ::::: :: :: ::::::::::: :: ::::: :: :::::::: ::::::::::::::: 
hamste AAGACAGGGACTATCACCACCTTTGAACACGCACATAACATGCGTGTGATGAAGTTCAGC 
             1450      1460      1470      1480      1490      1500 
210 
 
             1510      1520      1530      1540      1550      1560 
human  GTCAGCCCTGTTGTCAGAGTGGCCGTGGAGGCCAAGAACCCGGCTGACCTGCCCAAGCTG 
       ::::::::::: ::::::::::: ::::::::::::::::: :::::::::::::: ::: 
hamste GTCAGCCCTGTCGTCAGAGTGGCTGTGGAGGCCAAGAACCCAGCTGACCTGCCCAAACTG 
             1510      1520      1530      1540      1550      1560 
 
             1570      1580      1590      1600      1610      1620 
human  GTGGAGGGGCTGAAGCGGCTGGCCAAGTCCGACCCCATGGTGCAGTGCATCATCGAGGAG 
       :::::::: :::::::::::::: :: :: ::::: ::::::::::::::::: :::::: 
hamste GTGGAGGGCCTGAAGCGGCTGGCAAAATCTGACCCTATGGTGCAGTGCATCATTGAGGAG 
             1570      1580      1590      1600      1610      1620 
 
 
             1630      1640      1650      1660      1670      1680 
human  TCGGGAGAGCATATCATCGCGGGCGCCGGCGAGCTGCACCTGGAGATCTGCCTGAAGGAC 
       :: :: ::::: ::::: :: :: :: :: :::::::::::::: :::::::: :::::: 
hamste TCTGGGGAGCACATCATTGCTGGAGCAGGTGAGCTGCACCTGGAAATCTGCCTCAAGGAC 
             1630      1640      1650      1660      1670      1680 
 
             1690      1700      1710      1720      1730      1740 
human  CTGGAGGAGGACCACGCCTGCATCCCCATCAAGAAATCTGACCCGGTCGTCTCGTACCGC 
       :::::::::::::::::::::::::::::::::::::::::::: :: ::::: :::::  
hamste CTGGAGGAGGACCACGCCTGCATCCCCATCAAGAAATCTGACCCTGTTGTCTCATACCGG 
             1690      1700      1710      1720      1730      1740 
 
             1750      1760      1770      1780      1790      1800 
human  GAGACGGTCAGTGAAGAGTCGAACGTGCTCTGCCTCTCCAAGTCCCCCAACAAGCACAAC 
       ::::: :: :: :: ::::: :: ::::: ::::: :::::::: ::::::::::::::: 
hamste GAGACAGTGAGCGAGGAGTCAAATGTGCTGTGCCTGTCCAAGTCGCCCAACAAGCACAAC 
             1750      1760      1770      1780      1790      1800 
 
             1810      1820      1830      1840      1850      1860 
human  CGGCTGTACATGAAGGCGCGGCCCTTCCCCGACGGCCTGGCCGAGGACATCGATAAAGGC 
       ::  :::: :::::::: ::::::::::: :: :::::::::::::::::::: :: ::  
hamste CGATTGTATATGAAGGCCCGGCCCTTCCCTGATGGCCTGGCCGAGGACATCGACAAGGGT 
             1810      1820      1830      1840      1850      1860 
 
             1870      1880      1890      1900      1910      1920 
human  GAGGTGTCCGCCCGTCAGGAGCTCAAGCAGCGGGCGCGCTACCTGGCCGAGAAGTACGAG 
       :: ::::: :: :: ::::::::::::   :: :: ::::: :: :: :: ::::::::  
hamste GAAGTGTCTGCTCGCCAGGAGCTCAAGGCACGCGCACGCTATCTAGCTGAAAAGTACGAA 
             1870      1880      1890      1900      1910      1920 
 
             1930      1940      1950      1960      1970      1980 
human  TGGGACGTGGCTGAGGCCCGCAAGATCTGGTGCTTTGGGCCCGACGGCACCGGCCCCAAC 
       ::::: :: ::::: :::::::::::::::::::::::::: :: ::::: ::::::::: 
hamste TGGGATGTTGCTGAAGCCCGCAAGATCTGGTGCTTTGGGCCTGATGGCACTGGCCCCAAC 
             1930      1940      1950      1960      1970      1980 
 
             1990      2000      2010      2020      2030      2040 
human  ATCCTCACCGACATCACCAAGGGTGTGCAGTACCTCAACGAGATCAAGGACAGTGTGGTG 
       :: :: ::::: ::::::::::::::::::::::: :: :: :::::::::::::::::: 
hamste ATTCTTACCGATATCACCAAGGGTGTGCAGTACCTGAATGAAATCAAGGACAGTGTGGTG 
             1990      2000      2010      2020      2030      2040 
 
             2050      2060      2070      2080      2090      2100 
human  GCCGGCTTCCAGTGGGCCACCAAGGAGGGCGCACTGTGTGAGGAGAACATGCGGGGTGTG 
       :: ::::::::::::::::: ::::::::::: :: ::::::::::::::::: :::::: 
hamste GCTGGCTTCCAGTGGGCCACTAAGGAGGGCGCTCTCTGTGAGGAGAACATGCGTGGTGTG 
             2050      2060      2070      2080      2090      2100 
211 
 
             2110      2120      2130      2140      2150      2160 
human  CGCTTCGACGTCCACGACGTCACCCTGCACGCCGATGCCATCCACCGCGGAGGGGGCCAG 
       :::::::: ::::: :: :: ::::: :: :: :::::::::::::: ::::: :: ::: 
hamste CGCTTCGATGTCCATGATGTGACCCTACATGCTGATGCCATCCACCGAGGAGGTGGTCAG 
             2110      2120      2130      2140      2150      2160 
 
             2170      2180      2190      2200      2210      2220 
human  ATCATCCCCACAGCACGGCGCTGCCTCTATGCCAGTGTGCTGACCGCCCAGCCACGCCTC 
       ::::: :::::::: :: :: :: :: :::::::::::: :::: :: ::::: :::::: 
hamste ATCATTCCCACAGCTCGTCGTTGTCTGTATGCCAGTGTGTTGACTGCACAGCCCCGCCTC 
             2170      2180      2190      2200      2210      2220 
 
             2230      2240      2250      2260      2270      2280 
human  ATGGAGCCCATCTACCTTGTGGAGATCCAGTGTCCAGAGCAGGTGGTCGGTGGCATCTAC 
       :::::::: :::::::: :::::::: :::::::: :: ::::: :: :::::::::::: 
hamste ATGGAGCCTATCTACCTGGTGGAGATTCAGTGTCCTGAACAGGTCGTGGGTGGCATCTAC 
             2230      2240      2250      2260      2270      2280 
 
             2290      2300      2310      2320      2330      2340 
human  GGGGTTTTGAACAGGAAGCGGGGCCACGTGTTCGAGGAGTCCCAGGTGGCCGGCACCCCC 
       :: ::  ::::::::::::: ::::: ::::: :: :::::::::::::: ::::::::: 
hamste GGTGTCCTGAACAGGAAGCGTGGCCATGTGTTTGAAGAGTCCCAGGTGGCTGGCACCCCC 
             2290      2300      2310      2320      2330      2340 
 
             2350      2360      2370      2380      2390      2400 
human  ATGTTTGTGGTCAAGGCCTATCTGCCCGTCAACGAGTCCTTTGGCTTCACCGCTGACCTG 
       :::::::: :::::::::::::: :: ::::::::::::::::: :: :: ::::::::: 
hamste ATGTTTGTAGTCAAGGCCTATCTTCCAGTCAACGAGTCCTTTGGTTTTACAGCTGACCTG 
             2350      2360      2370      2380      2390      2400 
 
             2410      2420      2430      2440      2450      2460 
human  AGGTCCAACACGGGCGGCCAGGCGTTCCCCCAGTGTGTGTTTGACCACTGGCAGATCCTG 
        : :::::::: :: ::::: :: ::::::::::::::::: :::::::::::::: ::: 
hamste CGCTCCAACACTGGTGGCCAAGCTTTCCCCCAGTGTGTGTTCGACCACTGGCAGATTCTG 
             2410      2420      2430      2440      2450      2460 
 
             2470      2480      2490      2500      2510      2520 
human  CCCGGAGACCCCTTCGACAACAGCAGCCGCCCCAGCCAGGTGGTGGCGGAGACCCGCAAG 
       ::::: ::::: ::::::::::::::::: :::::::: :::::::: :::::::::::: 
hamste CCCGGGGACCCGTTCGACAACAGCAGCCGTCCCAGCCAAGTGGTGGCTGAGACCCGCAAG 
             2470      2480      2490      2500      2510      2520 
 
             2530      2540      2550      2560      2570        
human  CGCAAGGGCCTGAAAGAAGGCATCCCTGCCCTGGACAACTTCCTGGACAAATTGTAG 
       ::::: :: :: :: :: :::::::: :: ::::::::::::::::::::: ::::: 
hamste CGCAAAGGTCTAAAGGAGGGCATCCCAGCACTGGACAACTTCCTGGACAAACTGTAG 









7.2 Alignment of human and hamster elongation factor 2 amino acid sequences using a 
web based alignment tool.  
 
Comparison of: 
(A) ./wwwtmp/.26055.1.seq human 858 bp                                       
- 858 aa 
(B) ./wwwtmp/.26055.2.seq hamster 858 bp                                     
- 858 aa 
 using matrix file: BL50 (15/-5), gap-open/ext: -14/-4 E(limit)   
0.05 
 
  99.2% identity in 858 aa overlap (1-858:1-858); score: 5677 




               10        20        30        40        50        60 
human  MVNFTVDQIRAIMDKKANIRNMSVIAHVDHGKSTLTDSLVCKAGIIASARAGETRFTDTR 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
hamste MVNFTVDQIRAIMDKKANIRNMSVIAHVDHGKSTLTDSLVCKAGIIASARAGETRFTDTR 
               10        20        30        40        50        60 
 
               70        80        90       100       110       120 
human  KDEQERCITIKSTAISLFYELSENDLNFIKQSKDGAGFLINLIDSPGHVDFSSEVTAALR 
       :::::::::::::::::::::::::::::::::::.:::::::::::::::::::::::: 
hamste KDEQERCITIKSTAISLFYELSENDLNFIKQSKDGSGFLINLIDSPGHVDFSSEVTAALR 
               70        80        90       100       110       120 
 
              130       140       150       160       170       180 
human  VTDGALVVVDCVSGVCVQTETVLRQAIAERIKPVLMMNKMDRALLELQLEPEELYQTFQR 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
hamste VTDGALVVVDCVSGVCVQTETVLRQAIAERIKPVLMMNKMDRALLELQLEPEELYQTFQR 
              130       140       150       160       170       180 
 
              190       200       210       220       230       240 
human  IVENVNVIISTYGEGESGPMGNIMIDPVLGTVGFGSGLHGWAFTLKQFAEMYVAKFAAKG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
hamste IVENVNVIISTYGEGESGPMGNIMIDPVLGTVGFGSGLHGWAFTLKQFAEMYVAKFAAKG 
              190       200       210       220       230       240 
 
              250       260       270       280       290       300 
human  EGQLGPAERAKKVEDMMKKLWGDRYFDPANGKFSKSATSPEGKKLPRTFCQLILDPIFKV 
       :::::::::::::::::::::::::::::::::::::.::.::::::::::::::::::: 
hamste EGQLGPAERAKKVEDMMKKLWGDRYFDPANGKFSKSANSPDGKKLPRTFCQLILDPIFKV 
              250       260       270       280       290       300 
 
              310       320       330       340       350       360 
human  FDAIMNFKKEETAKLIEKLDIKLDSEDKDKEGKPLLKAVMRRWLPAGDALLQMITIHLPS 
       :::::::.:::::::::::::::::::::::::::::::::::::::::::::::::::: 
hamste FDAIMNFRKEETAKLIEKLDIKLDSEDKDKEGKPLLKAVMRRWLPAGDALLQMITIHLPS 
              310       320       330       340       350       360 
 
              370       380       390       400       410       420 
human  PVTAQKYRCELLYEGPPDDEAAMGIKSCDPKGPLMMYISKMVPTSDKGRFYAFGRVFSGL 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::. 
hamste PVTAQKYRCELLYEGPPDDEAAMGIKSCDPKGPLMMYISKMVPTSDKGRFYAFGRVFSGV 
              370       380       390       400       410       420 
213 
 
              430       440       450       460       470       480 
human  VSTGLKVRIMGPNYTPGKKEDLYLKPIQRTILMMGRYVEPIEDVPCGNIVGLVGVDQFLV 
       ::::::::::::::::::::.::::::::::::::::::::::::::::::::::::::: 
hamste VSTGLKVRIMGPNYTPGKKEELYLKPIQRTILMMGRYVEPIEDVPCGNIVGLVGVDQFLV 
              430       440       450       460       470       480 
 
              490       500       510       520       530       540 
human  KTGTITTFEHAHNMRVMKFSVSPVVRVAVEAKNPADLPKLVEGLKRLAKSDPMVQCIIEE 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
hamste KTGTITTFEHAHNMRVMKFSVSPVVRVAVEAKNPADLPKLVEGLKRLAKSDPMVQCIIEE 
              490       500       510       520       530       540 
 
              550       560       570       580       590       600 
human  SGEHIIAGAGELHLEICLKDLEEDHACIPIKKSDPVVSYRETVSEESNVLCLSKSPNKHN 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
hamste SGEHIIAGAGELHLEICLKDLEEDHACIPIKKSDPVVSYRETVSEESNVLCLSKSPNKHN 
              550       560       570       580       590       600 
 
              610       620       630       640       650       660 
human  RLYMKARPFPDGLAEDIDKGEVSARQELKQRARYLAEKYEWDVAEARKIWCFGPDGTGPN 
       ::::::::::::::::::::::::::::: :::::::::::::::::::::::::::::: 
hamste RLYMKARPFPDGLAEDIDKGEVSARQELKARARYLAEKYEWDVAEARKIWCFGPDGTGPN 
              610       620       630       640       650       660 
 
              670       680       690       700       710       720 
human  ILTDITKGVQYLNEIKDSVVAGFQWATKEGALCEENMRGVRFDVHDVTLHADAIHRGGGQ 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
hamste ILTDITKGVQYLNEIKDSVVAGFQWATKEGALCEENMRGVRFDVHDVTLHADAIHRGGGQ 
              670       680       690       700       710       720 
 
              730       740       750       760       770       780 
human  IIPTARRCLYASVLTAQPRLMEPIYLVEIQCPEQVVGGIYGVLNRKRGHVFEESQVAGTP 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
hamste IIPTARRCLYASVLTAQPRLMEPIYLVEIQCPEQVVGGIYGVLNRKRGHVFEESQVAGTP 
              730       740       750       760       770       780 
 
              790       800       810       820       830       840 
human  MFVVKAYLPVNESFGFTADLRSNTGGQAFPQCVFDHWQILPGDPFDNSSRPSQVVAETRK 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
hamste MFVVKAYLPVNESFGFTADLRSNTGGQAFPQCVFDHWQILPGDPFDNSSRPSQVVAETRK 
              790       800       810       820       830       840 
 
              850         
human  RKGLKEGIPALDNFLDKL 
       :::::::::::::::::: 
hamste RKGLKEGIPALDNFLDKL 









7.3 Schematics of commercial vectors used in the cloning and expression of elongation 



























Schematic 7.3.1 Vectors used in the mutation, transient and stable expression of wild type 
eEF2 and the eEF2 mutants Ala56 and Glu56 (a) Vector map of the pcDNA3.1 plasmid used in 
the transient expression of eEF2 (b) Vector map of FRT (pcDNA5/FRT) plasmid used in the 





7.4 Alignment of Hamster wild type (WT)/ Thr56Ala (Ala56) / Thr56Glu (Glu) Elongation 
factor 2  
Sequence comparrision of the wild type WT/ Thr56Ala Ala56 / Thr56Glu elongation factor 2 
constructs. Mutation of Thr56 is highlighted below  
Glu 56= CHO eEF2 Thr56Glu mutant sequence  
Ala56= CHO eEF2 Thr56Glu mutant sequence 
eEF2 = hamster eEF2 sequence (NCBI accession number M13708)  
WT=  Wild type eEF2 sequence  
 
Glu56      -------NGGGNNNGTTACTTAGCTTGGTACTGAGATCCGTCGCCATCCGCCACTATGGT 
Ala56      NCCNNNNNNNNN-------------NNGTACTGANATCCGTCGCCATCCGCCACTATGGT 
eEF2       -------------------------------------------------------atggt 
WT         ---NNNNNNNNNNNGTTACTTAGCTNNGNNCTGANANCCGTCGCCATCCGCCACTATGGT 
                                                                  ***** 
 
Glu56      GAACTTCACGGTAGACCAGATCCGTGCCATTATGGACAAGAAAGCCAACATCCGGAACAT 
Ala56      GAACTTCACGGTAGACCAGATCCGTGCCATTATGGACAAGAAAGCCAACATCCGGAACAT 
eEF2       gaacttcacggtagaccagatccgtgccattatggacaagaaagccaacatccggaacat 
WT         GAACTTCACGGTAGACCAGATCCGTGCCATTATGGACAAGAAAGCCAACATCCGGAACAT 
           ************************************************************ 
 
Glu56      GTCAGTCATCGCTCACGTGGACCACGGCAAGTCCACACTGACGGACTCCCTGGTGTGCAA 
Ala56      GTCAGTCATCGCTCACGTGGACCACGGCAAGTCCACACTGACGGACTCCCTGGTGTGCAA 
eEF2       gtcagtcatcgctcacgtggaccacggcaagtccacactgacggactccctggtgtgcaa 
WT         GTCAGTCATCGCTCACGTGGACCACGGCAAGTCCACACTGACGGACTCCCTGGTGTGCAA 
           ************************************************************ 
 
Glu56      GGCGGGTATCATCGCCTCTGCAAGAGCCGGTGAGACACGCTTCGAGGACACCCGCAAGGA 
Ala56      GGCGGGTATCATCGCCTCTGCAAGAGCCGGTGAGACACGCTTCGCCGACACCCGCAAGGA 
eEF2       ggcgggtatcatcgcctctgcaagagccggtgagacacgcttcacagacacccgcaagga 
WT         GGCGGGTATCATCGCCTCTGCAAGAGCCGGTGAGACACGCTTCACAGACACCCGCAAGGA 
           *******************************************.. ************** 
 
Glu56      CGAACAGGAGCGCTGCATCACTATCAAGTCCACGGCCATCTCCCTCTTCTATGAGCTCTC 
Ala56      CGAACAGGAGCGCTGCATCACTATCAAGTCCACGGCCATCTCCCTCTTCTATGAGCTCTC 
eEF2       cgaacaggagcgctgcatcactatcaagtccacggccatctccctcttctatgagctctc 
WT         CGAACAGGAGCGCTGCATCACTATCAAGTCCACGGCCATCTCCCTCTTCTATGAGCTCTC 
           ************************************************************ 
 
Glu56      TGAGAATGACCTGAACTTCATCAAGCAGAGCAAGGATGGATCTGGCTTTCTCATCAACCT 
Ala56      TGAGAATGACCTGAACTTCATCAAGCAGAGCAAGGATGGATCTGGCTTTCTCATCAACCT 
eEF2       tgagaatgacctgaacttcatcaagcagagcaaggatggatctggctttctcatcaacct 
WT         TGAGAATGACCTGAACTTCATCAAGCAGAGCAAGGATGGATCTGGCTTTCTCATCAACCT 




Glu56      CATCGACTCTCCAGGCCATGTGGATTTCTCCTCAGAGGTGACAGCTGCACTTCGTGTCAC 
Ala56      CATCGACTCTCCAGGCCATGTGGATTTCTCCTCAGAGGTGACAGCTGCACTTCGTGTCAC 
eEF2       catcgactctccaggccatgtggatttctcctcagaggtgacagctgcacttcgtgtcac 
WT         CATCGACTCTCCAGGCCATGTGGATTTCTCCTCAGAGGTGACAGCTGCACTTCGTGTCAC 
           ************************************************************ 
 
Glu56      CGATGGAGCTCTTGTGGTGGTGGACTGTGTGTCTGGTGTGTGCGTGCAGACTGAGACCGT 
Ala56      CGATGGAGCTCTTGTGGTGGTGGACTGTGTGTCTGGTGTGTGCGTGCAGACTGAGACCGT 
eEF2       cgatggagctcttgtggtggtggactgtgtgtctggtgtgtgcgtgcagactgagaccgt 
WT         CGATGGAGCTCTTGTGGTGGTGGACTGTGTGTCTGGTGTGTGCGTGCAGACTGAGACCGT 
           ************************************************************ 
 
Glu56      GCTGCGGCAGGCCATTGCCGAGCGCATCAAGCCTGTCCTGATGATGAATAAGATGGACCG 
Ala56      GCTGCGGCAGGCCATTGCCGAGCGCATCAAGCCTGTCCTGATGATGAATAAGATGGACCG 
eEF2       gctgcggcaggccattgccgagcgcatcaagcctgtcctgatgatgaataagatggaccg 
WT         GCTGCGGCAGGCCATTGCCGAGCGCATCAAGCCTGTCCTGATGATGAATAAGATGGACCG 
           ************************************************************ 
 
Glu56      TGCCCTGCTTGAGCTGCAGCTGGAGCCTGAGGAACTATACCAGACCTTCCAGCGCATTGT 
Ala56      TGCCCTGCTTGAGCTGCAGCTGGAGCCTGAGGAACTATACCAGACCTTCCAGCGCATTGT 
eEF2       tgccctgcttgagctgcagctggagcctgaggaactataccagaccttccagcgcattgt 
WT         TGCCCTGCTTGAGCTGCAGCTGGAGCCTGAGGAACTATACCAGACCTTCCAGCGCATTGT 
           ************************************************************ 
 
Glu56      GGAGAATGTCAACGTCATCATTTCCACCTATGGCGAGGGCGAGAGTGGACCCATGGGAAA 
Ala56      GGAGAATGTCAACGTCATCATTTCCACCTATGGCGAGGGCGAGAGTGGACCCATGGGAAA 
eEF2       ggagaatgtcaacgtcatcatttccacctatggcgagggcgagagtggacccatgggaaa 
WT         GGAGAATGTCAACGTCATCATTTCCACCTATGGCGAGGGCGAGAGTGGACCCATGGGAAA 
           ************************************************************ 
 
Glu56      TATTATGATTGACCCCGTCCTGGGCACTGTGGGCTTTGGCTCTGGCCTGCATGGCTGGGC 
Ala56      TATTATGATTGACCCCGTCCTGGGCACTGTGGGCTTTGGCTCTGGCCTGCATGGCTGGGC 
eEF2       tattatgattgaccccgtcctgggcactgtgggctttggctctggcctgcatggctgggc 
WT         TATTATGATTGACCCCGTCCTGGGCACTGTGGGCTTTGGCTCTGGCCTGCATGGCTGGGC 
           ************************************************************ 
 
Glu56      CTTCACTCTGAAGCAGTTTGCGGAGATGTATGTGGCTAAGTTTGCAGCAAAGGGTGAGGG 
Ala56      CTTCACTCTGAAGCAGTTTGCGGAGATGTATGTGGCTAAGTTTGCAGCAAAGGGTGAGGG 
eEF2       cttcactctgaagcagtttgcggagatgtatgtggctaagtttgcagcaaagggtgaggg 
WT         CTTCACTCTGAAGCAGTTTGCGGAGATGTATGTGGCTAAGTTTGCAGCAAAGGGTGAGGG 
           ************************************************************ 
 
Glu56      CCAGCTGGGGCCTGCTGAGCGGGCCAAGAAAGTGGAGGACATGATGAAGAAGTTGTGGGG 
Ala56      CCAGCTGGGGCCTGCTGAGCGGGCCAAGAAAGTGGAGGACATGATGAAGAAGTTGTGGGG 
eEF2       ccagctggggcctgctgagcgggccaagaaagtggaggacatgatgaagaagttgtgggg 
WT         CCAGCTGGGGCCTGCTGAGCGGGCCAAGAAAGTGGAGGACATGATGAAGAAGTTGTGGGG 








Glu56      AGATCGGTATTTTGATCCCGCCAATGGCAAATTCAGCAAGTCCGCTAACAGCCCTGATGG 
Ala56      AGATCGGTATTTTGATCCCGCCAATGGCAAATTCAGCAAGTCCGCTAACAGCCCTGATGG 
eEF2       agatcggtattttgatcccgccaatggcaaattcagcaagtccgctaacagccctgatgg 
WT         AGATCGGTATTTTGATCCCGCCAATGGCAAATTCAGCAAGTCCGCTAACAGCCCTGATGG 
           ************************************************************ 
 
Glu56      GAAGAAACTGCCACGCACCTTTTGCCAGCTCATCCTGGACCCCATCTTCAAGGTGTTTGA 
Ala56      GAAGAAACTGCCACGCACCTTTTGCCAGCTCATCCTGGACCCCATCTTCAAGGTGTTTGA 
eEF2       gaagaaactgccacgcaccttttgccagctcatcctggaccccatcttcaaggtgtttga 
WT         GAAGAAACTGCCACGCACCTTTTGCCAGCTCATCCTGGACCCCATCTTCAAGGTGTTTGA 
           ************************************************************ 
 
Glu56      CGCCATCATGAACTTCAGAAAGGAGGAGACGGCCAAGCTGATTGAGAAGCTGGATATCAA 
Ala56      CGCCATCATGAACTTCAGAAAGGAGGAGACGGCCAAGCTGATTGAGAAGCTGGATATCAA 
eEF2       cgccatcatgaacttcagaaaggaggagacggccaagctgattgagaagctggatatcaa 
WT         CGCCATCATGAACTTCAGAAAGGAGGAGACGGCCAAGCTGATTGAGAAGCTGGATATCAA 
           ************************************************************ 
 
Glu56      GCTGGACAGCGAGGACAAAGACAAGGAGGGCAAGCCCCTGCTGAAGGCTGTGATGCGCCG 
Ala56      GCTGGACAGCGAGGACAAAGACAAGGAGGGCAAGCCCCTGCTGAAGGCTGTGATGCGCCG 
eEF2       gctggacagcgaggacaaagacaaggagggcaagcccctgctgaaggctgtgatgcgccg 
WT         GCTGGACAGCGAGGACAAAGACAAGGAGGGCAAGCCCCTGCTGAAGGCTGTGATGCGCCG 
           ************************************************************ 
 
Glu56      GTGGCTGCCCGCAGGGGACGCCCTGCTGCAGATGATAACCATCCACCTCCCTTCCCCCGT 
Ala56      GTGGCTGCCCGCAGGGGACGCCCTGCTGCAGATGATAACCATCCACCTCCCTTCCCCCGT 
eEF2       gtggctgcccgcaggggacgccctgctgcagatgataaccatccacctcccttcccccgt 
WT         GTGGCTGCCCGCAGGGGACGCCCTGCTGCAGATGATAACCATCCACCTCCCTTCCCCCGT 
           ************************************************************ 
 
Glu56      CACCGCCCAGAAATACCGCTGCGAGCTGCTCTACGAGGGGCCACCTGATGATGAGGCGGC 
Ala56      CACCGCCCAGAAATACCGCTGCGAGCTGCTCTACGAGGGGCCACCTGATGATGAGGCGGC 
eEF2       caccgcccagaaataccgctgcgagctgctctacgaggggccacctgatgatgaggcggc 
WT         CACCGCCCAGAAATACCGCTGCGAGCTGCTCTACGAGGGGCCACCTGATGATGAGGCGGC 
           ************************************************************ 
 
Glu56      CATGGGCATTAAAAGCTGTGATCCCAAGGGTCCCCTTATGATGTACATTTCCAAGATGGT 
Ala56      CATGGGCATTAAAAGCTGTGATCCCAAGGGTCCCCTTATGATGTACATTTCCAAGATGGT 
eEF2       catgggcattaaaagctgtgatcccaagggtccccttatgatgtacatttccaagatggt 
WT         CATGGGCATTAAAAGCTGTGATCCCAAGGGTCCCCTTATGATGTACATTTCCAAGATGGT 
           ************************************************************ 
 
Glu56      GCCAACCTCCGACAAAGGCCGCTTCTACGCCTTTGGTAGAGTGTTCTCCGGGGTAGTGTC 
Ala56      GCCAACCTCCGACAAAGGCCGCTTCTACGCCTTTGGTAGAGTGTTCTCCGGGGTAGTGTC 
eEF2       gccaacctccgacaaaggccgcttctacgcctttggtagagtgttctccggggtagtgtc 
WT         GCCAACCTCCGACAAAGGCCGCTTCTACGCCTTTGGTAGAGTGTTCTCCGGGGTAGTGTC 








Glu56      GACAGGACTCAAGGTCCGCATCATGGGCCCCAACTACACGCCTGGGAAGAAGGAGGACCT 
Ala56      GACAGGACTCAAGGTCCGCATCATGGGCCCCAACTACACGCCTGGGAAGAAGGAGGACCT 
eEF2       gacaggactcaaggtccgcatcatgggccccaactacacgcctgggaagaaggaggaact 
WT         GACAGGACTCAAGGTCCGCATCATGGGCCCCAACTACACGCCTGGGAAGAAGGAGGACCT 
           *********************************************************.** 
 
Glu56      GTACCTGAAGCCCATCCAGAGAACCATCCTGATGATGGGCCGGTATGTGGAGCCAATTGA 
Ala56      GTACCTGAAGCCCATCCAGAGAACCATCCTGATGATGGGCCGGTATGTGGAGCCAATTGA 
eEF2       gtacctgaagcccatccagagaaccatcctgatgatgggccggtatgtggagccaattga 
WT         GTACCTGAAGCCCATCCAGAGAACCATCCTGATGATGGGCCGGTATGTGGAGCCAATTGA 
           ************************************************************ 
 
Glu56      GGACGTGCCCTGTGGGAACATTGTCGGGCTGGTTGGTGTAGACCAGTTTCTGGTGAAGAC 
Ala56      GGACGTGCCCTGTGGGAACATTGTCGGGCTGGTTGGTGTAGACCAGTTTCTGGTGAAGAC 
eEF2       ggacgtgccctgtgggaacattgtcgggctggttggtgtagaccagtttctggtgaagac 
WT         GGACGTGCCCTGTGGGAACATTGTCGGGCTGGTTGGTGTAGACCAGTTTCTGGTGAAGAC 
           ************************************************************ 
 
Glu56      AGGGACTATCACCACCTTTGAACACGCACATAACATGCGTGTGATGAAGTTCAGCGTCAG 
Ala56      AGGGACTATCACCACCTTTGAACACGCACATAACATGCGTGTGATGAAGTTCAGCGTCAG 
eEF2       agggactatcaccacctttgaacacgcacataacatgcgtgtgatgaagttcagcgtcag 
WT         AGGGACTATCACCACCTTTGAACACGCACATAACATGCGTGTGATGAAGTTCAGCGTCAG 
           ************************************************************ 
 
Glu56      CCCTGTCGTCAGAGTGGCTGTGGAGGCCAAGAACCCAGCTGACCTGCCCAAACTGGTGGA 
Ala56      CCCTGTCGTCAGAGTGGCTGTGGAGGCCAAGAACCCAGCTGACCTGCCCAAACTGGTGGA 
eEF2       ccctgtcgtcagagtggctgtggaggccaagaacccagctgacctgcccaaactggtgga 
WT         CCCTGTCGTCAGAGTGGCTGTGGAGGCCAAGAACCCAGCTGACCTGCCCAAACTGGTGGA 
           ************************************************************ 
 
Glu56      GGGCCTGAAGCGGCTGGCAAAATCTGACCCTATGGTGCAGTGCATCATTGAGGAGTCTGG 
Ala56      GGGCCTGAAGCGGCTGGCAAAATCTGACCCTATGGTGCAGTGCATCATTGAGGAGTCTGG 
eEF2       gggcctgaagcggctggcaaaatctgaccctatggtgcagtgcatcattgaggagtctgg 
WT         GGGCCTGAAGCGGCTGGCAAAATCTGACCCTATGGTGCAGTGCATCATTGAGGAGTCTGG 
           ************************************************************ 
 
Glu56      GGAGCACATCATTGCTGGAGCAGGTGAGCTGCACCTGGAAATCTGCCTCAAGGACCTGGA 
Ala56      GGAGCACATCATTGCTGGAGCAGGTGAGCTGCACCTGGAAATCTGCCTCAAGGACCTGGA 
eEF2       ggagcacatcattgctggagcaggtgagctgcacctggaaatctgcctcaaggacctgga 
WT         GGAGCACATCATTGCTGGAGCAGGTGAGCTGCACCTGGAAATCTGCCTCAAGGACCTGGA 
           ************************************************************ 
 
Glu56      GGAGGACCACGCCTGCATCCCCATCAAGAAATCTGACCCTGTTGTCTCATACCGGGAGAC 
Ala56      GGAGGACCACGCCTGCATCCCCATCAAGAAATCTGACCCTGTTGTCTCATACCGGGAGAC 
eEF2       ggaggaccacgcctgcatccccatcaagaaatctgaccctgttgtctcataccgggagac 
WT         GGAGGACCACGCCTGCATCCCCATCAAGAAATCTGACCCTGTTGTCTCATACCGGGAGAC 








Glu56      AGTGAGCGAGGAGTCAAATGTGCTGTGCCTGTCCAAGTCGCCCAACAAGCACAACCGATT 
Ala56      AGTGAGCGAGGAGTCAAATGTGCTGTGCCTGTCCAAGTCGCCCAACAAGCACAACCGATT 
eEF2       agtgagcgaggagtcaaatgtgctgtgcctgtccaagtcgcccaacaagcacaaccgatt 
WT         AGTGAGCGAGGAGTCAAATGTGCTGTGCCTGTCCAAGTCGCCCAACAAGCACAACCGATT 
           ************************************************************ 
 
Glu56      GTATATGAAGGCCCGGCCCTTCCCTGATGGCCTGGCCGAGGACATCGACAAGGGTGAAGT 
Ala56      GTATATGAAGGCCCGGCCCTTCCCTGATGGCCTGGCCGAGGACATCGACAAGGGTGAAGT 
eEF2       gtatatgaaggcccggcccttccctgatggcctggccgaggacatcgacaagggtgaagt 
WT         GTATATGAAGGCCCGGCCCTTCCCTGATGGCCTGGCCGAGGACATCGACAAGGGTGAAGT 
           ************************************************************ 
 
Glu56      GTCTGCTCGCCAGGAGCTCAAGGCACGCGCACGCTATCTAGCTGAAAAGTACGAATGGGA 
Ala56      GTCTGCTCGCCAGGAGCTCAAGGCACGCGCACGCTATCTAGCTGAAAAGTACGAATGGGA 
eEF2       gtctgctcgccaggagctcaaggcacgcgcacgctatctagctgaaaagtacgaatggga 
WT         GTCTGCTCGCCAGGAGCTCAAGGCACGCGCACGCTATCTAGCTGAAAAGTACGAATGGGA 
           ************************************************************ 
 
Glu56      TGTTGCTGAAGCCCGCAAGATCTGGTGCTTTGGGCCTGATGGCACTGGCCCCAACATTCT 
Ala56      TGTTGCTGAAGCCCGCAAGATCTGGTGCTTTGGGCCTGATGGCACTGGCCCCAACATTCT 
eEF2       tgttgctgaagcccgcaagatctggtgctttgggcctgatggcactggccccaacattct 
WT         TGTTGCTGAAGCCCGCAAGATCTGGTGCTTTGGGCCTGATGGCACTGGCCCCAACATTCT 
           ************************************************************ 
 
Glu56      TACCGATATCACCAAGGGTGTGCAGTACCTGAATGAAATCAAGGACAGTGTGGTGGCTGG 
Ala56      TACCGATATCACCAAGGGTGTGCAGTACCTGAATGAAATCAAGGACAGTGTGGTGGCTGG 
eEF2       taccgatatcaccaagggtgtgcagtacctgaatgaaatcaaggacagtgtggtggctgg 
WT         TACCGATATCACCAAGGGTGTGCAGTACCTGAATGAAATCAAGGACAGTGTGGTGGCTGG 
           ************************************************************ 
 
Glu56      CTTCCAGTGGGCCACTAAGGAGGGCGCTCTCTGTGAGGAGAACATGCGTGGTGTGCGCTT 
Ala56      CTTCCAGTGGGCCACTAAGGAGGGCGCTCTCTGTGAGGAGAACATGCGTGGTGTGCGCTT 
eEF2       cttccagtgggccactaaggagggcgctctctgtgaggagaacatgcgtggtgtgcgctt 
WT         CTTCCAGTGGGCCACTAAGGAGGGCGCTCTCTGTGAGGAGAACATGCGTGGTGTGCGCTT 
           ************************************************************ 
 
Glu56      CGATGTCCATGATGTGACCCTACATGCTGATGCCATCCACCGAGGAGGTGGTCAGATCAT 
Ala56      CGATGTCCATGATGTGACCCTACATGCTGATGCCATCCACCGAGGAGGTGGTCAGATCAT 
eEF2       cgatgtccatgatgtgaccctacatgctgatgccatccaccgaggaggtggtcagatcat 
WT         CGATGTCCATGATGTGACCCTACATGCTGATGCCATCCACCGAGGAGGTGGTCAGATCAT 
           ************************************************************ 
 
Glu56      TCCCACAGCTCGTCGTTGTCTGTATGCCAGTGTGTTGACTGCACAGCCCCGCCTCATGGA 
Ala56      TCCCACAGCTCGTCGTTGTCTGTATGCCAGTGTGTTGACTGCACAGCCCCGCCTCATGGA 
eEF2       tcccacagctcgtcgttgtctgtatgccagtgtgttgactgcacagccccgcctcatgga 
WT         TCCCACAGCTCGTCGTTGTCTGTATGCCAGTGTGTTGACTGCACAGCCCCGCCTCATGGA 








Glu56      GCCTATCTACCTGGTGGAGATTCAGTGTCCTGAACAGGTCGTGGGTGGCATCTACGGTGT 
Ala56      GCCTATCTACCTGGTGGAGATTCAGTGTCCTGAACAGGTCGTGGGTGGCATCTACGGTGT 
eEF2       gcctatctacctggtggagattcagtgtcctgaacaggtcgtgggtggcatctacggtgt 
WT         GCCTATCTACCTGGTGGAGATTCAGTGTCCTGAACAGGTCGTGGGTGGCATCTACGGTGT 
           ************************************************************ 
 
Glu56      CCTGAACAGGAAGCGTGGCCATGTGTTTGAAGAGTCCCAGGTGGCTGGCACCCCCATGTT 
Ala56      CCTGAACAGGAAGCGTGGCCATGTGTTTGAAGAGTCCCAGGTGGCTGGCACCCCCATGTT 
eEF2       cctgaacaggaagcgtggccatgtgtttgaagagtcccaggtggctggcacccccatgtt 
WT         CCTGAACAGGAAGCGTGGCCATGTGTTTGAAGAGTCCCAGGTGGCTGGCACCCCCATGTT 
           ************************************************************ 
 
Glu56      TGTAGTCAAGGCCTATCTTCCAGTCAACGAGTCCTTTGGTTTTACAGCTGACCTGCGCTC 
Ala56      TGTAGTCAAGGCCTATCTTCCAGTCAACGAGTCCTTTGGTTTTACAGCTGACCTGCGCTC 
eEF2       tgtagtcaaggcctatcttccagtcaacgagtcctttggttttacagctgacctgcgctc 
WT         TGTAGTCAAGGCCTATCTTCCAGTCAACGAGTCCTTTGGTTTTACAGCTGACCTGCGCTC 
           ************************************************************ 
 
Glu56      CAACACTGGTGGCCAAGCTTTCCCCCAGTGTGTGTTCGACCACTGGCAGATTCTGCCCGG 
Ala56      CAACACTGGTGGCCAAGCTTTCCCCCAGTGTGTGTTCGACCACTGGCAGATTCTGCCCGG 
eEF2       caacactggtggccaagctttcccccagtgtgtgttcgaccactggcagattctgcccgg 
WT         CAACACTGGTGGCCAAGCTTTCCCCCAGTGTGTGTTCGACCACTGGCAGATTCTGCCCGG 
           ************************************************************ 
 
Glu56      GGACCCGTTCGACAACAGCAGCCGTCCCAGCCAAGTGGTGGCTGAGACCCGCAAGCGCAA 
Ala56      GGACCCGTTCGACAACAGCAGCCGTCCCAGCCAAGTGGTGGCTGAGACCCGCAAGCGCAA 
eEF2       ggacccgttcgacaacagcagccgtcccagccaagtggtggctgagacccgcaagcgcaa 
WT         GGACCCGTTCGACAACAGCAGCCGTCCCAGCCAAGTGGTGGCTGAGACCCGCAAGCGCAA 
           ************************************************************ 
 
Glu56      AGGTCTAAAGGAGGGCATCCCAGCACTGGACAACTTCCTGGACAAACTGTAGAATATCCG 
Ala56      AGGTCTAAAGGAGGGCATCCCAGCACTGGACAACTTCCTGGACAAACTGTAAATAT-CCG 
eEF2       aggtctaaaggagggcatcccagcactggacaacttcctggacaaactgtag-------- 
WT         AGGTCTAAAGGAGGGCATCCCAGCACTGGACAACTTCCTGGACAAACTGTAGAATATCCG 













7.5 Elongation factor 2 kinase short hairpin RNA sequencing   
 
Design and sequencing of eEF2K shRNA plasmid.  
 






























100.0% identity in 54 nt overlap (1-54:419-472); score:  270 
E(10000): 1.6e-15 
 
               10        20        30        40        50     
Oligo  TCTCCTCATGCCTGCAACCGGATTTCTCGAGAAATCCGGTTGCAGGCATGAGCT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Query  TCTCCTCATGCCTGCAACCGGATTTCTCGAGAAATCCGGTTGCAGGCATGAGCT 






7.6 Qiagen RT2 Profiler PCR Array Mouse mTOR Signaling data 
7.6.1 mTOR signalling array gene description 
 
Details of all genes in the array: mTOR Signaling RT
2
 Profiler PCR Array from QIAGEN 




UniGene RefSeq Symbol Description Gene Name 
A01 Mm.6645 NM_009652 Akt1  
Thymoma viral proto-
oncogene 1  
Akt, PKB, PKB, 
Akt, PKBalpha, 
Rac 
A02 Mm.148007 NM_026270 Akt1s1 





A03 Mm.177194 NM_007434 Akt2  
Thymoma viral proto-





A04 Mm.235194 NM_011785 Akt3  
Thymoma viral proto-









A06 Mm.179091 NM_026908 Cab39l 








A07 Mm.1022 NM_009861 Cdc42 
Cell  division cycle 42 
homolog (S. cerevisiae) 
AI747189, 
AU018915 
























A11 Mm.295397 NM_145470 Deptor  














A12 Mm.290022 NM_145625 Eif4b 
Eukaryotic translation 




B01 Mm.3941 NM_007917 Eif4e 
Eukaryotic translation 





B02 Mm.6700 NM_007918 Eif4ebp1 
Eukaryotic translation 





B03 Mm.259516 NM_010124 Eif4ebp2 
Eukaryotic translation 



















B06 Mm.394930 NM_019827 Gsk3b 







B07 Mm.3879 NM_010431 Hif1a 






B08 Mm.334313 NM_008284 Hras1 
Harvey rat sarcoma virus 













B10 Mm.268521 NM_010512 Igf1 Insulin-like growth factor 1 
C730016P09Rik, 
Igf-1, Igf-I 
B11 Mm.29254 NM_008343 Igfbp3 Insulin-like growth factor AI649005, 
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binding protein 3 IGFBP-3, 
IGgfbp3 
B12 Mm.277886 NM_010546 Ikbkb 






C01 Mm.274846 NM_010562 Ilk Integrin linked kinase 
AA511515, 
ESTM24 
C02 Mm.4946 NM_008387 Ins2 Insulin II 
AA986540, Ins-
2, InsII, Mody, 
Mody4, 
proinsulin 




, IR, IR-A, IR-B 
C04 Mm.4952 NM_010570 Irs1 
Insulin receptor substrate 
1 
G972R, IRS-1 




















C07 Mm.270866 NM_177345 Mapkap1 
Mitogen-activated protein 




C08 Mm.289516 NM_019988 Mlst8 
MTOR associated protein, 






C09 Mm.21158 NM_020009 Mtor  














C11 Mm.10504 NM_011062 Pdpk1 
3-phosphoinositide 
dependent protein kinase 
1 
Pdk1 





D01 Mm.260521 NM_008839 Pik3ca Phosphatidylinositol 3- 6330412C24Rik, 
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D02 Mm.213128 NM_029094 Pik3cb 
Phosphatidylinositol 3-






D03 Mm.229108 NM_008840 Pik3cd 
Phosphatidylinositol 3-

















D06 Mm.260177 NM_008876 Pld2 Phospholipase D2 - 
D07 Mm.260288 NM_019411 Ppp2ca 
Protein phosphatase 2 
(formerly 2A), catalytic 
subunit, alpha isoform 
PP2A, R75353 
D08 Mm.26134 NM_028392 Ppp2r2b 
Protein phosphatase 2 
(formerly 2A), regulatory 










D09 Mm.275393 NM_138748 Ppp2r4 
Protein phosphatase 2A, 



















D11 Mm.48638 NM_178143 Prkaa2 
Protein kinase, AMP-





D12 Mm.458152 NM_031869 Prkab1 
Protein kinase, AMP-





E01 Mm.31175 NM_182997 Prkab2 
Protein kinase, AMP-





E02 Mm.6670 NM_016781 Prkag1 
Protein kinase, AMP-





E03 Mm.33649 NM_145401 Prkag2 
Protein kinase, AMP-









E04 Mm.166501 NM_153744 Prkag3 
Protein kinase, AMP-





E05 Mm.222178 NM_011101 Prkca Protein kinase C, alpha AI875142, Pkca 













E09 Mm.245395 NM_008960 Pten 









E10 Mm.319175 NM_053075 Rheb 
Ras homolog enriched in 
brain 
- 
E11 Mm.757  NM_016802 Rhoa 




E12 Mm.275811 NM_030168 Rictor 
RPTOR independent 







F01 Mm.379007 NM_009096 Rps6 Ribosomal protein S6 
MGC102571, 
MGC103209 
F02 Mm.301827 NM_009097 Rps6ka1 
Ribosomal protein S6 
kinase polypeptide 1 
Rsk1, p90rsk, 
rsk 
F03 Mm.268383 NM_011299 Rps6ka2 
Ribosomal protein S6 






F04 Mm.220417 NM_153587 Rps6ka5 
Ribosomal protein S6 







F05 Mm.394280 NM_028259 Rps6kb1 
Ribosomal protein S6 











F06 Mm.271937 NM_021485 Rps6kb2 
Ribosomal protein S6 
kinase, polypeptide 2 
70kDa, S6K2 
F07 Mm.209933 NM_028898 Rptor 
Regulatory associated 
protein of MTOR, complex 
1 
4932417H02Rik
, Rap, Raptor, 
mKIAA1303 







Rragb Ras-related GTP binding B 
MGC69750, 
MGC95567 











F12 Mm.28405 NM_011361 Sgk1 
Serum/glucocorticoid 
regulated kinase 1 
Sgk 














G03 Mm.288702 NM_027880 Telo2 
TEL2, telomere 






G04 Mm.222  NM_011640 Trp53 
Transformation related 
protein 53 
Tp53, bbl, bfy, 
bhy, p44, p53 
G05 Mm.224354 NM_022887 Tsc1 Tuberous sclerosis 1 
hamartin, 
mKIAA0243 
G06 Mm.30435 NM_011647 Tsc2 Tuberous sclerosis 2 Tcs2 
G07 Mm.271898 NM_009469 Ulk1 





G08 Mm.162025 NM_013881 Ulk2 






G09 Mm.282184 NM_009505 Vegfa 
Vascular endothelial 
growth factor A 
Vegf, Vegf120, 
Vegf164, 
Vegf188, Vpf  
G10 Mm.15607 NM_011697 Vegfb 
Vascular endothelial 
growth factor B 
VEGF-B, Vrf 
G11 Mm.1402 NM_009506 Vegfc 
Vascular endothelial 





























H02 Mm.163  NM_009735 B2m Beta-2 microglobulin 
Ly-m11, beta2-
m, beta2m 









H04 Mm.3317 NM_010368 Gusb Glucuronidase, beta 
AI747421, Gur, 
Gus, Gus-r, Gus-
s, Gus-t, Gus-u, 
Gut, asd, g 
H05 Mm.2180 NM_008302 
Hsp90ab
1 
Heat shock protein 90 








H06 N/A SA_00106 MGDC 
Mouse Genomic DNA 
Contamination 
MIGX1B 












H10 N/A SA_00103 PPC Positive PCR Control PPC 
H11 N/A SA_00103 PPC Positive PCR Control PPC 
H12 N/A SA_00103 PPC Positive PCR Control PPC 
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7.6.2 Raw data collected from the mTOR Signaling RT
2
 Profiler PCR Array from QIAGEN 
using CHO Flp-Inparental cell RNA samples taken 68 hours and 120 hours from culture.  
Symbol Well 
s'ȴt               




















Akt1  A01 -3.12 -1.63 8.7E+00  3.1E+00  2.82 N/A 2.82 OKAY 
Akt1s1  A02 5.05 5.89 3.0E-02 1.7E-02 1.80 N/A 1.80 B 
Akt2  A03 -1.98 -0.47 4.0E+00  1.4E+00  2.86 N/A 2.86 OKAY 
Akt3  A04 0.92 1.63 5.3E-01 3.2E-01 1.64 N/A 1.64 OKAY 
Cab39  A05 6.60 7.65 1.0E-02 5.0E-03 2.08 N/A 2.08 C 
Cab39l  A06 -2.29 -0.44 4.9E+00  1.4E+00  3.62 N/A 3.62 OKAY 
Cdc42  A07 3.61 4.43 8.2E-02 4.6E-02 1.77 N/A 1.77 B 
Chuk  A08 N/A N/A N/A N/A N/A N/A N/A C 
Ddit4  A09 3.71 3.37 7.7E-02 9.6E-02 0.79 N/A -1.26 B 
Ddit4l  A10 N/A N/A N/A N/A N/A N/A N/A C 
Deptor  A11 -1.07 -0.42 2.1E+00  1.3E+00  1.58 N/A 1.58 OKAY 
Eif4b  A12 N/A 7.65 N/A 5.0E-03 N/A N/A N/A C 
Eif4e  B01 1.92 2.28 2.6E-01 2.1E-01 1.29 N/A 1.29 A 
Eif4ebp1  B02 N/A N/A N/A N/A N/A N/A N/A C 
Eif4ebp2  B03 N/A 7.65 N/A 5.0E-03 N/A N/A N/A C 
Fkbp1a  B04 6.60 7.65 1.0E-02 5.0E-03 2.08 N/A 2.08 C 
Fkbp8  B05 0.88 0.87 5.4E-01 5.5E-01 1.00 N/A -1.00 OKAY 
Gsk3b  B06 -2.10 -0.63 4.3E+00  1.5E+00  2.78 N/A 2.78 OKAY 
Hif1a  B07 N/A 7.65 N/A 5.0E-03 N/A N/A N/A C 
Hras1  B08 -0.97 0.60 2.0E+00  6.6E-01 2.98 N/A 2.98 OKAY 
Hspa4  B09 4.82 2.95 3.5E-02 1.3E-01 0.27 N/A -3.64 B 
Igf1  B10 6.60 7.62 1.0E-02 5.1E-03 2.04 N/A 2.04 B 
Igfbp3  B11 6.60 6.60 1.0E-02 1.0E-02 1.00 N/A 1.00 B 
Ikbkb  B12 0.25 1.75 8.4E-01 3.0E-01 2.84 N/A 2.84 OKAY 
Ilk  C01 -0.73 -0.10 1.7E+00  1.1E+00  1.55 N/A 1.55 OKAY 
Ins2  C02 6.60 6.96 1.0E-02 8.0E-03 1.29 N/A 1.29 B 
Insr  C03 6.60 6.92 1.0E-02 8.2E-03 1.25 N/A 1.25 B 
Irs1  C04 2.33 3.78 2.0E-01 7.3E-02 2.74 N/A 2.74 B 
Mapk1  C05 3.19 1.92 1.1E-01 2.6E-01 0.42 N/A -2.40 A 
Mapk3  C06 6.60 7.65 1.0E-02 5.0E-03 2.08 N/A 2.08 C 
Mapkap1  C07 N/A 7.65 N/A 5.0E-03 N/A N/A N/A C 
Mlst8  C08 1.79 3.26 2.9E-01 1.0E-01 2.78 N/A 2.78 B 
Mtor  C09 2.23 3.77 2.1E-01 7.3E-02 2.92 N/A 2.92 B 
Myo1c  C10 6.57 5.43 1.1E-02 2.3E-02 0.46 N/A -2.19 B 
Pdpk1  C11 -1.01 0.63 2.0E+00  6.4E-01 3.13 N/A 3.13 OKAY 
Pik3c3  C12 4.43 4.48 4.6E-02 4.5E-02 1.04 N/A 1.04 B 
Pik3ca  D01 N/A N/A N/A N/A N/A N/A N/A C 
Pik3cb  D02 2.61 3.08 1.6E-01 1.2E-01 1.39 N/A 1.39 B 
Pik3cd  D03 6.60 6.70 1.0E-02 9.6E-03 1.08 N/A 1.08 B 
Pik3cg  D04 6.60 6.15 1.0E-02 1.4E-02 0.74 N/A -1.36 B 
Pld1  D05 3.12 4.38 1.2E-01 4.8E-02 2.41 N/A 2.41 B 
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Pld2  D06 N/A N/A N/A N/A N/A N/A N/A C 
Ppp2ca  D07 -4.55 -3.02 2.3E+01  8.1E+00  2.90 N/A 2.90 OKAY 
Ppp2r2b  D08 N/A 6.83 N/A 8.8E-03 N/A N/A N/A B 
Ppp2r4  D09 N/A 7.65 N/A 5.0E-03 N/A N/A N/A C 
Prkaa1  D10 3.36 3.16 9.8E-02 1.1E-01 0.87 N/A -1.14 B 
Prkaa2  D11 6.34 3.85 1.2E-02 6.9E-02 0.18 N/A -5.59 B 
Prkab1  D12 6.60 N/A 1.0E-02 N/A N/A N/A N/A C 
Prkab2  E01 1.94 3.64 2.6E-01 8.0E-02 3.26 N/A 3.26 B 
Prkag1  E02 6.25 6.43 1.3E-02 1.2E-02 1.14 N/A 1.14 B 
Prkag2  E03 -0.27 0.71 1.2E+00  6.1E-01 1.98 N/A 1.98 OKAY 
Prkag3  E04 N/A 7.65 N/A 5.0E-03 N/A N/A N/A C 
Prkca  E05 -0.24 0.88 1.2E+00  5.4E-01 2.18 N/A 2.18 OKAY 
Prkcb  E06 N/A 7.65 N/A 5.0E-03 N/A N/A N/A C 
Prkcc  E07 N/A N/A N/A N/A N/A N/A N/A C 
Prkce  E08 5.87 7.19 1.7E-02 6.8E-03 2.51 N/A 2.51 B 
Pten  E09 -3.08 -1.92 8.5E+00  3.8E+00  2.24 N/A 2.24 OKAY 
Rheb  E10 2.88 2.15 1.4E-01 2.2E-01 0.61 N/A -1.65 A 
Rhoa  E11 -4.62 -3.50 2.5E+01  1.1E+01  2.18 N/A 2.18 OKAY 
Rictor  E12 N/A N/A N/A N/A N/A N/A N/A C 
Rps6  F01 4.53 3.24 4.3E-02 1.1E-01 0.41 N/A -2.43 B 
Rps6ka1  F02 2.51 3.61 1.8E-01 8.2E-02 2.15 N/A 2.15 B 
Rps6ka2  F03 6.60 7.05 1.0E-02 7.5E-03 1.37 N/A 1.37 B 
Rps6ka5  F04 0.79 2.15 5.8E-01 2.2E-01 2.58 N/A 2.58 OKAY 
Rps6kb1  F05 -3.06 -1.59 8.4E+00  3.0E+00  2.78 N/A 2.78 OKAY 
Rps6kb2  F06 4.92 6.26 3.3E-02 1.3E-02 2.54 N/A 2.54 B 
Rptor  F07 -0.78 0.87 1.7E+00  5.5E-01 3.15 N/A 3.15 OKAY 
Rraga  F08 -2.20 -1.02 4.6E+00  2.0E+00  2.28 N/A 2.28 OKAY 
Rragb  F09 0.90 1.76 5.4E-01 2.9E-01 1.82 N/A 1.82 OKAY 
Rragc  F10 -2.96 -1.33 7.8E+00  2.5E+00  3.11 N/A 3.11 OKAY 
Rragd  F11 N/A 7.20 N/A 6.8E-03 N/A N/A N/A B 
Sgk1  F12 -0.07 1.76 1.1E+00  2.9E-01 3.57 N/A 3.57 OKAY 
Stk11  G01 3.95 3.89 6.5E-02 6.7E-02 0.96 N/A -1.04 B 
Stradb  G02 N/A N/A N/A N/A N/A N/A N/A C 
Telo2  G03 6.60 7.47 1.0E-02 5.6E-03 1.84 N/A 1.84 B 
Trp53  G04 6.60 7.65 1.0E-02 5.0E-03 2.08 N/A 2.08 C 
Tsc1  G05 6.60 7.65 1.0E-02 5.0E-03 2.08 N/A 2.08 C 
Tsc2  G06 5.35 4.76 2.5E-02 3.7E-02 0.67 N/A -1.50 B 
Ulk1  G07 6.60 N/A 1.0E-02 N/A N/A N/A N/A C 
Ulk2  G08 6.30 6.41 1.3E-02 1.2E-02 1.08 N/A 1.08 B 
Vegfa  G09 -1.98 -0.74 4.0E+00  1.7E+00  2.37 N/A 2.37 OKAY 
Vegfb  G10 -0.31 1.10 1.2E+00  4.7E-01 2.67 N/A 2.67 OKAY 
Vegfc  G11 6.60 7.65 1.0E-02 5.0E-03 2.08 N/A 2.08 C 
Ywhaq  G12 N/A N/A N/A N/A N/A N/A N/A C 
Actb  H01 -7.26 -6.19 1.5E+02  7.3E+01  2.11 N/A 2.11 OKAY 
B2m  H02 6.60 7.65 1.0E-02 5.0E-03 2.08 N/A 2.08 C 
Gapdh  H03 N/A N/A N/A N/A N/A N/A N/A C 
Gusb  H04 N/A N/A N/A N/A N/A N/A N/A C 





























Legend (taken from PCR array data analysis Excel spreadsheet tool: 
Fold-Change (2^(- Delta Delta Ct)) is the normalized gene expression (2^(- Delta Ct)) 
in the Test Sample divided the normalized gene expression (2^(- Delta Ct)) in the 
Control Sample.  
Fold-Regulation represents fold-change results in a biologically meaningful way. 
Fold-change values greater than one indicate a positive- or an up-regulation, and 
the fold-regulation is equal to the fold-change  
Fold-change values less than one indicate a negative or down-regulation, and the 
fold-regulation is the negative inverse of the fold-change.  
Fold-change and fold-regulation values greater than 2 are indicated in red; fold-
change values less than 0.5 and fold-regulation values less than -2 are indicated in 
blue. 
p-values: dŚĞƉǀĂůƵĞƐĂƌĞĐĂůĐƵůĂƚĞĚďĂƐĞĚŽŶĂ^ƚƵĚĞŶƚ ?Ɛƚ-test of the replicate 
2^(- Delta Ct) values for each gene in the control group and treatment groups, and 
p values less than 0.05 are indicated in red. 
Comments: 
 PdŚŝƐŐĞŶĞ ?ƐĂǀĞƌĂŐĞƚŚƌĞƐŚŽůĚĐǇĐůĞŝƐƌĞůĂƚŝǀĞůǇŚŝŐŚ ?AN ? ? ?ŝŶĞŝƚŚĞƌƚŚĞĐŽŶƚƌŽů
or the test sample, and is reasonably low in the other sample (< 30).  
dŚĞƐĞĚĂƚĂŵĞĂŶƚŚĂƚƚŚĞŐĞŶĞ ?ƐĞǆƉƌĞƐƐŝŽŶŝƐƌĞůĂƚŝǀĞůǇůŽǁŝŶŽŶĞƐĂŵƉůĞĂŶĚ
reasonably detected in the other sample suggesting that the actual fold-change 
value is at least as large as the calculated and reported fold-change result.  
This fold-change result may also have greater variations if p value > 0.05; therefore, 
it is important to have a sufficient number of biological replicates to validate the 
result for this gene.  
 PdŚŝƐŐĞŶĞ ?ƐĂǀĞƌĂŐĞƚŚƌĞƐŚŽůĚĐǇĐůĞŝƐƌĞůĂƚŝǀĞůǇŚŝŐŚ ?AN ? ? ? ?ŵĞĂŶŝŶŐƚŚĂƚŝts 
relative expression level is low, in both control and test samples, and the p-value 
for the fold-change is either unavailable or relatively high (p > 0.05).  
This fold-change result may also have greater variations; therefore, it is important 
to have a sufficient number of biological replicates to validate the result for this 
gene.  
 PdŚŝƐŐĞŶĞ ?ƐĂǀĞƌĂŐĞƚŚƌĞƐŚŽůĚĐǇĐůĞŝƐĞŝƚŚĞƌŶŽƚĚĞƚĞƌŵŝŶĞĚŽƌŐƌĞĂƚĞƌƚŚĂŶƚŚĞ
defined cut-off (deault 35), in both samples meaning that its expression was 
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